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Abstract
The branch of cytology known as cytopathology, studies and diagnoses diseases at a
cellular level, and is a useful method for detecting cancer. The procedures used to attain
cytological samples for diagnostic purposes, such as aspiration and exfoliative methods
are safe, accurate and cost-effective. Histochemical and immunohistochemical (IHC)
techniques are commonly applied to cytological samples to aid cancer diagnosis, however
multiple limitations occur using these methods for the diagnosis of thyroid cancer (TC)
and non-small cell lung cancer (NSCLC). Fine needle aspiration cytology (FNAC) is the
prominent diagnostic method used for the initial investigation of thyroid nodules but is
limited by the inability to accurately diagnose malignancy in follicular-patterned lesion.
As a result, more than 20% of cases under investigation for TC are classified as
cytologically “indeterminate”, requiring surgical resection for accurate diagnosis. In the
case of NSCLC, with the advent of targeted therapies, it is imperative to accurately
differentiate (NSCLC) subtypes in order to ensure efficacy of treatment for patients.
Immunohistochemistry and molecular techniques are increasingly part of the diagnostic
work-up of NSCLC patients however due to the limitation of small sample size,
overlapping morphological features and molecular characterisation, differential diagnosis
of NSCLC still proves challenging. Raman spectroscopy has shown promising results for
the detection of a variety of cancers, however to date there has been no evaluation of
Raman spectroscopy on cytology bronchoscopy samples or thyroid FNAC samples,
which may eliminate the limitations of current methods. This thesis explores the use of
Raman spectroscopy as an alternative or adjunct tool for the diagnosis of TC and NSCLC
using cytological specimens.

Declaration
I certify that this thesis which I now submit for examination for the award of Doctor of
Philosophy (PhD), is entirely my own work and has not been taken from the work of
others, save and to the extent that such work has been cited and acknowledged within
the text of my work.
This thesis was prepared according to the regulations for graduate study by research of
the Technological University Dublin and has not been submitted in whole or in part for
another award in any other third level institution.
The work reported on in this thesis conforms to the principles and requirements of the
TU Dublin's guidelines for ethics in research.
TU Dublin has permission to keep, lend or copy this thesis in whole or in part, on
condition that any such use of the material of the thesis be duly acknowledged.

Signature _________________________ Date _____________
(Declan O’Dea)

Acknowledgements
I would like to express my sincere appreciation and gratitude for my supervisors, Ms.
Alison Malkin and Prof. Fiona Lyng, for their support and advice throughout. I thank
them for their guidance, for all the time and effort they put into helping me with this
project, and for helping me grow as a scientist.
I would also to thank everybody in the RESC for their help along the way, in particular
I’d like to thank Damien Traynor, who taught me how to take a Raman spectrum and
whose help has been invaluable throughout. Thank you to Daniel Cullen, Adrian Maguire,
and Sebastian Nagorski who were willing to give up their time to help me with the data
mining aspect of the project.
This work would not have been possible without our collaborators, Dr. Finbar O’Connell,
Dr. Siobhán Nicholson, and Dr. Aoife Maguire from St. James’s Hospital Dublin, Prof.
Renzo Vanna from the Nanomedicine and Molecular Imaging Lab at Istituti Clinici
Scientifici Maugeri Spa – Società Benefit IRCCS, and Prof. Massimo Bongiovanni from
University Hospital of Lausanne CHUV. My sincerest thanks to them all.
An additional thank you to Hugh Byrne, the students, and post docs at FOCAS, for
making the last four years an enjoyable experience.
Thank you to my friends for their incredible support, and for helping me de-stress when
I needed it. I am forever grateful to my Mam, Dad, and family for all the encouragement
they have given me over the last four years, without it this would not have been possible.
And finally, I would like to say thank you to my wife Sabrina Moris. After stressful days
and late evenings, she always listened to me vent and made me laugh when I got home.
I’m incredibly lucky to have had her support.

Abbreviations list
AC

Adenocarcinoma

ALK

Anaplastic lymphoma kinase

ATCC

American Type Culture Collection

ATR

Attenuated total reflection

BAL

Bronchioalveolar lavage

BRF2

B-related factor 2

BW

Bronchial wash

CARS

Coherent anti-stokes Raman scattering

CCD

Charge coupled device

CT scan

Computerized axial tomography

CTLA-4

Cytotoxic T-lymphocyte-associated protein 4

DNA

Deoxyribonucleic acid

DTT

Dithiothreitol

EGFR

Epidermal growth factor receptor

EMT

Epithelial mesenchymal transition

FBS

Fetal bovine serum

FDA

Food and drug administration

FGFR

Fibroblast growth factor receptor

FISH

Fluorescent in situ hybridisation

FNA

Fine needle aspiration

FNAC

Fine needle aspiration cytology

FTC

Follicular thyroid carcinoma

FTIR

Fourier transform infrared

HER2

Human epidermal growth factor receptor 2

HPV

Human papillomavirus

IHC

Immunohistochemistry

IMS

Industrial methylated spirits

LDA

Linear discriminant analysis

LV

Latent vairable

MET

Mesenchymal Epithelial Transition

MRI

Magnetic resonance imaging

MTC

Medullary thyroid carcinoma

NNLS

Non-negative least squares analysis

NMCS

No malignant cells seen

NSCLC

Non-small cell lung cancer

NSCLC NOS Non-small cell lung cancer not otherwise specified
Pap

Papanicolaou

PBS

Phosphate buffered saline

PCA

Principal component analysis

PCR

Polymerase chain reaction

PDGF

Platelet derived growth factors

PD-L1

Programmed death-ligand 1

PLSDA

Partial least squares discriminant analysis

PTC

Papillary thyroid carcinoma

RPMI

Roswell Park Memorial Institute medium

SCC

Squamous cell carcinoma

SCLC

Small cell lung cancer

TC

Thyroid cancer

TKI

Tyrosine kinase inhibitor

TTF-1

Thyroid transcription factor 1

US

Ultrasound

VEGFR-2

Vascular endothelial growth factor receptor 2

Contents
Chapter 1: Cancer cytopathology and Raman spectroscopy ...................................................... 16
1.1 Thesis outline .................................................................................................................... 16
1.2 Cytopathology ................................................................................................................... 17
1.2.1 Introduction to cytopathology ................................................................................... 17
1.2.2 Normal cellular morphology and cancer nomenclature ............................................ 18
1.2.3 The identification of neoplastic changes with cytopathology ................................... 19
1.2.4 Benefits and limitations of current methods ............................................................. 21
1.3 Raman spectroscopy ......................................................................................................... 22
1.3.1 Raman spectroscopy for cancer diagnosis ................................................................. 22
1.3.2 Principle ..................................................................................................................... 23
1.3.3 Instrumentation ......................................................................................................... 26
1.3.4 Raman spectroscopic analysis of cytological samples ............................................... 28
1.4 Summary ........................................................................................................................... 29
1.4.1 Thesis objectives ........................................................................................................ 29
References .............................................................................................................................. 30
Chapter 2: Recent advances in the vibrational spectroscopic diagnosis of non-small cell lung
cancer .......................................................................................................................................... 34
Abstract ................................................................................................................................... 35
2.1 Lung cancer ....................................................................................................................... 36
2.1.1 Introduction to Lung Cancer ...................................................................................... 36
2.1.2 Current Treatment Options ....................................................................................... 38
2.1.3 Current Methods for Differential Diagnosis of NSCLC Subtypes ............................... 40
2.1.4 Bronchoscopy............................................................................................................. 40
2.1.5 NSCLC Tumour Classification Utilising Cytology Specimens ...................................... 41
2.1.6 Immunohistochemistry .............................................................................................. 41
2.1.7 Fluorescent in situ Hybridisation ............................................................................... 43
2.1.8 Current Research on Genomic Profiling..................................................................... 43
2.1.9 Limitations of Current Diagnostic Methods ............................................................... 44
2.2 Vibrational Spectroscopy .................................................................................................. 44
2.2.1 FTIR Spectroscopy for Lung Cancer Diagnosis ........................................................... 45
2.2.2 Raman Spectroscopy for Lung Cancer Diagnosis ....................................................... 48
2.2.3 Summary and Future Perspectives ............................................................................ 55
2.3 Conclusion ......................................................................................................................... 56

References .............................................................................................................................. 56
Chapter 3: Methodologies .......................................................................................................... 66
3.1 Study subjects, sample collection and preparation .......................................................... 66
3.1.1 Sample processing for BAL and BW samples ............................................................. 66
3.1.2 Slide preparation........................................................................................................ 66
3.2 Raman spectral acquisition and data pre-processing and analysis .................................. 67
3.2.1 Raman Measurement ................................................................................................ 67
3.2.2 Recording position of targeted cells unstained slide ................................................. 67
3.2.3 Smoothing .................................................................................................................. 68
3.2.4 Baseline removal ........................................................................................................ 68
3.2.5 Normalisation............................................................................................................. 68
3.2.6 Glass removal by non-negative least squares............................................................ 68
3.2.7 Outlier removal .......................................................................................................... 69
3.2.8 Principal component analysis .................................................................................... 69
3.2.9 Linear discriminant analysis ....................................................................................... 70
3.2.10 Partial least squares discriminant analysis .............................................................. 70
3.2.11 Cross validation ........................................................................................................ 71
3.2.12 Calculation of classification models performance scores ........................................ 71
3.3 Pap staining ................................................................................................................... 72
References .............................................................................................................................. 73
Chapter 4: Raman spectroscopic analysis of NSCLC using bronchoscopy cytology samples ..... 75
4.1 Introduction ...................................................................................................................... 75
4.2 Methods ............................................................................................................................ 77
4.2.1 Study subjects and sample collection ........................................................................ 77
4.2.2 Sample processing and slide preparation .................................................................. 77
4.2.3 Raman Measurement ................................................................................................ 77
4.2.4 Data pre-processing and analysis............................................................................... 78
4.2.5 Pap staining ................................................................................................................ 78
4.3 Results ............................................................................................................................... 79
4.3.1 Mean spectral analysis ............................................................................................... 79
4.3.2 Spectral comparison of the lymphocyte, bronchial, and squamous nuclei from
negative cases ..................................................................................................................... 84
4.3.3 Mean spectral analysis of cell nuclei from negative cases, SCC cases, and AC cases 86
4.3.4 Cytoplasmic spectra analysis ..................................................................................... 96

4.3.5 Spectral comparison of the cytoplasmic components of bronchial and squamous
cells from negative cases .................................................................................................... 97
4.3.6 Mean cytoplasm spectral analysis of cells from negative cases, SCC cases, and AC
cases .................................................................................................................................... 98
4.3.7 Principal component analysis .................................................................................. 104
4.3.8 PLSDA classification of NSCLC subtypes ................................................................... 121
4.4 Discussion........................................................................................................................ 150
4.4.1 Summary .................................................................................................................. 160
References ............................................................................................................................ 161
Chapter 5: Examination of Raman spectra from NSCLC cases with cytological analyses reported
as diagnostic or no malignant cells seen .................................................................................. 168
5.1 Introduction .................................................................................................................... 168
5.2 Methods .......................................................................................................................... 169
5.2.1 Study subjects and sample collection ...................................................................... 169
5.2.2 Sample processing and slide preparation ................................................................ 170
5.2.3 Raman Measurement .............................................................................................. 170
5.2.4 Data pre-processing and analysis............................................................................. 170
5.2.5 Pap staining .............................................................................................................. 171
5.3 Results ............................................................................................................................. 171
5.3.1 Comparative spectral analysis ................................................................................. 171
5.3.2 Principal component analysis .................................................................................. 185
5.3.3 PLSDA classification.................................................................................................. 190
5.4 Discussion........................................................................................................................ 193
References ............................................................................................................................ 196
Chapter 6: Comparison of the diagnostic effectiveness of applying Raman spectroscopy to
cytological specimens and tissue sections for NSCLC diagnosis ............................................... 199
6.1 Introduction .................................................................................................................... 199
6.2 Methods .......................................................................................................................... 200
6.2.1 Study subjects and sample preparation................................................................... 200
6.2.2 Sample processing and slide preparation ................................................................ 200
6.2.3 Raman Measurement .............................................................................................. 200
6.2.4 Data pre-processing and analysis............................................................................. 201
6.2.5 Haematoxylin and Eosin ........................................................................................... 201
6.3 Results ............................................................................................................................. 201
6.3.1 Wax contamination after digital wax removal......................................................... 207

6.3.2 Comparison of the mean Raman spectra from bronchial tissues............................ 210
6.3.3 Principal component analysis .................................................................................. 214
6.3.4 PLSDA classification of lung cancer subtypes .......................................................... 220
6.4 Discussion........................................................................................................................ 223
References ............................................................................................................................ 232
Chapter 7: Raman spectroscopy for the preoperative diagnosis of thyroid cancer and its
subtypes: an in vitro proof-of-concept study ........................................................................... 235
7.1 Introduction .................................................................................................................... 237
7.2 Materials and Methods ................................................................................................... 239
7.2.1 Cell cultures.............................................................................................................. 239
7.2.2 Raman Measurement .............................................................................................. 240
7.2.3 Data pre-processing and analysis............................................................................. 241
7.3 Results ............................................................................................................................. 241
7.3.1 Mean spectral analysis ............................................................................................. 241
7.3.2 Linear Discriminant Analysis .................................................................................... 246
7.4 Discussion........................................................................................................................ 253
7.5 Conclusion ....................................................................................................................... 257
References ............................................................................................................................ 257
Chapter 8: Development of a blood removal protocol suitable for thyroid FNAC samples ..... 261
8.1 Introduction ................................................................................................................ 261
8.2 Section A ......................................................................................................................... 263
8.2.1 Materials and Methods ............................................................................................ 263
8.2.2 Results ...................................................................................................................... 267
8.2.3 Discussion................................................................................................................. 279
8.3 Section B - Use of Raman spectroscopy for the discrimination between normal and
malignant FNAC samples prepared from resected thyroid specimens ................................ 282
8.3.1 Methods ................................................................................................................... 283
8.3.2 Results and discussion ............................................................................................. 285
8.4 Section C – Optimising the blood removal method for thyroid FNAC samples .............. 293
8.4.1 Methods ................................................................................................................... 293
8.4.2 Results and discussion ............................................................................................. 295
8.5 Summary and Conclusion ............................................................................................... 304
References ............................................................................................................................ 305
Chapter 9: Conclusion ............................................................................................................... 307

9.1 Summary of thesis components ..................................................................................... 307
9.2 Clinical Relevance............................................................................................................ 309
9.3

Future Work .............................................................................................................. 311

List of Publications ................................................................................................................ 313
Modules completed: ............................................................................................................. 314
•

Discipline specific ...................................................................................................... 314

•

Employability skills .................................................................................................... 314

Conference presentations: ................................................................................................... 314

Table of figures.
Figure
1.1
1.2

Page
18
20

1.3
1.4

24
28

2.1

45

2.2

49

4.1

80

4.2

81

4.3

82

4.4

86

Caption
ThinPrep vial for liquid based cytology collection.
A-D are stained with the Pap stain to provide contrast between cell
types and cell components. Slides were prepared from BALs using a
ThinPrep 2000. A The flat, polygonal cells marked by red arrows are
indicative of morphologically normal squamous cells. B The blue
arrow indicates morphologically normal bronchial cells. The ciliated
epithelium is columnar with cilia bound on the flat surface by a
terminal plate. C Depiction of malignant squamous cells with
abnormal nuclei and increased keratin in the cytoplasm, evident by the
uptake of the orange OG6 stain. D Malignant bronchial cells forming
an acinar structure with pale chromatin and rounded edges.
Energy level diagram for Rayleigh, Stokes and anti-stokes scattering.
Schematic of the instrumentation of the HORIBA-Jobin-Yvon XploRA
Raman spectrometer.
Flow diagram of the process involved in applying vibrational
spectroscopy to bronchoscopy obtained specimens for cancer
detection. After obtaining the cytology/biopsy sample the biological
material is stored in a preservative. The tissue section or cellular
material is then fixed to a substrate such as a glass slide and left
unstained for spectroscopic analysis. Using a laser or an infrared
source, spectra are obtained by collecting the Raman scattered light or
transmitted light. The spectral data are then pre-processed to minimise
noise and spectral contaminations. Diagnostic features are then
extracted from the data with multivariate analytical techniques.
Depiction of a Raman spectrum showing the different spectral regions
and the corresponding biomolecules associated with each region. The
spectrum which represents a bronchial epithelial cell nucleus was
baseline corrected and the non-negatively constrained least squares
method was used to remove spectral contaminants from the substrate.
Depiction of stained and unstained bronchial cells (a), squamous cells
(b), and lymphocytes (c). The Pap stain was applied to provide contrast
between cell types and components. The corresponding mean Raman
spectra (± standard deviation) taken from the nuclei of each cell type
are shown. (d) The mean Raman spectrum of bronchial epithelial cell
nuclei taken from negative cases (blue, n=70) (n=the number of spectra
used), (e) the mean Raman spectrum of squamous cell nuclei taken
from negative cases (black, n=94), and (f) the mean Raman spectrum
of lymphocyte nuclei taken from negative cases (red, n=80).
Keratinizing tumour cells with cytoplasmic projections taken from
patients with squamous cell carcinoma. The cells are stained with the
Pap stain which was applied subsequent to Raman analysis. A-C are
images taken at x400 magnification, D is taken at x200 magnification.
Tumourous glandular cells taken from patients with adenocarcinoma
carcinoma. The cells are stained with the Pap stain which was applied
subsequent to Raman analysis. A is taken at x200 magnification, B-D
are taken at x400 magnification.
The difference spectrum between the mean Raman spectrum of
squamous cell nuclei taken from negative cases and the mean Raman
spectrum of bronchial epithelial cell nuclei taken from negative cases
is depicted in blue. The difference spectrum between the mean Raman
spectrum of squamous nuclei taken from negative cases and the mean
Raman spectrum of lymphocyte nuclei taken from negative cases is
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shown in red. The difference spectrum between the mean Raman
spectrum of lymphocyte nuclei taken from negative cases and the mean
Raman spectrum of bronchial nuclei taken from negative cases is
depicted in green. Shading indicates regions of the spectrum that were
significantly different (P < .01).
Mean Raman spectrum of negative bronchial nuclei (n= 70). Mean
Raman spectrum of a bronchial cell nucleus from SCC cases (n= 150).
Mean Raman spectrum of a bronchial nucleus from AC cases (n= 63).
Shading denotes the standard deviation.
Difference spectrum between the mean Raman spectrum of bronchial
epithelial cell nuclei taken from negative cases and the mean Raman
spectrum of bronchial epithelial cell nuclei taken from SCC cases
(blue, n=150), and the mean Raman spectrum of bronchial epithelial
cell nuclei taken from AC cases (red, n=63) the difference spectrum
between the bronchial epithelial cell nuclei taken from SCC and AC
cases (green). Shading indicates regions of the spectrum that were
significantly different (P < .01).
Mean Raman spectrum of a negative squamous cell nucleus (n= 94).
Mean Raman spectrum of a squamous nucleus from SCC cases
(n=189). Mean Raman spectrum of a squamous nucleus from AC cases
(n=67). Shading denotes the standard deviation.
Difference spectrum between the mean Raman spectrum of squamous
cell nuclei taken from negative cases and the mean Raman spectrum of
squamous cell nuclei taken from SCC cases (blue, n=189). Difference
spectrum between the mean Raman spectrum of squamous cell nuclei
taken from negative cases and the mean Raman spectrum of the nuclei
of cells with cytoplasmic projections taken from SCC cases (black,
n=60). Difference spectrum between the mean Raman spectrum of
squamous cell nuclei taken from negative cases and the mean Raman
spectrum of squamous cell nuclei taken from AC cases (red, n=67).
Difference spectrum between the mean Raman spectrum of squamous
cell nuclei taken from SCC cases and the mean Raman spectrum of
squamous cell nuclei taken from AC cases (green). Shading indicates
regions of the spectrum that were significantly different (P < .01).
Mean Raman spectrum of a lymphocyte nucleus form negative cases
(n= 80). Mean Raman spectrum of a lymphocyte nucleus from SCC
cases (n=114). Mean Raman spectrum of a lymphocyte nucleus from
AC cases (n=58). Shading denotes the standard deviation.
Difference spectrum between the negative lymphocyte nuclear
spectrum and the SCC lymphocyte nuclear spectrum (blue, n=114), (b)
the AC lymphocyte nuclear spectrum (red, n=58). Difference spectrum
between the mean Raman spectrum of lymphocyte nuclei taken from
SCC cases and the mean Raman spectrum of squamous cell nuclei
taken from AC cases (green). Shading indicates regions of the
spectrum that were significantly different (P < .01).
Mean Raman spectra of cytoplasm from negative bronchial cells
(black, n= 33), and negative squamous cells (blue, n=98). Shading
denotes the standard deviation.
The difference spectrum between the mean Raman spectrum from the
cytoplasm of squamous cells from negative cases and the mean Raman
spectrum from the cytoplasm of bronchial cells from negative cases is
depicted in blue. Shading indicates regions of the spectrum that were
significantly different (P < .01).
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Mean Raman spectrum of a negative bronchial cell cytoplasm (n= 33).
Mean Raman spectrum of a bronchial cell cytoplasm from SCC cases
(n=68). Mean Raman spectrum of a bronchial cell cytoplasm from AC
cases (n=46). Shading denotes the standard deviation.
Difference spectrum between the mean Raman spectrum of negative
bronchial epithelial cell cytoplasm (n=33) and (a) and the mean Raman
spectrum of SCC bronchial epithelial cell cytoplasm (blue, n=68), (b)
the mean Raman spectrum of AC bronchial epithelial cell cytoplasm
(red, n=46). Difference spectrum between the mean Raman spectrum
of bronchial cell cytoplasm taken from SCC cases and the mean
Raman spectrum of bronchial cell cytoplasm taken from AC cases
(green). Shading indicates regions of the spectrum that were
significantly different (P < .01).
Mean Raman spectrum of a negative squamous cell cytoplasm (n= 98).
Mean Raman spectrum of a squamous cytoplasm from SCC cases
(n=91). Mean Raman spectrum of a squamous cytoplasm from AC
cases (n=43). Shading denotes the standard deviation.
Difference spectrum between the mean Raman spectrum of negative
squamous cell cytoplasm (n=98) and (a) and the mean Raman
spectrum of SCC squamous cell cytoplasm (blue, n=91), (b) the mean
Raman spectrum of AC squamous cell cytoplasm (red, n=43).
Difference spectrum between the mean Raman spectrum of squamous
cell cytoplasm taken from SCC cases and the mean Raman spectrum of
squamous cell cytoplasm taken from AC cases (green). Shading
indicates regions of the spectrum that were significantly different (P <
.01).
A PCA scatter plot of bronchial, squamous and lymphocyte nuclei
from negative cases shows that the bronchial and squamous spectra
form two distinct clusters along the first principal component. The
lymphocyte spectra are dispersed evenly along PC1 and PC2 and
cannot be discriminated from the bronchial or squamous cells. B The
loadings of PC1 show peaks assigned to
-1
glycogen/cholesterol/protein/phospholipids (420-690 cm ), nucleic
-1
acids (762-788 cm ), glycogen/cholesterol/saccharides/protein/nucleic
-1
acids (805-1011 cm ), glycogen/peaks related to collagen (1024-32
-1
-1
cm ), amide III/nucleic acid (1245-60 cm ), lipids/protein/amide I
-1
(1436-45, 1620-60 cm ) on the positive side, and peaks assigned to
-1
lipid/protein/nucleic acids/phosphates (1129-1200, 1351 cm ),
lipid/protein/COO /nucleic acids/cytosine (1450-1546, 1564-82, 1611
-1
cm ), and amide I disordered structure/β sheets/lipids (1680-1719 cm
1
) on the negative side.
Three-dimensional scatter plot of the first three principal components
showing no discrimination of spectra taken from the bronchial nuclei
of negative, SCC and AC cases.
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A Scatter plot showing spectra taken from the bronchial nuclei of SCC
and AC cases. The AC spectra form a tight cluster in the positive side
of PC4, whereas the SCC spectra are widely distributed along PC4.
-1
The loadings of PC4 indicate variation in methionine (715 cm ),
-1
-1
nucleic acids (779 cm ), saccharides (840, 860 cm ), phenylalanine
-1
-1
(1004 cm ), amide III/nucleic acids (1220 cm ), and amide I (1660
-1
cm ) associated with the positive side, and peaks assigned to protein
-1
-1
-1
(1100 cm ), glycogen (1145 cm ), nucleic acids/protein (1340 cm ),
-1
-1
lipid (1379 cm ), aspartic/glutamic acid (1400 cm ), protein/collagen
-1
-1
(~930, 1445 cm ), and COO (1585 cm ) associated with the negative
side.
PCA scatter plot of the first two principal components showing no
discrimination of spectra taken from the squamous nuclei of negative,
SCC and AC cases. PCA did not discriminate between the negative,
SCC and AC cases using a combination of PC that explained the first
95% of the variance in the dataset.
PCA scatter plot of the first two principal components showing no
discrimination of spectra taken from the squamous nuclei of SCC and
AC cases. PCA did not discriminate between the negative, SCC and
AC cases using a combination of PCs that explained the first 95% of
the variance in the dataset.
A Scatter plot showing the distribution of spectra taken from
lymphocyte nuclei of negative cases, SCC, and AC cases, along the
first and second PCs. PCA did not discriminate between the negative,
SCC and AC cases using a combination of PCs that explained the first
95% of the variance in the dataset.
PCA scatter plot showing spectra from the nuclei of lymphocytes,
bronchial, and squamous cells of negative cases, SCC cases and AC
cases, grouped according to a negative or malignant diagnosis. The
negative cases (blue circles) cannot be discriminated from the
malignant cases (blue circles) using PCA, which is depicted by the
distribution of spectra along the first and second PCs.
PCA scatter plot showing spectra from the nuclei of lymphocytes,
bronchial and squamous cells of SCC, and AC cases grouped
according to the lung cancer subtype. PCA did not discriminate
between the SCC and AC groups using a combination of PCs that
explained the first 95% of the variance in the dataset.
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A PCA scatter plot of spectra taken from the cytoplasm of bronchial
and squamous cells of negative cases shows that the bronchial and
squamous spectra form two distinct clusters along the first and second
principal components. B The loadings of PC1 show peaks assigned to
-1
cholesterol/lipids/methionine (409-695cm ),
protein/proline/hydroxyproline/saccharides/glycogen (853-57, 896-970
-1
-1
cm ), saccharides/lipids/proteins (1106-1125 cm ),
-1
-1
lipids/proteins/nucleic acids (1296-1333 cm ), amide I (1656 cm ),
-1
and lipids (1699-1751 cm ) on the positive side and the pyrimidine
-1
-1
ring breathing mode at 766 cm , phenylalanine (1006 cm ),
-1
tyrosine/nucleic acids (1159-91 cm ), amide III/nucleic acids (1217-1
-1
1268 cm ), the protein/lipid/saccharide peaks at 1356-1415 cm , the
-1
lipid/protein peak at 1445 cm , disaccharides/amide II/nucleic
-1
acids/COO (1460-1595 cm ), and amide I of disordered structure/β
-1
sheets (1674-1690 cm ) on the negative side. The loadings of PC2
-1
show peaks assigned to proline/valine/saccharides (~930 cm ) and
-1
amide I (1656 cm ) on the negative side.
A PCA scatter plot showing the discriminatory performance of a PCA
model developed using spectra taken from the bronchial cytoplasm of
negative, SCC and AC cases. A three dimensional scatter plot
demonstrates the discrimination of the three clusters of spectra. PC1
differentiates the SCC cases and the AC cases. A combination of PC2
and PC3 separates the negative cases from the SCC and AC cases. PC2
is mainly responsible for discriminating negative and AC spectra. PC3
discriminates the negative and SCC clusters. B The loadings of PC1
show positive peaks associated with amide III/nucleic acids (1250 cm
1
-1
-1
), proteins (~1330 cm ), lipids (1445 cm ), and negative peaks
-1
associated with amide I and II (~1500-1650 cm ). The loadings of PC2
show peaks assigned to proteins/carbohydrates/nucleic acids (735-890
-1
-1
cm ), phenylalanine (1000 cm ), amide III/nucleic acids (1200-1280
-1
-1
cm ), and amide I of disordered structure/β sheets (1690 cm ) on the
positive side and nucleotides/phosphatidylinositol/glycerol (570-620
-1
-1
cm ), carbohydrates/proteins/lipids (1100-1145 cm ), collagen (~1330
-1
-1
-1
cm ), protein (~1410 cm ), and amide I (1650 cm ) on the negative
side. The loadings of PC3 indicate positive peaks associated with
-1
-1
increased saccharides (850 cm ), proline/valine (930 cm ), and protein
-1
-1
(1410 cm ), and decreased phosphatidylinositol (~570-80 cm ), and
-1
amide I (1650 cm ).
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A PCA scatter plot of spectra from the cytoplasm of squamous cells
showing variance between the negative cluster and the SCC and AC
clusters along PC1, with some overlap. The majority of spectra from
negative cases are distributed in the negative side of PC1, whereas the
majority of spectra SCC and AC cases are distributed along the
positive side of PC1. The SCC and AC spectra form overlapping
clusters and cannot be discriminated with PCA. B The loadings of PC1
show peaks assigned to protein/collagen (1169, 1223, 1240-47, 1265-1
69, 1278, 1280, 1283, 1336, 1344, 1488 cm ) phenylalanine (995-1
-1
-1
1004 cm ), glycogen (1048 cm ), tyrosine (1165-1171 cm ), amide
-1
-1
III/ lipids (1219-92, ~1337 cm ), amide II (1472-89 cm ), and amide I
-1
of disordered structure/β sheets (1674-1688 cm ) on the positive side,
-1
and cholesterol (418, 424-432, 608, 614, 702 cm ), saccharides (451-1
-1
502 cm ), phosphatidylinositol/proteins (508-527 cm ),
-1
proteins/nucleic acids/carbohydrates/lipids (568-726 cm ),
-1
-1
proline/valine(935, ~950 cm ), amide I (1594-1657 cm ), and lipid
-1
(~1750 cm ) on the negative side.
A PCA scatter plot showing spectra from the cytoplasm of bronchial
and squamous cells of negative cases, SCC cases and AC cases,
grouped according to a negative or malignant diagnosis. The negative
and malignant cases cannot be discriminated. The malignant cases (red
circles) form a cluster along PC1, whereas the negative cases (blue
circles) are evenly distributed along PC1. B The loadings of PC1
-1
revealed a greater variation in phosphatidylinositol (575 cm ), glucose
-1
-1
(908 cm ), proline/valine/saccharides (~935 cm ), saccharide (1110
-1
-1
cm ) and amide I (1650cm ) in the negative cases. The loadings of
PC1 are similar to the loadings discriminating spectra from the
cytoplasm of bronchial and squamous cells from negative cases,
indicating that the variation explained by PC1 is likely the difference
between the bronchial and squamous cells.
A PCA scatter plot showing spectra from the cytoplasm of bronchial
and squamous cells of SCC, and AC cases grouped according to the
lung cancer subtype. The SCC and AC cases cannot be discriminated
with PCA, which is depicted with a plot of the first two PCs. The AC
cases (red circles) form a two distinct clusters along PC1. B The
loadings of PC1 are similar to the loadings discriminating spectra from
the cytoplasm of bronchial and squamous cells from negative cases,
indicating that the two distinct clusters are likely a separation of the
bronchial and squamous cells from AC cases.
LV score scatter plot of Raman spectra from bronchial nuclei of
negative cases (blue circles), squamous nuclei of negative cases (green
squares), and lymphocyte nuclei of negative cases (solid red circles).
The three-way classification model used the first 3 latent variables and
yielded sensitivities and specificities of 69-94% for discrimination
based on cell type. B and C Latent variables loadings of the developed
PLS-DA model for the dataset obtained from the bronchial, squamous,
and lymphocyte nuclei of negative cases.
A Scatter plot of the latent variables (LVs) obtained from the Raman
spectral dataset of bronchial nuclei from negative cases (blue circles),
SCC cases (green squares), and AC cases (solid red circles). B and C
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Latent variables loadings of the developed PLS-DA model for the
dataset obtained from bronchial nuclei.
A Scatter plot of the first two LVs obtained from the Raman spectral
dataset of squamous nuclei from negative cases (blue circles), SCC
cases (green squares), and AC cases (solid red circles). B Scatter plot
of the first and third LVs obtained from the Raman spectral dataset of
squamous nuclei from negative cases (blue circles), SCC cases (green
squares), and AC cases (solid red circles).
Latent variables from PLSDA of Raman spectra from squamous nuclei
of negative cases, SCC cases, and AC cases. ). A-C The Latent
variables loadings of the developed PLS-DA model for the dataset
obtained from squamous nuclei. A depicts LV1, B shows the loadings
of LV2, and C illustrates the loadings of LV3.
A Scatter plot of the LVs obtained from the Raman spectral dataset of
lymphocyte nuclei from negative cases (blue circles), SCC cases
(green squares), and AC cases (solid red circles). B and C Latent
variables loadings of the developed PLS-DA model for the dataset
obtained from lymphocyte nuclei.
A Scatter plot of the first and third LVs obtained from the Raman
spectral dataset of combined bronchial, squamous, and lymphocyte
nuclei. Representative spectra from each cell type from the negative,
SCC, and AC cases were grouped according to a negative or malignant
diagnosis. The negative cases (red circles) are discriminated from the
malignant cases (blue circles) along the first and third LVs. B and C
Latent variables loadings of the developed PLS-DA model for the
dataset obtained from bronchial, squamous, and lymphocyte nuclei.
A Scatter plot showing spectra from the bronchial, squamous, and
lymphocyte nuclei of SCC and AC cases grouped according to the lung
cancer subtype. The AC cases (red circles) are discriminated from the
SCC cases (blue circles) along the first and second LVs. B and C
Latent variables loadings of the developed PLS-DA model for the
dataset obtained from bronchial, squamous, and lymphocyte nuclei.
A Scatter plot of the LVs obtained from the Raman spectra taken from
the cytoplasm of bronchial cells from negative cases (blue circles),
SCC cases (green squares), and AC cases (solid red circles). B and C
Latent variables loadings of the developed PLS-DA model for the
dataset obtained from the cytoplasm of bronchial cells.
A Scatter plot of the LVs obtained from the Raman spectra taken from
the cytoplasm of squamous cells from negative cases (blue circles),
SCC cases (green squares), and AC cases (solid red circles). B and C
Latent variables loadings of the developed PLS-DA model for the
dataset obtained from the cytoplasm of squamous cells.
A Scatter plot showing spectra from the cytoplasm of bronchial and
squamous cells of negative cases, SCC cases and AC cases, grouped
according to a negative or malignant diagnosis. The negative cases
(green circles) are discriminated from the malignant cases (blue
circles) along the first and second LVs. B and C Latent variables
loadings of the developed PLS-DA model for the dataset obtained from
the cytoplasm of bronchial and squamous cells.
A Scatter plot showing spectra from the cytoplasm of bronchial and
squamous cells of SCC, and AC cases grouped according to the lung
cancer subtype. The AC cases (red circles) are discriminated from the
SCC cases (blue circles) along the first LV. B The Latent variable
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loadings of the developed PLS-DA model for the dataset obtained from
the cytoplasm of bronchial and squamous cells.
The mean Raman spectra (± standard deviation) taken from the nuclei
of bronchial epithelial cells from negative cases (black, n=70), TPSCC cases (blue, n=93), and FN-SCC cases (red, n=48).
Difference spectrum between the mean Raman spectrum of bronchial
epithelial cell nuclei taken from negative cases and (a) the mean
Raman spectrum of bronchial epithelial cell nuclei from TP-SCC cases
(blue, n=93), (b) the mean Raman spectrum of bronchial epithelial cell
nuclei from FN-SCC cases (red, n=48). (c) Difference spectrum
between the mean Raman spectrum of bronchial epithelial cell nuclei
from TP-SCC cases and the mean Raman spectrum of bronchial
epithelial cell nuclei from FN-SCC cases (green). Shading indicates
regions of the spectrum that were significantly different (P < 0.01).
The mean Raman spectra (± standard deviation) taken from the nuclei
of squamous cells from negative cases (black, n=94), TP-SCC cases
(blue, n=137), and FN-SCC cases (red, n=35).
Difference spectrum between the mean Raman spectrum of squamous
cell nuclei taken from negative cases and (a) the mean Raman
spectrum of squamous cell nuclei from TP-SCC cases (blue, n=137),
(b) the mean Raman spectrum of squamous cell nuclei from FN-SCC
cases (red, n=35). (c) Difference spectrum between the mean Raman
spectrum of squamous cell nuclei from TP-SCC cases and the mean
Raman spectrum of squamous cell nuclei from FN-SCC cases (green).
Shading indicates regions of the spectrum that were significantly
different (P < 0.01)
The mean Raman spectra (± standard deviation) taken from the nuclei
of bronchial epithelial cells from negative cases (black, n=70), TP-AC
cases (blue, n=25), and FN-AC cases (red, n=21).
Difference spectrum between the mean Raman spectrum of bronchial
epithelial cell nuclei taken from negative cases and (a) the mean
Raman spectrum of bronchial epithelial cell nuclei from TP-AC cases
(blue, n=25), (b) the mean Raman spectrum of bronchial epithelial cell
nuclei from FN-AC cases (red, n=21). (c) Difference spectrum
between the mean Raman spectrum of bronchial epithelial cell nuclei
from TP-AC cases and the mean Raman spectrum of bronchial
epithelial cell nuclei from FN-AC cases (green). Shading indicates
regions of the spectrum that were significantly different (P < 0.01).
The mean Raman spectra (± standard deviation) taken from the nuclei
of squamous cells from negative cases (black, n=94), TP-AC cases
(blue, n=25), and FN-AC cases (red, n=20).
Difference spectrum between the mean Raman spectrum of squamous
cell nuclei taken from negative cases and (a) the mean Raman
spectrum of squamous cell nuclei from TP-AC cases (blue, n=25), (b)
the mean Raman spectrum of squamous cell nuclei from FN-AC cases
(red, n=20). (c) Difference spectrum between the mean Raman
spectrum of squamous cell nuclei from TP-AC cases and the mean
Raman spectrum of squamous cell nuclei from FN-AC cases (green).
Shading indicates regions of the spectrum that were significantly
different (P < .01).
A PCA scatter plot of bronchial cells from from negative cases, TP-SCC
cases, and FN-SCC cases. The spectra from TN cases and TP-SCC cases
form two adjacent, overlapping clusters along the first PC. The spectra
taken from bronchial cells of FN-SCC cases were distributed evenly
8

along PC1 and PC2 and could not be discriminated using PCA. B On
the positive side of the first principal component peaks at 650, 850, 925,
1004, 1210-1280 cm-1, ~1350, 1450, and 1680 cm-1 can be
distinguished. While peaks at and 780 cm-1 and 1500-1645 cm-1 can be
distinguished on the negative side.
PCA scatter plot of spectra taken from squamous cells from TN cases,
TP-SCC cases, and FN-SCC cases shows no separation with even
distribution along the first two principal components.
A PCA scatter plot of bronchial cells from TN cases, TP-AC cases, and
FN-AC cases. The spectra from TP-AC cases and FN-AC cases form
two distinct clusters along the first principal component. The spectra
from negative cases are dispersed along the first two PCs and cannot
be discriminated. B. On the positive side of the first principal
component, peaks at 650, 850, 1210-1280, 1350, 1420-50, 1680 cm-1
can be distinguished. While peaks at 780, 1105, 1500-1650 cm-1 can be
distinguished on the negative side.
A PCA scatter plot of squamous cells from TN cases, TP-AC cases,
and FN-AC cases. The spectra from TP-AC cases and FN-AC cases
form two distinct clusters along the first principal component. The
spectra from TN cases are dispersed along the first two PCs and cannot
be discriminated. B. On the positive side of the first principal
component, peaks at 650, 850, 1004 cm-1, 1210-1270, ~1360, 1420-50,
and ~1680 cm-1 can be distinguished. While peaks at 780 cm-1 and
1480-1655 cm-1 can be distinguished on the negative side.
Cases of SCC stained with Haematoxylin and Eosin. A-F show nests
of malignant squamous epithelial cells with large eosinophilic
cytoplasm and intercellular bridges. A-D are at x200 magnification, E
and F are at x400 magnification.
Cases of AC stained with Haematoxylin and Eosin. A-F show
adenocarcinomas with acinar formation, mucinous vacuoles and signet
ring cells. A-D are at x200 magnification, E and F are at x400
magnification.
Normal tissue stained with Haematoxylin and Eosin. A shows normal
bronchial epithelium with mucinous glands at x200 magnification. B
shows normal mucinous glands at x400 magnification. C shows
normal bronchial epithelium at x400 magnification. D shows normal
bronchial epithelium at x200 magnification. E and F show normal
bronchial epithelium at x400 magnification.
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Case of NSCLC-NOS stained with Haematoxylin and Eosin. A
and B show abnormal cellular and nuclear morphology however
there are no defining characteristics for AC or SCC. A is at x200
magnification, B is at x400 magnification.
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Case of Atypical carcinoid stained with Haematoxylin and Eosin. A
and B Sheets of tumour cells that have uniform round nuclei. The
tumour cells form nests which are sharply distinct from the stroma. A
is at x200 magnification, B is at x400 magnification.
Mean Raman spectrum of the grouped negative tissue (black, n= 112).
Mean Raman spectrum of the grouped malignant tissue (red, n=119).
Shading denotes the standard deviation. The spectral data has been
subject to NNLS for removal of wax peaks, however strong wax peaks
remain in the spectra at 1060 and 1294 cm-1.
A PCA scatter plot of processed negative and malignant tissue shows a
separation on the fifth principal component with even distribution
along the first principal component. B Wax spectral peaks influence
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213
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214
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215
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216

6.13

217-218
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219

the fifth principal component, along which the spectra from negative
and malignant tissue are separated. Shading denotes the wax related
peaks influencing the fifth principal component.
Mean spectrum taken from negative tissue (n= 112 spectra). Wax
related peaks in the ranges of 877 to 895, 1050 to 1072, 1115 to 1183,
1280 to 1311, and 1400 to 1500 cm-1 were removed for analysis.
Shading denotes the standard deviation.
Difference spectrum between the mean Raman spectrum of negative
tissue and the mean Raman spectrum taken from SCC tissue (blue,
n=141), AC tissue (red, n=70), NSCLC-NOS (green, n=25), atypical
carcinoid (magenta, n=25), and grouped spectra from malignant tissue
(light blue, n=119). Shading indicates regions of the spectrum that
were significantly different (P < 0.01). Variables were excluded from
spectral analysis in the ranges of 877 to 895, 1050 to 1072, 1115 to
1183, 1280 to 1311, and 1400 to 1500 cm-1, as the spectra indicated
wax contamination.
Difference spectrum between the mean Raman spectrum of SCC tissue
(n=141) and the mean Raman spectrum taken from AC tissue (n=70).
Variables were excluded from spectral analysis in the ranges of 877 to
895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and 1400 to 1500 cm-1,
as the spectra indicated wax contamination.
A PCA scatter plot of processed negative and malignant tissue shows a
separation on the fourth principal component with comparable
distribution along the first principal component. B Fourth PC after wax
contribution was removed. On the positive side of the fourth principal
component, phenylalanine related peak 570 cm-1, 1004 cm-1 and 1585
cm-1 can be distinguished. While peaks at 715, 850, 925, 1233, and
1645 cm-1 can be distinguished on the negative side. Variables were
excluded from PCA analysis in the ranges of 877 to 895, 1050 to 1072,
1115 to 1183, 1280 to 1311, and 1400 to 1500 cm-1, as the spectra
indicated wax contamination.
PCA scatter plot of SCC and AC tissue shows no separation with even
distribution along the first two principal components. Variables were
excluded from PCA analysis in the ranges of 877 to 895, 1050 to 1072,
1115 to 1183, 1280 to 1311, and 1400 to 1500 cm-1, as the spectra
indicated wax contamination.
A. PCA scatter plot of processed SCC, AC and NSCLC-NOS tissue
shows that the SCC and NSCLC-NOS spectra form two distinct
clusters along the second principal component. The AC spectra are
dispersed along the second PC and cannot be discriminated from SCC
or NSCLC. B. On the positive side of the second principal component,
peaks at 715, 780, 1185, 1200, ~1360, and ~1575 cm-1 can be
distinguished. While some peaks at 560, 1004, 860, 930, 1030, 10751114, 1230, and 1650 cm-1 can be distinguished on the negative side.
Variables were excluded from PCA analysis in the ranges of 877 to
895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and 1400 to 1500 cm-1,
as the spectra indicated wax contamination.
A Scatter plot of the principal component scores of representative
spectra from negative, SCC, AC, NSCLC-NOS, and atypical carcinoid
tissue. A combination of PC1 and PC3 separates the SCC and AC
clusters from the negative, NSCLC-NOS and atypical carcinoid
spectra, with some overlap. The negative, NSCLC-NOS, and atypical
carcinoid tissue shows similar distribution along the first and third
principal components. B Loadings from PC1 and PC3. Variables were
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excluded from PCA analysis in the ranges of 877 to 895, 1050 to 1072,
1115 to 1183, 1280 to 1311, and 1400 to 1500 cm-1, as the spectra
indicated wax contamination.
LV score scatter plot of Raman spectra from negative tissue (blue
circles), and grouped spectra from malignant tissue (red circles).
Variables were excluded from PCA analysis in the ranges of 877 to
895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and 1400 to 1500 cm-1,
as the spectra indicated wax contamination.
LV score scatter plot of Raman spectra from negative tissue (blue
circles), SCC tissue (green circles), and AC tissue (red circles).
Variables were excluded from PCA analysis in the ranges of 877 to
895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and 1400 to 1500 cm-1,
as the spectra indicated wax contamination.
Mean Raman spectrum of the benign cell line (NThy-ori 3-1) with the
standard deviation shown as shading, and the different spectral regions
with corresponding biomolecules.
Difference spectrum between (a) Nthy-ori 3-1 (benign) and FTC cell
line XTC1; (b) Nthy-ori 3-1 and PTC cell line K1; (c) Nthy-ori 3-1 and
PTC cell line TPC1. Shading indicates regions of the spectrum that
were significantly different (p<0.05).
Difference spectrum between (a) Nthy-ori 3-1 (benign) and 8505C
(UTC); and (b) Nthy-ori 3-1 and C643 (UTC). Shading indicates
regions of the spectrum that were significantly different (p<0.05).
Difference spectrum between (a) Nthy-ori 3-1 (benign) and
CRL1803TT (MTC); (b) Nthy-ori 3-1 and MZCRC1 (MTC). Shading
indicates regions of the spectrum that were significantly different
(p<0.05).
Scatter plot of the linear discriminant scores of the benign spectra and
representative spectra from each TC subtype using PC-LDA.
Blood scale index used to classify patient samples as having no blood
contamination (Group 0), low contamination (Group 1), medium
contamination (Group 2), and heavy contamination (Group 3).
Group 2 samples which received 5 cytolyt washes and 3 minutes H2O2
on the slide. (a) Prepared using a gynae filter for ThinPrep®, and (b)
Prepared using a non-gynae filter. The red arrows highlight areas with
an accumulation of blood debris. (a) and (b) are at x400 magnification.
(a) Group 0 cells representing a negative control for the presence of
blood (sample 10). (b) Group 1 which received blood removal
treatment (sample 2). The comparable presentation of the slides
indicates that microscopic traces of blood have been successfully
removed from sample 2. (a) and (b) are at x200 magnification.
A positive control for the presence of blood (sample 11). (b) Group 2
which received blood removal treatment (sample 6). The red arrows
highlight areas with an accumulation of blood debris. (a) and (b) are at
x200 magnification.
(a) A positive control for the presence of blood (sample 11). (b) Group
3 which received blood removal treatment (sample 8). The red arrows
highlight areas with an accumulation of blood debris. (a) and (b) are at
x200 magnification.
(a) Group 0 cells representing a negative control for the presence of
blood (sample 10). (b) Group 1 which received blood removal
treatment (sample 3). The comparable presentation of the slides
indicates that microscopic traces of blood have been successfully
removed from sample 3. (a) and (b) are at x400 magnification.
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(a) A positive control for the presence of blood (sample 11). (b) Group
2 which received blood removal treatment (sample 5). The red arrows
highlight areas with an accumulation of blood debris. (a) and (b) are at
x400 magnification.
(a) A positive control for the presence of blood (sample 11). (b) Group
3 which received blood removal treatment (sample 7). The red arrows
highlight areas with an accumulation of blood debris. (a) and (b) are at
x400 magnification.
Mean spectrum of a HeLa cell line. The cells were not contaminated
with blood and are used as a reference spectrum or negative control.
Spectrum of blood representing the positive control.
Raman spectrum taken from a group I sample indicating burning. Cells
were exposed to H2O2 on the ThinPrep slide. There are no distinct
biological features in the spectrum.
Difference spectra of the HeLa cells in group 1. (a) corresponds to
sample 1 in Table 8.2 (b) the difference spectra for sample 2, (c) the
difference spectra for sample 3, this sample was subjected to 4 CytoLyt
washes and 3 minutes exposure to hydrogen peroxide.
Difference spectra of the HeLa cells in group 2. (a) corresponds to
sample 4 in Table 8.2 (b) the difference spectra for sample 5, (c) the
difference spectra for sample 6, this sample was subjected to 5 CytoLyt
washes and 5 minutes exposure to hydrogen peroxide.
Difference spectra of the HeLa cells in group 3 (a) corresponds to
sample 7 in Table 4.2 (b) the difference spectra for sample 8, (c) the
difference spectra for sample 9.
Depiction of how the samples were combined to yield sufficient
cellular material for Raman spectroscopic analysis.
(a) Mean spectra of the benign thyroid cells (N1) and the thyroid
cancer cells (T1), (b) the difference spectrum between benign thyroid
cells and thyroid cancer cells with the statistically significant Raman
peaks highlighted in grey. Shading indicates regions of the spectrum
that were significantly different (p<0.05).
(a) Mean spectra of the benign thyroid cells N2 and the thyroid cancer
cells (T2), (b) the difference spectrum between benign thyroid and
thyroid cancer. Shading indicates regions of the spectrum that were
significantly different (p<0.05).
PCA scores plot of benign thyroid cells (orange) and tumour cells
(blue) attained from FNAC samples. (a) Scatter plot of T1 (blue) and
N1 (orange) using PC2 and PC3. (b) Scatter plot of T2 (blue) and N2
(orange) using PC2 and PC5.
Loadings plot of PC2 discriminating the benign and cancer cells in
Figure 8.18 (a), Peaks with higher intensity highlight the prominent
differences between benign and cancerous thyroid cells.
Loadings plot of PC5 discriminating the benign and cancer cells in
Figure 8.18 (b).
Steel slide ThinPrep® made with sample 1 post treatment. No cellular
material can be seen.
Depiction of cellular material and debris on the steel slide after the
sample received treatment. The cell marked with a red box and shown
at a greater magnification was targeted for spectroscopic analysis.
Acquired with the laser power set to 50% the raw spectra indicate the
presence of biological peaks with a high background signal.
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Depiction of cellular material and debris on the steel slide after the
sample received treatment. The cell marked with a red box and shown
at a greater magnification was targeted for spectroscopic analysis.
Acquired with the laser power set to 50% the raw spectra indicate the
presence of biological peaks with a high background signal.
Depiction of cellular material and debris on the steel slide after the
sample received treatment. The cell marked with a red box and shown
at a greater magnification was targeted for spectroscopic analysis.
Acquired with the laser power set to 100% the raw spectra indicate a
strong biological signal with a high background signal.
Depiction of cellular material and debris on the steel slide after the
sample received treatment. The cell marked with a red box and shown
at a greater magnification was targeted for spectroscopic analysis.
Acquired with the laser power set to 100% the raw spectra indicate a
strong biological signal with a high background signal. Acquired with
the laser power set to 100% the raw spectra indicate a strong biological
signal with a high background signal.
Depiction of cellular material and debris on the steel slide after the
sample received treatment. The cell marked with a red box and shown
at a greater magnification was targeted for spectroscopic analysis.
Acquired with the laser power set to 100% the raw spectra indicate a
strong biological signal with a high background signal. Acquired with
the laser power set to 100% the raw spectra indicate a strong biological
signal with a high background signal.
The mean spectrum taken from the nuclei of cells in sample 5. The
spectrum has been processed with Savitsky-Golay smoothing,
rubberband baseline subtraction, and vector normalisation, to
maximise the intensity of cellular signals and minimise noise. Strong
cellular peaks in the processed spectrum are not swamped by blood
peaks.
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blood.
Tentative peak assignments for the significant Raman bands identified
by spectral variation analysis
The sensitivity, specificity and classification accuracy of a PC-LDA
model for discriminating the benign spectra from the thyroid cancer
cells.
Overview of the number of washes and method of H2O2 treatment used
for each sample.
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Chapter 1: Cancer cytopathology and Raman spectroscopy
1.1 Thesis outline
This thesis explores the use of Raman spectroscopy as an alternative or adjunct tool for
the diagnosis of cancer using cytological specimens, in particular non-small cell lung
cancer (NSCLC) and thyroid cancer (TC). The ability of Raman spectroscopy to detect
cancer is based on the production of a cellular biochemical fingerprint in the form of a
spectrum. The first chapter will describe the background of cytopathology and the
principle of Raman spectroscopy. As the primary objective of the PhD is based on
investigating the use of Raman spectroscopy for the discrimination of NSCLC subtypes,
Chapter 2 reviews the recent advances made for the diagnosis of NSCLC using vibrational
spectroscopy. The spectral processing and analytical methods used throughout the thesis
are detailed in Chapter 3. The work presented in Chapters 4 and 5 provide a body of
evidence that demonstrates the suitability of using Raman spectroscopy on bronchoscopy
cytology samples for the detection and differentiation of NSCLC subtypes. In Chapter 6,
Raman spectroscopy was applied to bronchial tissue sections with the aim to identify the
diagnostically relevant peaks, if any, discriminating the negative tissue and malignant
tissues, and to comparatively analyse the diagnostic effectiveness of applying Raman
spectroscopy to cytology specimens and tissue specimens.
As the secondary objective of the PhD is based on investigating the use of Raman
spectroscopy for the discrimination of thyroid cancer subtypes, Chapter 7 demonstrates
the ability of Raman spectroscopy to discriminate between thyroid cancer subtypes using
cell line models. The first section of Chapter 8 describes a blood removal protocol,
developed using cell lines, to prepare thyroid FNAC (fine needle aspiration cytology)
samples for Raman analysis. The blood removal method is then applied thyroid FNAC
samples taken from surgically removed thyroid specimens and the method is optimised
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further, allowing the identification of molecular differences between benign and
malignant thyroid samples. In the final section of Chapter 8, the application of Raman
spectroscopy to residual thyroid FNAC samples is achieved with further optimisation of
the blood removal protocol.

1.2 Cytopathology
1.2.1 Introduction to cytopathology
Cytology, the study of cells, and pathology, which is the study of disease, have been
combined since the 19th century to form a branch of cytology known as cytopathology,
which studies and diagnoses diseases at a cellular level 1. Cytological analysis allows a
more complete analysis of cell components in comparison to tissue sections, as cytology
allows whole cells to be visualised on a slide, whereas tissue sections are often cut and
viewed in profiles 2. Another advantage cytology has over histology is that the procedures
used to attain cytological samples for diagnostic purposes are safe and complications
rarely occur.
Aspiration cytology, such as fine needle aspiration (FNA) utilises a thin needle to aspirate
cells from the area of interest. It is frequently used to investigate readily accessible
palpable lesions in cases of thyroid cancer, breast cancer, and malignancy in the lymph
nodes. Lesions identified by CT-scan can also be sampled by ultrasound guided FNA 3–
6

. Exfoliative cytology, which is instrumental in cancer detection and screening, involves

the collection of exfoliated cells from the surface of the suspicious lesion. Exfoliative
specimens are obtained from brushings, washings, urine, sputum, scrapings, and smears,
and are routinely used in the diagnostic workup of lung cancer, oral cancer, bladder
cancer, skin cancer and cervical cancer

7–10

. After the clinician obtains the cytology

sample, the biological material is stored in a vial with preservative solution, as shown in

17

Figure 1.1. For cytological analysis, aspirated or exfoliated cells are fixed to a slide and
identified microscopically.

Figure 1.1. ThinPrep vial for liquid based cytology collection.
1.2.2 Normal cellular morphology and cancer nomenclature
To use cytopathology for the identification of disease, one must first have an
understanding of the regular function and growth patterns of the normal cells. Using
cytopathology for cancer diagnosis, cells are firstly categorised as either of epithelial or
nonepithelial origin, based on patient data and the cell morphology. There are four
prominent types of epithelia including squamous epithelium, glandular epithelium,
ciliated epithelium, and mesothelium, each have different morphologies11. On cytology,
non-cancerous squamous cells are commonly flat, polygonal, vary in size, have
distinguished cytoplasm, and they tend to retain their shape during preparation due to
high keratin content. Normal glandular epithelium generally presents as cuboidal or
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columnar cells on cytology. Their cytoplasm may be transparent due to the accumulation
of secretory products, and the nuclei are typically polarised, and are clear or have
moderate granularity with small nucleoli. The cytological presentation of non-cancerous
ciliated epithelium is often columnar with cilia bound on one flat surface by a terminal
plate. These cells are regularly seen in respiratory tract. Lining the body’s cavities,
mesothelial cells are cuboidal on cytology with transparent or lightly granular nuclei,
which may have nucleoli, and a dense perinuclear space. Cancers derived from epithelial
origin are classified as carcinomas and can be further classified based on the cell type
from which the cancer originated11. Squamous cell carcinomas are derived from
squamous epithelium, glandular epithelium give rise to adenocarcinomas, and carcinomas
originating from the mesothelia are called mesotheliomas. Conversely, cancers derived
from non-epithelial origins include sarcomas (malignancies of muscle, connective tissue
and bone), leukemias (cancers of blood cells), and other cancers of specialised tissues
such as lymphomas, which are cancers of the lymphatic system11.
1.2.3 The identification of neoplastic changes with cytopathology
Microscopically observable changes in cell morphology have been recognised as
indicators for cancer since the 19th century 1. Stains are routinely applied to allow the
observation of cells. The field of cytopathology advanced in the 1930s and 1940s with
the development of the Papanicolaou (Pap) stain, which provides a visible contrast
between cell components and different cell types, allowing the observation of an array of
cytoplasmic and nuclear features

1,12

. Cell chromatin pattern is revealed by the

Haematoxylin stain, and cytoplasmic contents are highlighted with acidic stains. Keratin
is stained a bright orange and metabolically active cells are stained as green, enabling the
differentiation and accurate identification of cell types12.
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Knowledge of normal cell configurations permits abnormalities and pathological
processes such as carcinogenesis to be identified

11,13

. Cell abnormalities indicative of

cancer includes changes in the cell size or shape, cell nuclear size, nuclear configuration,
and changes in the number and size of nucleoli, in comparison to normal cells of the same
origin. Specific nuclear aberrations may be used as prognostic indicators, and can be
characteristic of certain tumour types. For example, nuclear polylobulation is a typical
characteristic of many adenocarcinomas, and diffuse heterochromatin is a prevalent trait
in small cell lung cancers 11,14. Recognising the abnormal cytological patterns associated
with cancer is imperative for making an accurate diagnosis on stained cytology samples.
Figure 1.2 depicts morphologically normal and abnormal squamous cells and bronchial
cells stained with a Pap stain.

Figure 1.2 A-D are stained with the Pap stain to provide contrast between cell types and
cell components. Slides were prepared from BALs using a ThinPrep 2000. A The flat,
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polygonal cells marked by red arrows are indicative of morphologically normal squamous
cells. Image was taken at x200 magnification. B The blue arrow indicates
morphologically normal bronchial cells. The ciliated epithelium is columnar with cilia
bound on the flat surface by a terminal plate. Image was taken at x400 magnification. C
Depiction of malignant squamous cells with abnormal nuclei and increased keratin in the
cytoplasm, evident by the uptake of the orange OG6 stain. Image was taken at x1000
magnification. D Malignant bronchial cells forming an acinar structure with pale
chromatin and rounded edges. Image was taken at x400 magnification.
As well as the Pap stain, Immunohistochemistry (IHC) is another diagnostic method
commonly applied to cytological samples to aid cancer diagnosis 15–17. IHC is concerned
with the identification and distribution of cellular components through pinpointing
specific antigens 18. The application of IHC can be used to identify specific cell types by
labelling tissue specific biomarkers. The method is based on antigen-antibody
interactions, where the location of antibody binding is visualised by direct or secondary
antibody labelling methods 19.
1.2.4 Benefits and limitations of current methods
Cytopathology for cancer diagnosis is a cost effective, accurate and safe diagnostic tool,
commonly used for breast, thyroid, lung, and pancreatic cancers. Overall diagnostic
sensitivities for breast, thyroid, pancreatic and lung cancers range from 77 – 100%, and
diagnostic specificities range from 75.4% - 100%, using cytology

20–23

. Despite the

benefits of cytology for cancer diagnosis, a substantial rate of false negatives is reported,
with indeterminate and false negatives on cytology of 1.2-10.6% of breast cancer cases,
20% of pancreatic cancer cases, 16% of squamous cervical cancers, 52% of glandular
cervical cancers, and over 20% of thyroid cancer cases being reported

20–22,23

. With

current diagnostic techniques, well differentiated tumours exhibiting minimal neoplastic
changes, and benign features indistinguishable from malignant features lead to diagnostic
challenges for cytopathologists 20–22,24. As heterogeneity is a feature of many tumours and
morphological interpretation can be difficult, the use of adjunct diagnostic tools such as
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IHC are used to improve the accuracy of diagnosis and reduce the rate of indeterminate
and false diagnoses. Despite the effectiveness of IHC, the use of labels inhibits subsequent
testing of the cellular material.
To overcome current limitations and maximise the cell sample, there is a need for a new
label-free diagnostic tool for cytology that can detect neoplastic changes not evident by
cellular morphology, and can objectively distinguish benign and malignant cells. As
many enhanced diagnostic techniques such as nucleic acid amplification techniques and
biomarkers are destructive of the diagnostic sample, they do not overcome limitations
facing cytopathology. The application of deep learning technology in medical image
classification is a new field for cancer detection, and automated image interpretation is
very promising, yet deep learning for medical image processing is still in its infancy and
most likely will not aid diagnostic cytology in the near future 25. Vibrational spectroscopic
techniques, including Fourier transform infrared (FTIR) spectroscopy and Raman
spectroscopy have been shown to be highly sensitive tools for detecting malignancy,
however Raman spectroscopy is better suited to cytology due to having a smaller laser
point size that can target single cells and cellular components. Raman spectroscopy
provides comprehensive detail about the intracellular biochemistry in a non-destructive
manner and without the use of labels. As Raman spectroscopy is being investigated here
as an alternative or adjunct diagnostic method for cytology, it will be discussed in the
next section in more detail.

1.3 Raman spectroscopy
1.3.1 Raman spectroscopy for cancer diagnosis
Using Raman spectroscopy on cytological material could present as a new minimally
invasive diagnostic tool for cancer, as this spectroscopic technique has been shown to be
highly sensitive to neoplastic changes 26–28. Raman spectroscopy is a label-free diagnostic
22

technique which requires minimal sample preparation and allows the rapid acquisition of
detailed biochemical information. As the energy of the detected scattered radiation
corresponds to vibrational energy modes of specific molecules, a detailed spectral
fingerprint of a cell can be obtained, allowing for an objective assessment of the cellular
components

29

. Statistical analysis of the spectra is needed to expose details about the

biochemical composition of a sample, and any minute molecular and structural changes
induced by a cancerous state can be detected.
1.3.2 Principle
Raman spectroscopy is based on a scattering phenomenon. Scattering results from the
interaction between the photons and materials, such as molecules. As shown
schematically in figure 1.3, most photons colliding with molecules do not change their
energy after the collision. These collisions are called elastic collisions and the result of
these collisions is elastic scattering called Rayleigh scattering. Rayleigh scattering is a
two-photon process as a result of which there may be a change in direction of light but no
net change in frequency. On the other hand, inelastic collisions, after which the incident
photons change their energy, lead to inelastic scattering during which exchange of
vibrational energy occurs. The process is defined as Raman scattering. Raman scattering
is also a two-photon process by which a change in the energy of the colliding photon
occurs from hvo to hvo ± hvs where vo is the incident photon frequency, vs is the
frequency of the characteristic vibration of the scattering molecule and h is Planck’s
constant.
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Figure 1.3: Energy level diagram for Rayleigh, Stokes and anti-stokes scattering30.

For a molecular vibration to be Raman active, the net molecular polarisability must be
changed. The polarisability (α) represents the ability of an applied electric field, E, to
induce a dipole moment, μ0, in an atom or molecule. This process is represented
mathematically by the equations below 31–34:
𝜇 = 𝛼𝐸

Equation 1.1

where 𝛼 is the polarisability and 𝐸 is the strength of the electric field of the applied
electromagnetic radiation. This external electric field varies with time 𝑡 and oscillates at
frequency 𝜈 with amplitude 𝐸0. This can be given as:
𝐸 = 𝐸0cos2𝜋𝜈𝑡

Equation 1.2
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This external oscillating electric field will induce an oscillating dipole moment in the
molecule, the frequency of which will be the same as that of the electric field. This is
given as:
𝜇 = 𝛼𝐸0𝑐𝑜𝑠2𝜋𝜈𝑡

Equation 1.3

For a molecule vibrating with a frequency 𝑣0, the nuclear displacement Q is written as
𝑄 = 𝑄0𝑐𝑜𝑠2𝜋𝑣0𝑡

Equation 1.4

where 𝑄0 is a vibrational amplitude of nuclear displacement.
The polarisability of a molecule bond thus varies with nuclear displacement. α is a linear
function of Q if the amplitude of vibration is small, the polarisability of the molecule can
be approximated using the Taylor series expansion:
𝛿𝛼

𝛼 = 𝛼0 +(𝛿Q) 𝑄 +…

Equation 1.5

0

𝛿𝛼

where 𝛼0 is the equilibrium polarisability, (𝛿Q) is polarisability derivative which
0

describes the change in polarisability.
Combining equations 1.4 and 1.5 yields:
𝛿𝛼

𝛼 = 𝛼0 + (𝛿Q) 𝑄0𝑐𝑜𝑠2𝜋𝑣0𝑡

Equation 1.6

0

and substituting this value for 𝛼 into equation 1.3 gives:
𝛿𝛼

𝜇 = 𝛼0𝐸0𝑐𝑜𝑠2𝜋𝑣𝑡 + (𝛿Q) 𝑄0𝐸0(𝑐𝑜𝑠2𝜋𝑣0𝑡)(𝑐𝑜𝑠2𝜋𝑣𝑡)

Equation 1.7

0

Finally, a standard trigonometric identity can be applied:
1

𝑐𝑜𝑠𝐴 𝑐𝑜𝑠𝐵 = 2[cos(𝐴 − 𝐵) + cos(A + B)]

Equation 1.8
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This allows equation 1.7 to be written as:
𝛿𝛼

𝜇 = 𝛼0𝐸0𝑐𝑜𝑠2𝜋𝑣𝑡 + (𝛿Q)

Q0 E0
0

2

[𝑐𝑜𝑠2(𝑣 − 𝑣0 )𝑡 + 𝑐𝑜𝑠2𝜋(𝑣 + 𝑣0 )𝑡]

Equation 1.9

The oscillating polarisation reradiates light at the same frequency and thus the scattered
light has components of the frequencies represented in Equation 1.9. The first term of
equation 1.9 represents Rayleigh scattering (the frequency of the scattered photon is equal
to the frequency of the incident photon, ν), while the second term corresponds to the
Raman scattering of frequency (Stokes scattering) and (anti-Stokes scattering). At
ambient temperature, most of the molecules are in their vibrational ground state.
According to the Boltzmann distribution, a much smaller number of molecules are in a
vibrationally excited state. Therefore, the chances for a Raman interaction which transfer
vibrational energy to a molecule and leave a quantum of lower energy are much higher
than an interaction which leaves a quantum of higher energy. Raman scattering processes
are referred to as Stokes, resulting in quanta of lower energy, or anti-Stokes resulting in
quanta of higher energy 32. At room temperature, as most of the molecules are generally
in the ground vibrational state, Stokes Raman scattering most commonly occurs and is
usually measured. A plot of intensity of scattered light versus energy difference between
the incident light and the Raman scattered light is called Raman shift, is a Raman
spectrum. Raman shift is usually expressed in wavenumbers (cm-1).
1.3.3 Instrumentation
The source of monochromatic laser light can be different wavelengths, depending on the
intent of the experiment. The intensity of the laser light, which is adjustable, is determined
by a neutral density filter or by pin holes. In order to ensure only the laser light stimulates
the sample, an interference filter acts as a clean-up tool. Joining the Raman spectrometer
with a microscope makes it possible to analyse biological samples as the objective lenses
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deliver the laser while collecting the back scattered light. To inhibit interference from
Rayleigh scattering, the notch filter reflects scattered light of the same wavelength as the
incident laser and allows inelastically scattered light to pass through. A grating then
disperses the light. The spectral resolution is determined by multiple factors including;
the groove intensity of the grating (typically 300-1800 grooves/mm), the wavelength of
the excitation source, and the distance between the grating and the detector. A charge
coupled device (CCD) detector is used to collect the light as it allows a multichannel
operation, so that the entire Raman spectrum can be detected in a single spectrum. A
schematic of the HORIBA-Jobin-Yvon XploRA Raman spectrometer is shown in figure
1.4.
The material the sample is fixed to, the substrate, may contribute background noise to the
spectrum. Glass is the most applicable substrate for the clinical setting as it is cost
effective, and the signals derived from glass can be removed computationally to derive
the cellular signal35. A 785 nm laser source is capable of revealing comprehensive detail
about the intracellular biochemistry of a sample, however glass cannot be used a substrate
with this laser line as the fluorescence is strong at 785 nm, swamping the biological peaks
in the Raman spectrum. As the 785 nm laser requires more expensive substrates, this laser
line may not be suitable for clinical application, and may be better utilised in research.
Another difficulty in translating Raman spectroscopy to routine clinical use is the
insensitivity of the technique, as only 1 in 1x108 photons are Raman scattered36. Higher
wavelength laser lines such as 1064 nm, produce weaker Raman signals, and may not be
optimal for use in clinics. In order to be effective in a clinical setting, the method of
Raman spectroscopy utilised must therefore be cheap and maximise sensitivity. In this
project, a 532 nm laser was utilised to maximise the Raman signal, and glass was used as
a substrate to support the tissue.
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Figure 1.4. Schematic of the instrumentation of the HORIBA-Jobin-Yvon XploRA
Raman spectrometer.
1.3.4 Raman spectroscopic analysis of cytological samples
Raman spectroscopy has a multitude of attributes making it suitable for this study. As
cytological specimens are less invasive than tissue biopsies, an accurate diagnostic
technique which is applicable to cytology samples would reduce the need for invasive
biopsy procedures. With a laser resolution of 1 µm, Raman spectroscopy is capable of
analysing single cells and cellular components and is an ideal technique for investigating
cytology samples. Further, this spectroscopic technique has demonstrated the ability to
detect malignancies in a multitude of studies. In particular, the diagnostic capabilities of
applying Raman spectroscopy to cytology samples has previously been demonstrated
with bladder cancer, oral cancer, and cervical cancer 37–39.
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1.4 Summary
Cytological methods are minimally invasive and are routinely used for the diagnosis of
many cancers. However, many tumours are heterogeneous and morphological
interpretation can be difficult with current staining and IHC techniques. Raman
spectroscopy is a label free vibrational spectroscopic technique based on the inelastic
scattering of light, and has been shown in many studies to be a promising tool for cancer
diagnosis. As Raman spectra contain detailed biochemical information, statistical
analysis can be applied to the spectral dataset to detect molecular alterations associated
with cancer, allowing an objective analysis of cytological specimens. If Raman
spectroscopy shows the ability to differentiate tumour types based on their biochemical
fingerprint, then the potential to improve the diagnostic accuracy of cytology and preserve
residual material for subsequent molecular analysis for therapeutics is of clinical value.
1.4.1 Thesis objectives
The broad objectives of this thesis are to investigate the feasibility of applying Raman
spectroscopy to cytological specimens to detect non-small cell lung cancer (NSCLC) and
thyroid cancer. A more detailed description of the aims are;
1) To explore the feasibility of applying Raman spectroscopy to bronchoalveolar
lavage (BAL) and bronchial wash (BW) samples to provide a marker free
diagnosis of NSCLC subtypes, and to identify the biochemical changes
responsible for the classification.
2) To investigate the potential of Raman spectroscopy to identify malignant
signatures in NSCLC cases with clinical cytological analyses reported as
diagnostic or no malignant cells seen (NMCS).
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3) To analyse Raman spectra taken from bronchial tissues and compare the
diagnostic effectiveness of applying Raman spectroscopy to bronchoscopy
attained cytological samples and tissue samples for NSCLC diagnosis.
4) To investigate the Raman profiles of thyroid cancer cell lines, and to build a
classifier based on the Raman spectra to discriminate between the benign and
malignant cell lines.
5) To optimise a blood removal protocol suitable to prepare thyroid FNAC samples
for Raman analysis.
6) To discriminate between benign and malignant cells from thyroid FNAC samples.
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Abstract
Lung cancer is the leading cause of cancer deaths worldwide accounting for 1.69 million
deaths in 2015. Studies have indicated a 5 year survival rate of 8% to 15% in western
countries, although a survival rate as low as 1% has been demonstrated for late stage
diagnosis. With the advent of targeted therapies, it is imperative to accurately differentiate
non-small cell lung cancer (NSCLC) subtypes in order to ensure efficacy of treatment for
patients. Immunohistochemistry and molecular techniques for the diagnosis of NSCLC
are increasingly part of the diagnostic algorithm and clinical work-up of lung cancer
patients, however due to the limitation of small sample size, overlapping morphological
features and molecular characterisation, differential diagnosis of NSCLC still proves
challenging. Vibrational spectroscopy has shown promising results for the detection of a
variety of cancers and a limited number of studies have focused on lung cancer. Yet to
date there has been no published evaluation of vibrational spectroscopy on cytology
bronchoscopy samples which may eliminate the necessity for an invasive biopsy
procedure. Following an introduction to the epidemiology and etiological factors
associated with NSCLC, currently used diagnostic methods and their limitations are
presented. A thorough review of Raman and FTIR spectroscopic methods in lung cancer
diagnosis is then presented. On review of the literature, vibrational spectroscopy offers
an alternative or adjunct diagnostic method to be applied in bronchoscopy cytology
samples.
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2.1 Lung cancer
2.1.1 Introduction to Lung Cancer
With an estimated 2.1 million new cases and 1.76 million deaths in 2018, lung cancer
persists as the most common cancer worldwide, and represents the highest cancer
incidence and mortality rates in both developed and less developed countries 1,2. Studies
have indicated a 5 year survival rate of 8% to 15% in developed countries, although a
survival rate as low as 1% has been reported for late stage diagnosis

3–5

. Global lung

cancer incidence trends indicate that athough western regions such as Northern America
and Europe have the highest rates of incidence, the rate of incidence is declining in these
regions, while increasing in less developed regions

6,7

. These trends can be directly

correlated with smoking prevalence, as cigarette smoking is responsible for
approximately 85% of lung cancer cases 8. Other risk factors for non-smokers include
passive cigarette smoking and air pollution 9.
Lung cancer is divided into two main categories, small cell lung cancer (SCLC)
accounting for an estimated 13%-14% of cases, and non-small cell lung cancer (NSCLC),
which is the most common form of lung cancer accounting for approximately 85% of
cases

10–13

. Furthermore, NSCLC includes different histological subtypes including

squamous cell carcinoma (SCC), adenocarcinoma (AC) and large cell carcinoma. AC is
more prevalent in non-smokers and accounts for the largest portion of all lung cancer
cases at 44%, SCC is the second most common subtype, accounting for approximately
26% of lung cancer cases

10

. An epidemiological study14 examining sex differences in

lung cancer incidence and survival reported that women are more commonly diagnosed
at an earlier stage of lung cancer, and at an earlier age than men. The study also indicated
that regardless of age and stage of the disease at diagnosis, women have an increased
survival in comparison to men, and this is most evident with the AC subtype. Irrespective
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of sex, patient prognosis is dependent on the stage of the disease at diagnosis

15

. Table

2.1 illustrates the approximate 5 year survival rates for different stages of NSCLC 16–20.

Table 2.1. Progression stage, estimated 5 year survival rate, and appropriate treatments
for each stage of NSCLC 16–25.
Stage of
NSCLC

Progression stage

Approximate
5-year
survival rate
(%)

Treatment

Stage IA

Localised (<3cm)

75

Lobectomy/radiotherapy

Stage IB

Localised (3-5cm)

55

Lobectomy/radiotherapy

Stage
IIA

Localised (5-7cm) OR Spread to
nearby lymph nodes (<5cm)

50

Lobectomy/adjuvant
chemotherapy/radiotherapy

Stage
IIB

Spread to nearby lymph
nodes/diaphragm/mediastinal
pleura/parietal pericardium/bronchus
(5-7cm)
OR no spreading and >7cm

40

Lobectomy/adjuvant
chemotherapy/radiotherapy

Stage
IIIA

Spread to local lymph
10-35
nodes/heart/trachea/oesophagus/phrenic
nerve/ present in more than one lobe
(>7cm)

Radiotherapy/

Spread to lymph nodes of opposite lung <5
OR spread to lymph nodes in the
mediastinum and one or more of the
areas mentioned in stage IIIA or a main
blood vessel

Radiotherapy/

Metastasised to another body part,
other lung, caused malignant pleural
effusion/pericardial effusion

Combination of cytotoxic
chemotherapies/ palliative
care/ tyrosine kinase
inhibitors/radiotherapy

Stage
IIIB

Stage IV

<5

37

chemotherapy/immunotherapy/
tyrosine kinase inhibitors

chemotherapy/immunotherapy/
tyrosine kinase inhibitors

2.1.2 Current Treatment Options
Therapeutic strategies and patient management are dependent on the stage, subtype, and
mutation status of the malignancy

26

. Patients diagnosed with early stage (stage I and

stage II) lung cancer may avail of potentially curative treatment through surgical
resection. Although patients with early stage lung cancer have a 5 year survival rate of
over 70%, and chemotherapy post-surgery has been shown to benefit some stage II
patients, the risk of metastatic recurrence after surgery remains as high as 70%

13,15,27

.

However, over half of patients are diagnosed at advanced stage and are not eligible for
surgical resection. Treatments available for advanced stage disease include platinum
based chemotherapies, radiotherapy, immunotherapies and molecular targeted therapies,
including tyrosine kinase inhibitors (TKIs)

16–20,28

. In recent years combining

chemotherapy with the appropriate TKIs has been shown to increase progression free
survival of patients with advanced stage AC, although there is currently no cure 28.
Understanding the underlying molecular pathways involved with cancer cell progression
drives the development of novel therapeutics, and identifying and targeting molecules
that drive neoplastic proliferation has become a major tool for combatting lung cancer.
Specific therapies that inhibit carcinogenic pathways are now available for NSCLC
patients with genetic aberrations such as epidermal growth factor receptor (EGFR)
mutations, BRAF mutations and anaplastic lymphoma kinase (ALK) fusion
translocations 19,26,29. The EGFR gene encodes a receptor tyrosine kinase and mutations
of this gene are commonly observed in lung AC. EGFR mutations are reported in
approximately 50% of Asian AC patients, and 20% of Western patients with AC

30

.

Patients that are EGFR mutation positive have exhibited sensitivity to TKIs, such as
Gefitinib, which has been implemented in treatment regimens since 2003

31

. Another

molecular targeted therapy, Crizotinib, is recommended as first-line treatment for patients

38

with ALK gene rearrangements, which are present in approximately 3-6% of AC patients,
particularly in non-smokers

19,32–34

. The BRAF gene encodes a protein in the serine

threonine kinase family, and mutations are present in 1-3% of NSCLC patients 35,36. Two
therapies that target proteins in the serine threonine kinase family, dabrafinib and
trametinib, have been approved for patients with the BRAF mutation, and have been
shown to slow tumour growth 37,38.
As EGFR, ALK and BRAF mutations are targetable aberrations observed in AC, and as
TKIs are associated with increased progression free survival and a lower toxicity than
chemotherapeutic agents, molecular testing for these mutations on bronchoscopy
cytology samples has now become a major part of the diagnostic work up of NSCLC, and
is considered imperative for formulating treatment strategies 26,39–41.
Chemotherapy remains the cornerstone treatment strategy for most patients with SCC, as
targeting the potentially actionable mutations currently shows little therapeutic benefit for
patients with SCC. Although, the recent approval of the monoclonal antibody,
Necitumumab, as first-line therapy in metastatic SCC has been shown to improve overall
survival of patients with EGFR mutations 42.
The use of immunotherapeutics for patients with SCC is increasing. With the recent
approval of three immune checkpoint inhibitors, nivolumab, atezolizumab and
pembrolizumab, for SCC patients with PD-L1 positive tumours, patients receiving
immunotherapy demonstrate prolonged overall survival, increased objective response
rate and progression free survival, compared with systemic chemotherapy

21–25,43–45

.

Testing for PD-L1, which is an immune molecule capable of inhibiting an anticancer
immune response, is now part of the routine diagnostic algorithm of SCC

46–49

, and

expression is measured by the tumour proportion score. Patients with a proportion score
greater than 50% may avail of first-line treatment with immunotherapy.
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The increasing preference for personalised therapeutics for the treatment of NSCLC, is
not only due to the negative side effects imparted on patients by non-selective
chemotherapy, but also the increased progression free survival exhibited by patients in
receipt of targeted therapies compared to chemotherapy

50,51

. Research for novel

therapeutic markers is ongoing and includes studies investigating targetable molecules
that drive carcinogenic progression such as FGFR, VEGFR-2, DDR2, P13 Kinase and
PDGF, as well as novel immunotherapies 49,52. As more targets and subsequent therapies
are discovered, retaining adequate sample during the diagnostic work up of NSCLC for
molecular testing will be imperative for future treatment planning.
2.1.3 Current Methods for Differential Diagnosis of NSCLC Subtypes
With the introduction of targeted therapies and immunotherapies, distinction between
NSCLC and small cell lung cancer (SCLC) although paramount, is no longer adequate
and further sub-classification of NSCLC is required. Although the most common
symptoms associated with lung cancer are cough, dyspnea, chest pain and haemoptysis,
lung cancer often presents with no symptoms until it has reached advanced stages,
resulting in the majority of patients presenting with distant metastasis of the disease at
diagnosis 16,53. The following paragraphs detail the current methods used to acquire lung
samples for analysis and the diagnostic tests used.
2.1.4 Bronchoscopy
Bronchoscopy is employed as an investigatory technique subsequent to the detection of
an abnormality within the lung using CT scanning or X-rays 54. Flexible bronchoscopy
was first developed during the 1960s and remains one of the principal diagnostic methods
in pulmonology. In the case of suspected lung cancers, the main focus of bronchoscopy
is to attain a sample of the suspicious lesion for diagnostic analysis

55

. At present,

morphological evaluation of small specimens is the principal method used to
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differentially diagnose lung cancers. Accordingly, flexible bronchoscopy has evolved
with the addition of adjunct applications including navigational bronchoscopy,
endobronchial ultrasound, and bronchial thermoplasty, making it an effective method for
obtaining minimally invasive cytology samples 56.
2.1.5 NSCLC Tumour Classification Utilising Cytology Specimens
Small biopsy and cytology samples are the primary methods used for NSCLC diagnosis
as these inflict less discomfort on the patients and still allow accurate identification of
malignancy. Abrasive and exfoliative methods such as bronchial washing, brushing and
bronchioalveolar lavage (BAL) are frequently utilised to attain samples from
bronchoscopy for cytological analysis 57–59. According to international multidisciplinary
classification systems approximately 70% of lung cancer histological subtypes are
diagnosed by assessing the predominant cytological pattern of small biopsies and
cytological specimens, making cytological analysis a commonly implemented diagnostic
method for NSCLC

60–62

. When a tumour does not show standard morphologic criteria

for SCC or AC, immunohistochemical markers are used for further classification. Current
guidelines suggest a vigilant use of immunohistochemstry (IHC) for diagnosis as limited
cell sample remains for molecular testing for therapeutics, such as Fluorescent in situ
hybridisation (FISH) and molecular sequencing 61.
2.1.6 Immunohistochemistry
IHC is concerned with the identification and distribution of cellular components through
pinpointing specific antigens 63. The application of IHC can be used to identify specific
cell types by labelling tissue specific biomarkers. The method is based on antigenantibody interactions, where the location of antibody binding is visualised by direct or
secondary antibody labelling methods

64

. This is an effective technique used to

41

discriminate between the different subtypes of NSCLC, and double IHC staining has been
shown to be effective in the detection of AC 65.
A systematic review by Desai et al.29 analysed data published between 2000 and 2012
and identified IHC as the most commonly used molecular testing technique for
identifying biomarkers for the differential diagnosis of SCC and AC. The most frequently
used biomarkers for this distinction are thyroid transcription factor 1 (TTF-1), EGFR, and
the tumour suppressor gene p63

29,49,50

pulmonary

differentiation,

morphogenesis

immunoreactivity in ACs

and

66,67

. TTF-1 modulates genes responsible for
and

has

exhibited

elevated

. The genomic profile of AC has also displayed an

association with EGFR mutations 68, therefore the high prevalence of EGFR mutations in
AC, alongside the recent development of molecular targeted therapies, makes it an
effective marker for diagnosis as well as treatment strategy 69. In contrast, p63 has been
noted to display significantly higher positivity in SCCs than in ACs, making it a useful
diagnostic indicator for SCC 66.
While IHC may be required to aid diagnosis in some cases, the technique is becoming
increasingly applied in the realm of therapy prediction. It is not only imperative for the
detection of treatment sensitive tumours, but also for the identification of those patients
who may suffer ill effects where specific agents may be contraindicated. Despite the
efficacy of IHC for the differential diagnosis of NSCLC subtypes, this diagnostic
technique has multiple limiting factors. Although dual staining methods are now
applicable with IHC, an additional slide is still required, significantly reducing the scant
cellular material available for subsequent molecular testing. IHC also relies on the use of
large molecules such as antibodies to label molecular structures, which interfere with
further investigation of intrinsic molecular properties 70,71.
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2.1.7 Fluorescent in situ Hybridisation
FISH is an effective molecular testing technique for identifying fusion genes and has been
approved by the FDA as the gold standard method for the detection of ALK
rearrangements in NSCLC

72,73

. As IHC does not directly detect the ALK fusion gene,

not all fusion positive tumours are positive using IHC 74,75. FISH however has the ability
to directly detect ALK fusions and also has an overall sensitivity and specificity higher
than IHC for the identification of ALK gene aberrations in NSCLC 74,76. Despite being a
powerful technique needed for ALK testing and identifying patients that may respond to
molecular targeted therapy, FISH requires the limited residual sample left over from
diagnosis.
2.1.8 Current Research on Genomic Profiling
In the era of personalised therapies and as new molecular markers are discovered,
molecular testing is becoming part of the routine diagnostic workup of NSCLC. Current
research is investigating potential molecular markers which may act as therapeutic targets
or predictors of response to therapy 77–79.
Genomic and molecular profiles of AC and SCC are being developed using techniques
applicable on archival cancer samples such as mass spectrometry and next generation
sequencing. These techniques have been used to investigate the genomic profile of AC
and have identified some high frequency mutations associated with the AC subtype, such
as EGFR, MET, FGFR and HER2 39,77–79.
Genomic hybridisation has been used in a number of studies to explore the genephenotype relationship of NSCLC subtypes, and research using this technique has
identified entire chromosomal regions and individual genes which are applicable for the
discrimination of AC and SCC. Using residual bronchial brush samples, Su et al.80
identified 19 genes that are applicable for the discrimination of SCC and AC, many of the
43

genes associated with epidermis development and cell adhesion and may present as
potential therapeutic markers. Lockwood et al.81 identified an entire chromosomal region
(8p12) which may be valuable for profiling NSCLC subtypes. A gene within this region,
BRF2, was identified as a SCC specific genetic amplification, and indicates that this gene
is a promising marker for SCC. As BRF2 encodes a protein involved in transcription
initiation and facilitates in transcribing proteins required for cell growth, it may present
as a novel target for future therapies.
With the expanding demand for genomic profiling there is an increased demand on
limited cell sample. The optimisation of diagnostic processes is therefore paramount to
retain cellular material for subsequent molecular analysis such as genomic profiling.
2.1.9 Limitations of Current Diagnostic Methods
Although IHC is a highly accurate technique for discriminating SCC and AC, this
diagnostic technique significantly reduces the amount of sample available for subsequent
molecular testing, and as previously discussed, molecular profiling of the tumour is
paramount in order to ensure efficacy of treatment. The demand for limited samples is
ever increasing, this drives the need for an alternative diagnostic method which can be
applied to small tissue and cytology samples without compromising subsequent
applications

70,71

. In response to the need for new diagnostic methods, the investigation

of alternative methods such as vibrational spectroscopy has been growing in recent years.
The following section will discuss vibrational spectroscopy methods, such as Fourier
Transform Infrared (FTIR) spectroscopy and Raman spectroscopy, as alternative
techniques for the diagnosis of lung cancer.

2.2 Vibrational Spectroscopy
Vibrational spectroscopy uses electromagnetic radiation to probe vibrations within
molecules, and allows analysis of such molecular vibrations
44

82

. Molecular vibrational

energies are routinely investigated using Fourier transform infrared (FTIR) spectroscopy
and Raman spectroscopy. Figure 2.1 demonstrates the process involved in applying
vibrational spectroscopy to biological specimens for cancer detection.

Figure 2.1. Flow diagram of the process involved in applying vibrational spectroscopy to
bronchoscopy obtained specimens for cancer detection. After obtaining the cytology/biopsy
sample the biological material is stored in a preservative. The tissue section or cellular material
is then fixed to a substrate such as a glass slide and left unstained for spectroscopic analysis. Using
a laser or an infrared source, spectra are obtained by collecting the Raman scattered light or
transmitted light. The spectral data are then pre-processed to minimise noise and spectral
contaminations. Diagnostic features are then extracted from the data with multivariate analytical
techniques.

2.2.1 FTIR Spectroscopy for Lung Cancer Diagnosis
Fourier transform infrared (FTIR) spectroscopy is a label free vibrational spectroscopic
technique, which necessitates minimal sample pre-treatment
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82–84

. When applied to

biological tissue, the FTIR spectrum reveals comprehensive detail about the molecular
content of the tissue. Intracellular changes induced by cancer states may be detected as
variations from the spectral profile of normal tissue. The use of FTIR spectroscopy for
lung cancer diagnosis has been investigated for over 20 years, with previous reports
examining the applicability of FTIR spectroscopy for lung cancer investigation using in
vitro models and ex vivo samples 85,86. The in vitro studies included exploring the ability
of FTIR spectroscopy to discriminate normal and cancer cells, and assessing lung cancer
cells response to therapy 87,88. Lee et al.87 differentiated normal and lung cancer cell lines
and reported differences in nucleic acid and phospholipid bands in the malignant lines.
Sulé-Suso et al.88 demonstrated the ability of FTIR spectroscopy to detect therapeutic
response in lung cancer cell lines after the addition of a chemotherapeutic agent. The
FTIR spectra indicated an increase in phosphate groups in the cells after the addition of
the chemotherapeutic agent. The spectral changes detected were correlated with cell
survival, showing that FTIR spectroscopy may potentially identify treatment sensitive
cells. The study also demonstrates the suitability of FTIR spectroscopy for single cell
analysis.
Although cell line studies provide proof of concept, stronger evidence to support the
feasibility of using FTIR spectroscopy for lung cancer diagnosis are provided by applying
the technique to surgically resected samples. A pilot study conducted by Sun et al.89 used
surgically resected tissue from 60 patients and applied a variation of FTIR spectroscopy,
attenuated total reflection (ATR) FTIR spectroscopy to collect spectra from malignant
and non-malignant tissues. The study showed the ability to detect the presence of lung
malignancy with a sensitivity, specificity and accuracy of 96.7%. In addition to allowing
the classification of neoplastic changes with high diagnostic accuracy, analysis of FTIR
spectra reveals the molecular differences between malignant and non-malignant lung
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tissue. Yano et al.85,90 described the increase in glycogen content of NSCLC tissue
sections compared to non-cancerous tissue sections.
Akalin et al.91 used a machine based learning approach to show that spectral profiles can
distinguish between normal and cancerous tissues with high accuracy. They also reported
the ability of IR spectroscopy to accurately classify SCLC, as well as the NSCLC
subtypes AC and SCC. The authors indicated that this method may potentially be used to
identify clinically significant subtypes of AC, although training and test data sets of
adequate size were not available for their study. Further classification of AC into
prognostically different groups was achieved by Grosserueschkamp et al.92. Using
representative spectra for each subtype a supervised classifier was constructed. The first
and second level random forests separated between normal tissue, diseased tissue and
lung cancer subtypes. The third level random forest enabled further classification of AC
into prognostically relevant subtypes, the favourable non-mucinous lipidic subtype, less
favourable papillary and acinar subtypes, and the poor solid and micropapillary subtypes.
A discrimination accuracy of 97% for cancer subtypes and 95% for AC subtypes was
reported 92.
As cytological samples are the least invasive samples to attain for the diagnosis of
NSCLC, several studies have assessed the ability of FTIR spectroscopy to characterise
lung cancer using pulmonary cytological samples. Ghosal et al.93,94 have demonstrated
the feasibility of applying FTIR spectroscopy to sputum samples to detect lung cancer.
Using two wavenumbers (1031.7, 1409.7 cm-1) to develop a predictive model, lung cancer
cells were identified with a sensitivity and specificity over 91%. Lewis et al.95 generated
FTIR spectra from sputum cell pellets, and identified an increase in glycogen in the lung
cancer cells. This finding is in accordance with multiple studies and signifies that elevated
glycogen content may be a useful diagnostic biomarker for lung cancer using FTIR
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spectroscopy

85,86,90

. These studies demonstrate that applying this powerful diagnostic

technique to cytological specimens for the detection of lung cancer in a clinical setting is
a realistic prospect. In addition, FTIR spectroscopic analysis of sputum samples may be
a cost effective and fast tool for lung cancer screening due to the non-invasive procedure
of obtaining sputum samples and high throughput FTIR technology. In order for the
application of FTIR spectroscopy to progress from a research setting to preclinical or
clinical trials, an interdisciplinary approach is required to validate the performance of
spectral biomarkers with a sufficient number of patients. The complexity and current
availability of these validated models is a significant limitation for the application FTIR
for lung cancer diagnosis.
2.2.2 Raman Spectroscopy for Lung Cancer Diagnosis
Raman spectroscopy has been discussed as a promising tool for cancer diagnostics for
over 20 years 96. Multiple reviews have illustrated how this spectroscopic technique has
demonstrated favourable results for the identification of cancerous tissue and has the
potential to improve cancer diagnostics in a variety of cancers including brain, breast,
skin, lung and gastrointestinal cancer

97–100

. As with FTIR spectroscopy, Raman

spectroscopy is a form of non-invasive, label free vibrational spectroscopy, however
Raman spectroscopy relies on the detection of inelastically scattered light

83,101,102

. The

Raman spectrum is a plot of the intensity of the scattered light versus the change in energy
given in wavenumbers (cm-1), and represents a detailed biochemical fingerprint of the
cellular components, as shown in figure 2.2. As Raman spectroscopy provides
comprehensive details about the composition of tissues, biochemical changes in
cancerous tissue may be detected in the Raman spectra. Combining Raman spectroscopy
with multivariate analysis can enable a highly accurate classification of tissue types and
malignancy. In recent years, many studies have shown the efficacy of Raman
48

spectroscopy for detecting lung cancer in vitro, ex vivo and intraoperatively. Work by Jess
et al.103 showed the potential of Raman spectroscopy for grading of lung neoplasia in
cellular samples. The cell lines utilised in the study were representative of three groups,
normal cells (primary normal bronchial epithelial cells HBEpCs), cells with extended
lifespan (HBEpCs retrovirally transduced with either human papillomavirus (HPV) type
16 E7 or CDK4), and immortalised or malignantly transformed cells (BEP2D and
AsbTB2A). BEP2D is a human bronchial epithelial cell line expressing HPV18, and
AsbTB2A is a transformed cell line derived from BEP2D following exposure to asbestos.
A multivariate classification model based on linear discriminant analysis classified the
cell types with accuracies ranging from 58% - 77%. Normal cells were discriminated
from all abnormal cell types with a sensitivity of 91% and specificity of 75%. The Raman
spectra indicated that normal cells, cells with extended lifespan, and immortalised and
transformed cells, could be characterised by their DNA, protein, amide and lipid content,
suggesting that Raman spectroscopy may identify stage of lung cancer development 103.
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Figure 2.2. Depiction of a Raman spectrum showing the different spectral regions and the
corresponding biomolecules associated with each region. The spectrum which represents a
bronchial epithelial cell nucleus was baseline corrected and the non-negatively constrained least
squares method was used to remove spectral contaminants from the substrate.

The efficacy of Raman spectroscopy for the in vitro discrimination of normal and
cancerous cells was also investigated by Oshima et al.104. Five lung cell lines from
different histological origins were analysed (MRC-5 from normal, RERF-LC-MS from
AC, EBC-1 from SCC, Lu-65 from large cell undifferentiated, and RERF-LC-MA from
small cell carcinoma). The study showed that step-wise linear discrimination analysis of
the Raman spectra allowed the label-free detection of each histological cell type with an
accuracy of 100%, validating the effectiveness of Raman spectroscopy for cancer cell
diagnosis.
In addition to the assessment of in vitro models, the applicability of using Raman
spectroscopy for the assessment of surgically resected samples has been explored. Using
a 1064nm laser to eliminate background fluorescence, Kaminaka et al.105 investigated the
molecular differences between normal and malignant lung tissue. Spectra with a high
signal to noise ratio were obtained and distinct Raman bands at 1448 and 1666 cm-1
differentiated the normal and cancer spectral profiles. This demonstrated that an increase
in collagen content in lung cancer tissue is detectable with Raman spectroscopy.
In 2012 Pavićević et al.106 applied Raman spectroscopy to tissue samples from an array
of different tumour types, which included lung SCC, and AC. Using PCA and a neural
network algorithm, the SCC and AC subtypes were correctly classified with accuracies
of 83.3% and 91.7% respectively. Normal and tumour tissue spectra were also
discriminated with an overall sensitivity of 95%. Huang et al.107 applied Raman
spectroscopy to biopsy samples to differentiate normal, AC, and SCC tissue and
discovered significant differences between the spectra of normal and cancerous tissue.
50

The Raman spectra indicated that the malignant tissue was characterised by an increase
of nucleic acids, tryptophan and phenylalanine, in comparison to the normal tissue, while
the AC and SCC subtypes were discriminated by a different ratio of peak intensities at
1455 cm-1 and 1655 cm-1, corresponding to a variation in lipid to protein ratio.
Gao et al.

108,109

applied another form of Raman spectroscopy, Coherent anti-Stokes

Raman Scattering (CARS), to frozen lung tissue samples, differentiating normal and
benign tumours, cancerous and non-cancerous tissues, and subsets of lung cancers. The
authors developed a highly accurate classification system which delineated malignant
tissue from normal tissue with classification accuracy over 91%, and successfully
differentiated small cell and NSCLC. An investigation by Magee et al.110 using surgically
resected samples achieved a sensitivity of 84% and a specificity of 61% for the
discrimination of normal and cancer tissue, reporting that tumour tissue could be
characterised by an increase in DNA and a decreased level of porphyrin in comparison to
the normal tissue. In addition to showing the effectiveness of Raman spectroscopy to
detect cancerous tissue, this study was the first to demonstrate a prognostic ability of
Raman spectroscopy to predict cancer recurrence in patients with a sensitivity and
specificity of 73% and 74% respectively 110.
The CARS variant of Raman spectroscopy utilises multiple pulsed laser beams that
interact with the sample through a wave mixing process and produces a signal that is
much higher than the spontaneous Raman signal. With no interference from fluorescence,
it has been shown to be a suitable method for the differential diagnosis of NSCLC, while
preserving tissue specimens for follow up diagnostic tests

111–113

. Xu et al.112 applied

CARS as part of a multimodal imaging technique to unfixed, unstained lung tissue to
effectively differentiate normal lung tissue, cancer tissue, and desmoplastic tissue. In
another study by Gao et al.113, a label free diagnostic system was developed by applying
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a 3D imaging strategy in conjunction with CARS to differentiate NSCLC subtypes.
Human AC and SCC cell lines were grown in mouse models, and the tumours were
excised after 2 weeks of growth. By acquiring individual 2D images of the same field of
view from different imaging depths, the authors created a 3D data structure of the tissue.
The system enabled a more accurate analysis of whole cells and nuclear size, overcoming
the limitations of 2D sections. The NSCLC subtypes were differentiated with an accuracy
of 97%, proving the ability of vibrational spectroscopy to improve the current diagnostic
algorithm with minimal sample consumption and without hindering additional molecular
testing.
Surface enhanced Raman spectroscopy (SERS) has also been applied to biological
samples including saliva and cell derived exosomes to characterise biomolecular
differences between normal lung and lung cancer

114,115

. Zhang et al.116 examined the

prospects of implementing SERS in lung cancer diagnostics by applying SERS
technology to lung tissue sections and developing a PC-LDA classifier to analyse the
data. The study identified characteristic changes in the cancer spectra associated with
increased DNA, carotenoids, lipids and proteins. After performing PC-LDA, a ROC
curve was constructed to evaluate the performance of the developed classifier, and a
diagnostic sensitivity of 95.7% and specificity of 95.7% was achieved for the
discrimination of normal and malignant lung tissue.
The use of Raman spectroscopy to improve the in vivo diagnosis of lung cancer has also
been investigated and presents as an exciting clinical application for the real-time
diagnosis of NSCLC, which may prevent the need for surgical biopsy procedure. In 2008
Short et al.117 designed an endoscopic Raman probe and acquired the first in vivo lung
Raman spectra. With 1-2 second integration times and filters to reduce noise and
fluorescence, quality Raman spectra were acquired in the high frequency spectral range
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from normal, dysplastic, and tumour sites. Analysis of the spectral profiles showed large
variations between the SCC and normal tissue, although due to the low number of patients
involved in the study the authors could not rule out interpatient variability as a potential
cause. The following year a pilot study by Magee et al.118 then provided proof of concept
for the suitability of applying Raman spectroscopy for the in vivo diagnosis of lung
cancer. Using a biomedical filtered fibre optic probe and a method to reduce background
fluorescence, clear Raman spectra were acquired from ex vivo normal and malignant lung
tissue. Spectral variation analysis identified increased peak intensities for amide I (1655
cm-1), amide III (1260 cm-1), and phenylalanine (1002 cm-1) in the tumour spectra. The
normal and tumour spectra were also classified with 100% accuracy using PCA leave one
out cross validation. In 2016, a single centre clinical investigation with 80 patients
explored the adjunct application of Raman spectroscopy with bronchoscopic methods for
the in vivo detection of lung cancer

119

. Real time point laser Raman spectroscopy (1

second per spectrum) was performed on 280 sites from non-malignant and malignant lung
lesions. Multivariate analysis of the spectra differentiated the normal, benign and
malignant tissue with a sensitivity of 90% and specificity of 65%.
Raman technology also has the potential to help clinicians decide which lesions are
suitable for biopsy, as the adjunct use of in vivo Raman spectroscopy with bronchoscopy
methods has been shown to detect preneoplastic lesions with sensitivity and specificity
above 90% 120. These studies show that Raman spectroscopy is a highly sensitive method
for the in vivo diagnosis of lung cancer, and now with the ability to detect tumours in the
peripheral lung with novel miniature Raman probe technology

121

, and the capacity to

produce clear spectra from weak Raman signals, further multicentre clinical trials are
warranted.
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In addition to in vivo and ex vivo studies, others have explored the feasibility of applying
Raman spectroscopy combined with data mining methods to body fluid samples for lung
cancer diagnosis. These are promising, cost effective methods and would allow simple
and reliable screening to detect early stage malignancy. Analysing the serum of patients
with NSCLC, Wang et al.122 were able to obtain distinct Raman spectral profiles for stage
I, stage II, and advanced stage NSCLC. Comparative analysis of the mean spectral
profiles for each stage of NSCLC revealed multiple peaks involved in the carcinogenic
progression of NSCLC. Cancer progression corresponded with a decrease in all of the
analysed peak intensities. The authors noted that protein and phospholipid content was
significantly reduced in the serum samples of NSCLC patients, evident by a decreased
peak intensity at 1658 cm-1. With PCA and discriminant analysis, spectra taken from the
sera of healthy people and patients with stage I- IV NSCLC were differentiated with an
overall accuracy of 92%. Other studies have shown that Raman spectroscopy also has the
potential to characterise lung cancer and detect malignancy with high diagnostic
sensitivities and specificities with non-invasive samples such as saliva and urine 115,123,124.
Applying Raman spectroscopy to these minimally invasive specimen types may be an
effective tool for NSCLC screening and staging without the need for bronchoscopy. The
translation of these technologies into a clinical setting now requires successful
randomised clinical trials before they are accepted.
As discussed in this review, applying Raman spectroscopy to tissue sections has shown
the ability to discriminate between non-malignant and malignant lung tissue, and between
NSCLC subtypes. Raman technology has also been successfully applied to single cells,
effectively identifying malignancy. However, based on a comprehensive review of the
literature it appears no studies have investigated the use of Raman spectroscopy on
bronchoscopy cytology samples, which would align with the current sampling techniques
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for lung cancer. In light of the research to date, applying this technique to cytology
samples may present as a minimally invasive method for identifying and discriminating
NSCLC subtypes and treatment sensitive tumours. This method may be used to provide
an accurate diagnosis and retain sufficient sample for ancillary molecular tests,
maximising the use of limited samples.
2.2.3 Summary and Future Perspectives
Small tissue and cytology samples are often the only specimens available for the diagnosis
and molecular analysis of NSCLC. Current diagnostic methods for NSCLC consume
much of the available sample, and with an increasing demand for the sample for ancillary
molecular tests, an alternative accurate diagnostic method is desirable. As vibrational
spectroscopic techniques are label free, highly sensitive and allow the rapid detection of
intracellular biochemical information, they address the limitations of current diagnostic
methods and are a potential option for the differential diagnosis of NSCLC. As vibrational
spectroscopy is non-destructive, the unstained slides can be used for subsequent analysis.
Numerous studies have demonstrated the ability of vibrational spectroscopic techniques
to accurately detect and discriminate lung cancer subtypes using tissue and cell samples.
As the process of obtaining cell specimens is minimally invasive, future research may
investigate the viability of using vibrational spectroscopic methods on bronchoscopy
cytology samples. A previous study has already shown the ability of FTIR spectroscopy
to characterise lung cancer cells using cytological samples, and although Raman
spectroscopy has been investigated on lung carcinoma samples in vitro, ex vivo, and in
vivo, to our knowledge it has never been used on bronchoscopy attained cytology samples
95,104,107,109,120

.

As probe based Raman spectroscopy is developing and is a promising technique for the
in vivo diagnosis of cancer, development in the application of Raman spectroscopy for
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the in vivo diagnosis of NSCLC may present with many promising advantages for clinical
setting

119,125,126

. It can be used at a lower cost than other imaging techniques including

magnetic resonance imaging (MRI) and ultrasound, in addition to giving real time
information on biochemical composition in high resolution with no stains or labels 99.

2.3 Conclusion
As the identification of NSCLC subtype is pertinent for the development of treatment
regimens, an enhanced label-free, rapid, and even automated diagnostic technique would
be largely beneficial. Integrating vibrational spectroscopic methods into the diagnostic
algorithm for lung cancer offers the ability to provide an accurate diagnosis and discover
new molecular markers for the discrimination of NSCLC subtypes. Vibrational
spectroscopic methods may be useful for the non-destructive analysis of small unstained
bronchoscopy attained samples, without compromising subsequent ancillary molecular
tests. These techniques have the potential to reduce the need for surgical biopsies, and
may be economically advantageous by saving medical resources.
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Chapter 3: Methodologies
3.1 Study subjects, sample collection and preparation
This study had approval from the Research Ethics Committee, Dublin Institute of
Technology (now Technological University Dublin) as well as SJH/AMNCH Research
Ethics Committee. BALs and BWs were collected from patients during bronchoscopy for
suspected lung cancer. Informed consent to use residual cell sample was obtained from
each patient at a previous clinical appointment. Lung cancer was subsequently confirmed
through final clinical diagnosis and final histology was recorded.
3.1.1 Sample processing for BAL and BW samples
Cellular material was isolated by breaking down the mucus with a solution consisting of
10µM Dithiothreitol (DTT), a mucolytic agent, in Cytolyt. Samples then underwent
centrifugation at 3000 rpm for 10 min and supernatant was poured off leaving a cell pellet.
The pellet was then resuspended in PreservCyt and transferred to a ThinPrep® vial.
3.1.2 Slide preparation
The sample vial was placed into a ThinPrep® 2000 Processor which first thoroughly
mixed the sample to disperse the cells by rotating the filter. A gentle vacuum is then
created in the ThinPrep® filter to collect a monolayer of cells on the filter membrane.
The cells collected on the filter membrane are then gently pressed against the ThinPrep®
glass slide and natural attraction and positive air pressure helps the cells to adhere to the
slide in a 20 mm circle. The slide was then deposited into a fixative solution of 95%
ethanol before being removed from the alcohol and allowed to air dry. ThinPrep® glass
slides were used as the substrate for Raman spectroscopic analysis throughout this study.
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3.2 Raman spectral acquisition and data pre-processing and analysis
3.2.1 Raman Measurement
Raman spectra were acquired using a HORIBA Jobin Yvon XploRATM system
(Villeneuve d’Ascq, France) which consists of an Olympus microscope BX41 supplied
with a x100 objective (MPlanN, Olympus, NA = 0.9). A 532 nm diode laser source was
utilised during the study and was set at 100% power, which gave 8 mW at the objective.
The confocal hole was set at 100 µm and coupled to a slit of aperture 100 µm. The system
was calibrated to the 520 cm-1 spectral line of Silicon and the 1200 lines per mm grating
was used. Using Silicon, the laser line was calibrated to yield maximum signal intensity.
Backscattered light was detected using an air-cooled CCD detector (Andor, 1024 x 256
pixels). The software implemented to manage the spectrometer was Labspec V6.0. The
spectral range was 400-1800 cm-1 and each spectrum corresponds to the average of two
accumulations of 30 seconds. Spectra were also recorded from 300 vacant locations on a
ThinPrep® glass slide with identical exposure time in order to obtain representative
background glass spectra.
3.2.2 Recording position of targeted cells unstained slide
Each ThinPrep® glass slide has the word ‘ThinPrep®’ printed on the upper side of the
glass. Before recording spectra from the slide, the centre of the dot in the ‘i’ in the printed
word ‘ThinPrep’ was set as the 0-0 XY co-ordinate. Having a reference point on the slide
allowed the XY co-ordinates of target cells to be recorded and stored in a separate ‘coordinate file’ that was correlated to the spectra. At a later date, targeted cells could be
identified by setting the 0-0 point as previously explained, and opening the co-ordinate
file using the Labspec 6 software.
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To reduce interference from random and irrelevant variations within the spectral data,
pre-processing of the Raman spectra is needed before chemometric analysis.
3.2.3 Smoothing
The Savitzky-Golay smoothing technique reduces spectral noise and can enhance the
biochemical signal. The Savitzky-Golay method uses a least squares technique to fit a
window of wavenumbers to a polynomial function, retaining features such as band width
and height1. Fifth order filtering with a 15-point window was used throughout.
3.2.4 Baseline removal
The rubberband baseline correction method finds a polygonal line with edges at the
spectral minima or ‘troughs’. Another computational method of background subtraction
is the subtraction of a polynomial of certain order2. The rubberband method was applied
throughout this thesis, aside from Chapter 7. A fifth order polynomial baseline correction
was applied to the cell line data in Chapter 7 as the rubberband method did not adequately
correct the baseline.
3.2.5 Normalisation
The spectra were vector normalised to reduce intensity variations caused by excitation
power, this allows for reliable analysis of minute changes in the spectra. Vector
normalisation is a scaling method whereby each variable is divided by a scaling factor
which is different for each variable, returning a vector of unit length 1. A vector
normalised spectrum is normalised to the square root of the sum of the squared value of
all variables for the spectrum 2,3.
3.2.6 Glass removal by non-negative least squares
As described by Ibrahim et al.4, non-negative least squares analysis (NNLS) is a technique
which uses a function to calculate the weighted contribution of a set of input spectra in a
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sample spectrum. Similar to the classical least squares fitting technique, it assumes that a
sample spectrum is the sum of the base components contributing to the spectrum. As the
input spectra take on only non-negative values, the NNLS function incorporates nonnegative constraints on the input spectra, meaning only positive values can contribute to
the approximation of the sample spectrum5. Thus, spectra from cellular components, such
as nucleic acids, proteins, lipids, and the independently recorded glass spectra were used
as input spectra to fit the sample spectra and remove the glass contribution.
3.2.7 Outlier removal
Grubbs’ test was used to identify and remove outliers from the data. The outlier is
detected by calculating the difference between the test value and the mean, and then
dividing the value of the difference by the standard deviation of the dataset. If the ratio is
greater than +/-2, the object is considered an outlier and is removed. The Grubbs test
detects one outlier in the dataset at a time. If an outlier is detected, it is removed and the
test is reiterated.
3.2.8 Principal component analysis
The identification of cancer biomarkers using Raman spectroscopy requires the
translation of the Raman signal into a diagnosis with data mining techniques. Alterations
between spectra are detected and evaluated using machine learning software and
correlated to histopathological results attained from gold standard diagnostic methods.
This data can then be used to design a classification system to discriminate between
normal and cancerous tissues. Additionally, the wavenumbers of important spectral bands
may also be correlated to specific biomolecules and may identify pathways involved with
disease progression, proliferation and more.
There are numerous statistical techniques for the analysis of biological Raman spectra.
Principal component analysis (PCA) is an unsupervised data reduction technique that is
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extensively used in relation to cancer research. It is used to identify variances within the
data which may classify individual spectra into groups6–8.
PCA reduces the dimensionality of the data while retaining most of the variance within
the dataset. This is achieved through several mathematical steps, initially the mean is
subtracted from the dataset to produce a new data set, the mean centred matrix. Then the
covariance matrix of the mean centred matrix is computed by calculating the linear
relationships between individual spectra. Principal components (PC) and scores, or
eigenvectors and eigenvalues, are then calculated for the covariance matrix, with each PC
explaining independent sources of variance and having a corresponding score. The PC
with the highest score explains most of the variance in the dataset, and is called the first
PC. The PCs are organised in order of the proportion of variance they explain, from the
highest to lowest. Further analysis of the data is then done using the calculated scores of
each variable in relation to each PC 6–8.
3.2.9 Linear discriminant analysis
Linear discriminant analysis (LDA) is another technique that is routinely amalgamated
with PCA to develop a predictive model based on the Raman spectra. When implemented
with the PCA model, the LDA classification system increases classification accuracy by
using the PC scores. LDA is a member of a class of methods which use linear decision
boundaries for classification. The LDA method identifies linear functions that maximise
the separation between different classes, and minimises the within-class covariance
matrix, allowing classification of data into different classes6,9.
3.2.10 Partial least squares discriminant analysis
Partial least squares discriminant analysis (PLS-DA) mean centres the Raman spectral
data to identify the diagnostically significant variations between the groups. PLSDA
reduces dimensionality of the data by considering the correlated relationships between
70

the spectral dataset and the class membership. The PLS components, or latent variables
(LVs), are rotated to maximise the covariance between spectral variation and class
membership. This supervised approach finds the LVs in the multivariate space that
maximise the separation of groups and enables discrimination between known
classifications of samples (negative, cancer etc.) based on the diagnostically relevant
spectral variations.

10,11

. The required number of latent variables was utilised in each

model to set the cross-validation classification error average at 5%. The analysis was
performed using the PLS toolbox (Eigenvector Research, Wenatchee, WA) in the Matlab
(Mathworks Inc., Natick, MA) scripting environment, and cross validated using leave one
out cross validation.
3.2.11 Cross validation
Cross validation is implemented to evaluate the performance of a classification model in
accurately determining pathological status. The method used in this study was venetian
blinds cross validation. In venetian blinds validation, each validation set is developed
using every nth spectrum in the data, starting at spectrum 1 through n. For example, in a
10-fold venetian blinds validation, each validation set or fold i is built taking spectra from
the dataset of a 10-multiple position until the end of the dataset (samples i, i + 10,
i + 2(10), i + 3(10), …). Once the folds are developed, 10 models are trained with 10–
1 folds, and tested with the remaining fold, rotating the testing fold until all of them have
been used. The overall performance of the model is determined as the average
performance of the 10 models 12.
3.2.12 Calculation of classification models performance scores
The ability of a classifier to detect pathology can be measured by evaluating the
sensitivity, specificity, and diagnostic accuracy of the model. The sensitivity of a
technique is determined as the proportion of cases with a disease that are accurately
71

detected. The specificity of a model is the ability of the model to accurately detect those
without disease, and diagnostic accuracy describes the proportion of correctly classified
cases among all the classified cases.

Sensitivity =

Specificity =

Diagnostic accuracy =

𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑝𝑜𝑖𝑡𝑖𝑣𝑒+𝐹𝑎𝑙𝑠𝑒 𝑛𝑒𝑙𝑔𝑎𝑡𝑖𝑣𝑒

𝑇𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 +𝐹𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒

×100

×100

𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒
(𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 + 𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝑓𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒)

×100

3.3 Pap staining
This was conducted after collecting Raman spectra from the target cells. Slides were
rehydrated in normal saline (0.9% NaCl) for 60 seconds before being washed in water.
Harris haematoxylin was added for 5 minutes and then washed off with water. The
Haematoxylin was then differentiated with acid alcohol for 2 seconds and checked.
Complete removal of the haematoxylin from the cell cytoplasm was checked promptly
with a light microscope, ensuring the slide did not dry. The slide was then submerged in
water to blue the bound stain. Following quick washes in 70% and 95% ethanol, O.G 6
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solution was applied for 3 minutes. The slides were then washed rapidly in 95% alcohol
and stained with E.A 50 solution for 4 minutes. After washing rapidly in 95% ethanol,
the slides were transferred through a series of two washes of absolute alcohol and then
into histoclear before coverslipping. The stained slides were then reviewed
microscopically. The recorded cells were mapped by their XY coordinates and accurately
categorised into databases according to their cell type.
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Chapter 4: Raman spectroscopic analysis of NSCLC using
bronchoscopy cytology samples
4.1 Introduction
Lung cancer persists as the most common cancer worldwide1. According to the
GLOBOCAN 2018 report 2, lung cancer represents the highest cancer incidence and
mortality rates in both developed and less developed countries, with approximately 2.1
million new cases and 1.76 million deaths in 2018. Studies have indicated a 5 year
survival rate of 8% to 15% in developed countries, although a survival rate as low as 1%
has been reported for late stage diagnosis 3–5. Incidence trends can be directly correlated
with smoking prevalence, as cigarette smoking is responsible for 85% of lung cancer
cases 6–8.
There are two prominent types of lung cancer, small cell lung cancer (SCLC) accounting
for an estimated 13%-14% of cases, and non-small cell lung cancer (NSCLC), which is
the most common form of lung cancer accounting for approximately 85% of cases

9–12

.

NSCLC constitutes two prominent histological phenotypes including squamous cell
carcinoma (SCC), adenocarcinoma (AC) and large cell carcinoma. AC accounts for the
largest portion of all lung cancer cases at 44%, followed by SCC at 26% 9. Historically,
both SCC and AC were treated clinically and therapeutically the same, however with the
recent availability of differential treatment options for AC and SCC patients, accurate
subtyping of NSCLC is becoming increasingly important in the therapeutic algorithm
13,14,15–22,23–26

.

In approximately 80% of cases patients are diagnosed through the analysis of cytological
material or a small tumour biopsy. For decades, bronchoscopic techniques such as
bronchial brushing, bronchial washing (BW) and bronchoalveolar lavage (BAL) have
been used to obtain cytological samples of suspicious pulmonary lesions. Studies
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investigating the efficacy of these techniques for diagnosing malignancy have indicated
sensitivities for malignancy ranging from approximately 30% - 71%

27–30

.

Immunohistochemistry (IHC) can be applied to improve the differential diagnosis of
NSCLC to approximately 85%31, and additional molecular testing techniques may be
utilised to aid the detection of targetable mutations. These include fluorescent in situ
hybridisation (FISH), and sequencing techniques

32,33

. However, these methods cannot

always be applied and for many patients the small diagnostic sample is often fully utilised
to classify the NSCLC subtype, and ancillary molecular tests cannot be performed. For
these patients a repeat biopsy is needed to complete the clinical work-up of the patient.
As more molecular targets and subsequent personalised therapies are discovered,
retaining adequate sample during the diagnostic work up of NSCLC for molecular testing
is becoming increasingly important. Implementing a label free diagnostic technique in the
diagnostic algorithm of NSCLC would allow subsequent use of the limited sample for
molecular profiling. In this context Raman spectroscopy is a promising emerging tool.
Raman spectroscopy is a label free vibrational spectroscopic technique based on the
inelastic scattering of light 34,35. It has shown favourable results for detecting malignancy
in multiple cancer types including brain, breast, skin, gastrointestinal, oesophageal and
lung cancer 36–39. The ability of Raman spectroscopy to detect lung malignancy has been
investigated using biopsy samples, and in vivo, with reported diagnostic sensitivities up
to 91% 40–45. Despite the efficacy of Raman spectroscopy for the detection of lung cancer,
to our knowledge it has never been applied to bronchoscopy attained bronchial washes,
or BAL cytology samples.
Applying Raman spectroscopy for cancer prediction requires data mining techniques to
translate the Raman signal into a diagnosis. A supervised classifier is developed using a
database of spectra from patient samples with known histopathological results attained
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from gold standard diagnostic methods. The spectra are evaluated to identify relationships
between the spectra and their known histopathological result. This data can then be used
to design a classification model to predict the diagnosis of new patient samples.
Additionally, the wavenumbers of important spectral bands may also be correlated to
specific biomolecules and may give insight into the biochemical composition of the cells.

The aim of this study was to investigate the feasibility of applying Raman spectroscopy
to BAL or BW samples to provide a marker free diagnosis of NSCLC subtypes, and to
identify the biochemical changes responsible for the classification. For this study,
samples were grouped according to their final gold standard histopathological diagnosis
as characterised by a pathologist.

4.2 Methods
4.2.1 Study subjects and sample collection
As described in chapter 3 section 3.1.
This study utilised BALs and BWs collected from 24 patients (9 female, 15 males). Lung
cancer was confirmed through final clinical diagnosis and final histology was recorded:
12 squamous cell carcinoma, 5 adenocarcinoma, and 7 negative (no cancer diagnosed).
4.2.2 Sample processing and slide preparation
As described in chapter 3 section 3.1.1-2.
4.2.3 Raman Measurement
As described in chapter 3 section 3.2.1-2.
Spectra were taken from the nuclei of morphologically normal looking bronchial
epithelial cells, squamous cells, and lymphocytes. For each bronchial and squamous cell,
spectra were also recorded from the cell cytoplasm. On SCC cases, spectra were also
taken from the nuclei of morphologically abnormal squamous cells, although spectra
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could not be acquired from the cytoplasm due to photodegradation using a 532 nm laser46.
On AC cases morphologically abnormal cells (Figure 4.3) were not targeted as they could
not be identified on the unstained slides. For each sample, we aimed to take spectra from
fifteen of each cell type. For each cell, one measurement was recorded from the nucleus,
with the system set us as described in chapter 3 section 3.2.1-2. As the cell cytoplasm is
thin, and therefore there was more interference from glass, it was difficult to acquire
quality spectra. Thus for each sample we aimed to take spectra from the cytoplasm of 5
to 15 cells of each cell type.
4.2.4 Data pre-processing and analysis
All spectral data analysis was conducted using MATLAB software. Data were processed
as described in chapter 3 section 3.2.3-.7.
The data was analysed using Principal Component Analysis (PCA), as described in
chapter 3 section 3.2.8. Partial least squares discriminant analysis (PLS-DA) with
venetian blind cross-validation was also employed to the mean centered Raman spectral
data to identify the diagnostically significant variations between the groups, as described
in chapter 3 section 3.2.10-12.
4.2.5 Pap staining
Following Raman spectroscopy, slides were stained using the Papanicolaou staining
method as described in chapter 3 section 3.3. Using the XY co-ordinates recorded as
described in chapter 3 section 3.2.2, the spectra were correlated with their cell type and
categorised into separate databases according to their cell type.
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4.3 Results
4.3.1 Mean spectral analysis
Figure 4.1 depicts three cell types targeted in this study and the mean nuclear spectra for
each cell type taken from negative cases. Applying the Pap stain to slides analysed with
Raman spectroscopy enabled the targeted cell types to be identified as bronchial epithelial
cells (Figure 4.1 (a)), squamous cells (Figure 4.1(b)), and lymphocytes (Figure 4.1(c)).
The morphologically abnormal or malignant squamous cells (Figure 4.2) were also
targeted. These cells were observed in SCC cases where malignancy was evident on
cytology. The standard deviations in Figure 4.1 d-f show that there was minimal variation
between the spectra from individual cells. The significant spectral differences between
the nuclei of lymphocytes, bronchial and squamous cells from negative cases are shown
by the difference spectra in Figure 4.4. The features in the nuclear spectra taken from
bronchial cells, squamous cells, and lymphocytes of AC and SCC cases that differ from
the cells of negative cases are demonstrated by the difference spectra in Figures 4.6, 4.8
and 4.10. Significance was determined using Student’s t-test and values of p<0.01 were
considered to be statistically significant. Table 4.1. shows the tentative peak assignments
for the prominent significant Raman bands identified by spectral variation.
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Figure 4.1. Depiction of stained and unstained bronchial cells (a), squamous cells (b), and
lymphocytes (c). The Pap stain was applied to provide contrast between cell types and
components. The corresponding mean Raman spectra (± standard deviation) taken from
the nuclei of each cell type are shown. (d) The mean Raman spectrum of bronchial
epithelial cell nuclei taken from negative cases (blue, n=70) (n=the number of spectra
used), (e) the mean Raman spectrum of squamous cell nuclei taken from negative cases
(black, n=94), and (f) the mean Raman spectrum of lymphocyte nuclei taken from
negative cases (red, n=80). Images were taken at x1000 magnification.
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Figure 4.2. Representative keratinizing tumour cells with cytoplasmic projections taken
from patients with squamous cell carcinoma. The cells are stained with the Pap stain
which was applied subsequent to Raman analysis. Images were taken at x1000
magnification.
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Figure 4.3. Representative tumourous glandular cells taken from patients with
adenocarcinoma carcinoma. The cells are stained with the Pap stain which was applied
subsequent to Raman analysis. Image A was taken at x400 magnification, B-D were taken
at x1000 magnification.
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Table 4.1. Tentative peak assignments for the prominent significant Raman bands
identified by spectral variation analysis47,48.
Wavenumber Raman peak assignments
(cm-1)
~420/30/40

cholesterol

509

protein

580

phosphatidylinositol

486-526

Polysaccharides, proteins

590

Protein/glycerol

640

Tyrosine/methionine

657/~700/10

Methionine

735

Thiocyanate

~780

Nucleic acids

830-920

Polysaccharides/proline/valine/collagen

~930

Proline/valine/saccharides

1006

phenylalanine

1024-32

glycogen/peaks related to collagen

1106-1125

saccharides/lipids/proteins

1175-1200

Nucleic acids/phophates

1210-1280

Amide III/nucleic acids

~1340-50

Nucleic acids/protein/lipids

~1380

lipid

1420-50

Proteins/lipids

~1480

Amide II

~1500-1600

Amide II/ nucleic acids

~1580

COO-

1600-1666

Amide I

~1680

Amide Idisordered structure/β
sheets/lipids

~1700-1740

lipids
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4.3.2 Spectral comparison of the lymphocyte, bronchial, and squamous nuclei
from negative cases
Based on many significant differences the Raman spectra from lymphocytes, squamous
cells and bronchial cells could be differentiated from each other. Spectral differences
between the squamous cell nuclei of negative cases (Figure 4.4) and the bronchial cell
nuclei of negative cases corresponded to peaks relative to proteins and lipids (421-421500, 530- 690, 762-84, 1024-32, 1129-200, 1205-06, 1345-61, 1379-1459, 1470-1546,
1611, 1620-60, 1680-1727 cm-1), saccharides (421- 500, 920-68, 1024-32, 1129-200 cm1

) and nucleic acids (762-84, 1129-200, 1315-20, 1345-61, 1450-59, 1564-82 cm-1). The

squamous cells showed an increased peak intensity in peaks assigned to glycogen /
cholesterol / protein / phospholipids (421-690 cm-1), glycogen / cholesterol / saccharides
/ protein/nucleic acids (762-1011 cm-1), glycogen and peaks related to collagen (1024-32
cm-1), lipids / protein / amide I (1436-44, 1620-60 cm-1) in comparison to the bronchial
cells. The bronchial cells showed an increased peak intensity in peaks assigned to lipid /
protein / nucleic acids / phosphates (1129-1200, 1205, 1230, 1315-20, 1345-61, 13791430 cm-1), and lipid / protein / COO- / nucleic acids / cytosine (1450-1546, 1564-82,
1611 cm-1) in comparison to the squamous cells.
The squamous cells from negative cases displayed an elevated peak intensity at 460-95,
519-615, 633-90, 710-963, 991-1017, 1040-62, 1070-96, 1221-40, 1245-60, and 16071665 cm-1 compared to the lymphocytes from negative cases. This corresponds to more
glycogen / cholesterol / protein / phospholipids / nucleic acids / phenylalanine (460-1017
cm-1), saccharides / protein / lipid (1040-62, 1070-96 cm-1),amide III / nucleic acid (122140, 1245-60 cm-1) lipid / protein (1435-45 cm-1), and amide I (1607-1665 cm-1) content
in the squamous cells (Figure 4.4). The lymphocytes from negative cases were associated
with elevated peak intensities assigned to lipids / saccharides / nucleic acids (1107-16,
1130-51, 1172-96, 1338-63, 1373-80 cm-1), amide II / lipid / protein (1450-1547 cm-1),
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COO- (1578-96 cm-1), cytosine (1605 cm-1), and amide I disordered structure/β
sheets/lipids (1680-1719 cm-1) in comparison to the squamous cells from negative cases.
The difference spectrum between the lymphocytes from negative cases and bronchial
cells from negative cases shows significant differences across the entire spectrum (Figure
4.4). The lymphocytes from negative cases displayed an increased peak intensity in peaks
assigned to proteins and lipids (421-683), amide II / protein / lipid (1450-1562 cm-1),
COO- (1581-97 cm-1), amide I (1607-57 cm-1) and amide I disordered structure / β sheets
/ lipids (1680-1719 cm-1) in comparison to the bronchial cells from negative cases. The
bronchial cells showed increased peak intensities in peaks assigned to glycogen /
cholesterol / saccharides / protein / nucleic acids (752-1017 cm-1), glycogen / protein /
lipids / saccharides (1022-1099 cm-1), nucleic acids / amide III / proteins (1146-1325 cm1

), lipid / protein (1433-47 cm-1), nucleic acids (1576 cm-1), and the amide I peak from

1662-70 cm-1 in comparison to the lymphocytes from negative cases.
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Figure 4.4. The difference spectrum between the mean Raman spectrum of squamous cell
nuclei taken from negative cases and the mean Raman spectrum of bronchial epithelial
cell nuclei taken from negative cases is depicted in blue. The difference spectrum between
the mean Raman spectrum of squamous nuclei taken from negative cases and the mean
Raman spectrum of lymphocyte nuclei taken from negative cases is shown in red. The
difference spectrum between the mean Raman spectrum of lymphocyte nuclei taken from
negative cases and the mean Raman spectrum of bronchial nuclei taken from negative
cases is depicted in green. Shading indicates regions of the spectrum that were
significantly different (P < 0.01).

4.3.3 Mean spectral analysis of cell nuclei from negative cases, SCC cases, and
AC cases
4.3.3.1 Bronchial cell analysis

The mean Raman spectra taken from the bronchial cell nuclei of negative, SCC, and AC
cases are shown in Figure 4.5. Spectral differences between the bronchial cell nuclei of
86

negative cases and the bronchial nuclei from AC and SCC cases corresponded to peaks
relative to lipids (433, 569-626, 1282-1297, 1288-1310, 1468, 1470-1477 cm-1) proteins
(502-513, 525, 569-626, 640, 650, 819-826, 834-899, 920, 915- 928, 972-1000, 1008,
1214-1258, 1429, 1468, 1419-1448, 1597-1663 cm-1), and nucleic acids (676-688, 764788, 1231-1258, 1323-1326, 1416, 1429, 1576 cm-1), as shown in Figure 4.6. The
difference spectra of the bronchial cells in AC and SCC cases had similar profiles, with
peaks at 509, 599-626, 788, 848, 920, 988, 1023, 1223, 1240-1248, 1288-1297, 1429,
1467, 1597-1661 cm-1 differentiating them from the bronchial cells of negative cases. The
bronchial cells from AC and SCC patients showed a decreased peak intensity at 509, 599626, 1470, 1597-1661 cm-1, and an increased peak intensity at 788, 848, 920, 988, 1223,
1230, 1240-1248, 1288-1297, and 1429 cm-1, relative to the bronchial cells of negative
cases. This corresponds to a lower level of cholesterol, phosphatidylinositol, lipids, and
amide I, and an increase in collagen related peaks, nucleic acids, polysaccharides, proline
/ glycogen, amide III and lipids in the bronchial cells of NSCLC patients.
Bronchial cells from SCC patients displayed an elevated peak intensity at 509, 1100,
1340, 1379, 1401, 1410, ~1445 cm-1, 1480 and 1655 cm-1 compared to the bronchial cells
from AC patients, corresponding to increased lipid, protein, nucleic acid and amide I
content (Figure 4.6). An increase in methionine (~700 cm-1), tryptophan / nucleic acids/
phosphatidylinositol (760-776 cm-1), saccharides (~840, 860-900 cm-1), phenylalanine
(1006 cm-1), lipids / saccharides / proteins / nucleic acids (1130-1206 cm-1) amide III /
nucleic acids (1215, 1280 cm-1), amide II (1555 cm-1), amide I peaks at 1611-1628 cm-1,
and amide I of disordered structure / β sheets (1690 cm-1) was associated with spectra
from AC patients.
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Figure 4.5. Mean Raman spectra of negative bronchial cell nuclei (n= 70), bronchial cell
nuclei (n= 150) from SCC cases, and bronchial cell nuclei (n= 63) from AC cases.
Shading denotes the standard deviation.
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Figure 4.6. Difference spectrum between the mean Raman spectrum of bronchial
epithelial cell nuclei taken from negative cases and the mean Raman spectrum of
bronchial epithelial cell nuclei (blue, n=150) taken from SCC cases, and the mean Raman
spectrum of bronchial epithelial cell nuclei (red, n=63) taken from AC cases the
difference spectrum between the bronchial epithelial cell nuclei taken from SCC and AC
cases (green). Shading indicates regions of the spectrum that were significantly different
(P < 0.01).

4.3.3.2 Squamous cell analysis

The mean Raman spectra taken from the squamous cell nuclei of negative, SCC, and AC
cases are shown in Figure 4.7. The differences between the spectra taken from the
squamous cell nuclei of negative cases and the spectra taken from the squamous cell
nuclei of AC and SCC cases corresponded to peaks relative to proteins and lipids (408,
504-518, 584-88, 596-620, ~645, ~652, ~700, ~840, ~880, 989-1006, 1150-1200, 1205,
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1219-43, ~1330, 1435-46, 1456-1477, 1520-1570, and 1611-1703 cm-1) carbohydrates
(~495 467-73, 486-98, 551, and 836-840 cm-1), and nucleic acids (~692, ~780, 1219-43,
~1320, 1330, 1346-58, 1513-16, and 1520-72 cm-1), as shown in Figure 4.8. The
difference spectra of the squamous cells taken from AC and SCC cases display peaks at
495, 504, 597-607, 626, 1200-206, 1219-29, 1318-1323, 1456-62, 1526, 1534-38, 156772, and >1600 cm-1 differentiating them from the squamous cells of negative cases
(Figure 4.8). The squamous cells from the AC and SCC cases showed decreased peak
intensities at 495, 504, 597-608, 626, 1318-1323, 1456-1462, and >1600 cm-1, and
increased peak intensities at 1200-1206, 1219-1229, 1526, 1534-1538, and 1567-1572
cm-1, relative to the squamous cells from negative cases. This corresponds to a lower level
of proteins (504, 597-607, 1318-23, 1456, >1600 cm-1), glycerol/methionine (626 cm-1),
and guanine (1318-23 cm-1), and an increase in protein (1200-206 cm-1), glycogen
(1022/23 cm-1), amide III / nucleic acids (1220-29 cm-1), amide II (1526 cm-1) and
tryptophan / nucleic acids (1534-38, 1567-72 cm-1) in the squamous cells of AC and SCC
cases relative to the squamous cells of negative cases. Squamous cells from SCC cases
also have an alteration in nucleotide conformation (600 cm-1), and display elevated
nucleic acids (~780, 1513-1516 cm-1), protein / collagen related peaks (878-84, 1435-46
cm-1), and a lower level of cholesterol / lipids (408, 429-36, 440-45 cm-1), polysaccharides
(467-73, 486-95 cm-1), methionine (652-56 cm-1), guanine (1346-58 cm-1), and
phenylalanine (989-1006 cm-1) compared to the squamous cells of negative cases.
Squamous cells from SCC cases displayed an elevated peak intensity at 586, 627-47,
1370, and 1387-91 cm-1, compared to the squamous cells from AC cases, corresponding
to increased lipid and methionine content (Figure 4.8). Elevated cholesterol (408,
~430cm-1), phospholipids (717 cm-1), amide II (1548-59 cm-1), phenylalanine (1002 cm1

), tyrosine (632 cm-1), nucleic acids (762-774, 1175-1199 cm-1), polysaccharides (~840,
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860-900 cm-1), amide III (1280 cm-1), and amide I (1625-1628 cm-1) was associated with
the spectra from AC patients in comparison to the SCC patients.
The spectra taken from the nuclei of squamous cells with cytoplasmic projections (Figure
4.8) indicated many biochemical changes in the malignant cells. A reduced level of
carbohydrates, cholesterol, phosphatidylinositol, and methionine is evident in the
malignant cells by the lower peak intensities at ~408, ~430, 457-98, 567-70, 575-83, 58992, 595-641, 655-660, 681-707, and 711-24 cm-1 (Figure 4.8). The malignant cells also
show an increase in tryptophan (760 cm-1), DNA (780 cm-1), proline / tyrosine (847-56,
864-86 cm-1), and amide III / lipids / nucleic acids / saccharides (1220-54, 1278-85, 13501415, 1420-25, 1435-46, 1473-78 cm-1). The nuclei of both morphologically normal and
abnormal squamous cells in SCC cases are similar. In comparison to the squamous cells
of negative cases, both the squamous cells with cytoplasmic projections and
morphologically normal squamous cells from SCC cases display decreased peak
intensities at 408, 430-36, 441-45, 457-60, 467-73, 486-95, 505-18, 597-620, 626-41,
655-56, 692, 700-07, 1318-21, 1611, and 1620-31 cm-1, and increased peak intensities at
780, 878-84, 1022, 1048, 1220-43, and 1435-46 cm-1. This corresponds to an increase in
DNA (780 cm-1), the protein / lipid band at ~1445 cm-1, glycogen (1023, 1048 cm-1) and
amide III (1220-54, 1278-85 cm-1), and a decrease in carbohydrates, phosphatidylinositol,
methionine and amide I.
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Figure 4.7. Mean Raman spectra of negative squamous cell nuclei (n= 94), squamous cell
nuclei (n=189) from SCC cases, and squamous cell nuclei (n=67) from AC cases. Shading
denotes the standard deviation.
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Figure 4.8. Difference spectrum between the mean Raman spectrum of squamous cell
nuclei taken from negative cases and the mean Raman spectrum of squamous cell nuclei
(blue, n=189) taken from SCC cases. Difference spectrum between the mean Raman
spectrum of squamous cell nuclei taken from negative cases and the mean Raman
spectrum of the nuclei (black, n=60) of cells with cytoplasmic projections taken from
SCC cases. Difference spectrum between the mean Raman spectrum of squamous cell
nuclei taken from negative cases and the mean Raman spectrum of squamous cell nuclei
(red, n=67) taken from AC cases. Difference spectrum between the mean Raman
spectrum of squamous cell nuclei taken from SCC cases and the mean Raman spectrum
of squamous cell nuclei taken from AC cases (green). Shading indicates regions of the
spectrum that were significantly different (P < 0.01).
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4.3.3.3 Lymphocytes

The mean Raman spectra taken from the lymphocyte nuclei of negative, SCC, and AC
cases are shown in Figure 4.9. Spectral differences between the lymphocytes of negative
cases and the lymphocyte nuclei from AC and SCC cases corresponded to peaks relative
to proteins (524, ~630, 650, ~704-714, 719-45, 847-55, 1005, 1205, 1219-54, ~1298,
1346-60, 1387-1426, 1440-53, 1458, 1491-1534, 1584-93, 1603-1674, 1611-55 , 166772cm-1), lipids (415-54, 502-35, 574-636, ~1298, 1304-09, ~1368, 1387-1426, 1440-53,
1458, 1702-1707, ~1747--54 cm-1), carbohydrates (460-79, 522-67, 847-55, cm-1) and
nucleic acids (673-76, 719-45, 789-821, 828-30, 1060, 1219-54, 1304, 1346-60, 142229, 1458, 1476-80 cm-1), as shown in Figure 4.10. The difference spectra of lymphocytes
from AC and SCC cases had decreased peaks at 419-425, 470-473, 487-489, 519-22, 590,
623-628, 1611-1655, ~1750 cm-1 , and increased peaks at 1367-69, 1387-94 and 1422-26
cm-1 differentiating them from the lymphocytes of negative cases (Figure 4.10). This
corresponds to a lower level of cholesterol (419-25cm-1), polysaccharides (470-73, 48789), phosphatidylinositol (519-22), glycerol (590), protein (1611-55), and lipid (~1750)
in the lymphocytes of AC and SCC cases relative to the lymphocytes of negative cases.
This also indicates an increase in phospholipids (1367), lipids (1387-94), and deoxyribose
(1422-1426) in the lymphocytes of SCC and AC patients.
Lymphocytes from SCC cases displayed elevated cytosine and tyrosine (1204, 1210,
1154-1178, 1605-1608 cm-1), saccharides (847-55 cm-1), phenylalanine (1004 cm-1),
amide III (1219-54 cm-1), protein and lipid peaks at 1034 cm-1, 1052 cm-1, and 1400-1445
cm-1, and amide I (1655 cm-1) compared to the lymphocytes from AC cases (Figure 4.10).
Conversely, increased cholesterol and polysaccharides (430, 462-65, 524-87, 608 cm-1),
phosphatidylinositol (520, 594, 766-74 cm-1), methionine (631-35, 651-55 cm-1),
thiocynate (735 cm-1), nucleic acids (729-51, 782-822, 1183-93, 1341-57 cm-1), and
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protein and lipid peaks at 1106, 1307-13, 1341-57, 1378-9, 1472-1539, 1576-94, 1702,
and 1747-53 cm-1, were associated with the spectra from the lymphocytes from AC cases
in comparison to the lymphocytes from SCC cases.

Figure 4.9. Mean Raman spectra of lymphocyte nuclei from negative cases (n= 80),
lymphocyte nuclei (n=114) from SCC cases, and lymphocyte nuclei (n=58) from AC
cases. Shading denotes the standard deviation.
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Figure 4.10. Difference spectrum between the negative lymphocyte nuclear spectrum and
the SCC lymphocyte nuclear spectrum (blue, n=114), (b) the AC lymphocyte nuclear
spectrum (red, n=58). Difference spectrum between the mean Raman spectrum of
lymphocyte nuclei taken from SCC cases and the mean Raman spectrum of squamous
cell nuclei taken from AC cases (green). Shading indicates regions of the spectrum that
were significantly different (P < 0.01).

4.3.4 Cytoplasmic spectra analysis
Figure 4.11 shows the mean spectra taken from the cytoplasm of bronchial and squamous
cells from negative cases. As the lymphocyte cytoplasm is characteristically small,
spectra cannot be acquired from the cytoplasm of lymphocytes without spectral
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contamination from the nucleus as the Raman laser has a spot size of approximately 1
µm. For this reason lymphocytes were not included in this section.

Figure 4.11. Mean Raman spectra of cytoplasm from negative bronchial cells (black, n=
33), and negative squamous cells (blue, n=98). Shading denotes the standard deviation.
4.3.5 Spectral comparison of the cytoplasmic components of bronchial and
squamous cells from negative cases
The difference spectrum between the spectra taken from the cytoplasm of squamous cells
from negative cases and the spectra taken from the cytoplasm of bronchial cells from
negative cases displays significant peaks at 409-32, 449-537,542-47, 556-608, 620-695,
732-43, 764-68, 853-87, 896-970, 985-1054, 1068-85, 1106-1114, 1121-25, 1159-91,
1217-1268, 1296-1333, 1356-1415, 1434-43, 1462-1523, 1531-36, 1542-95, 1636-66,
1673-82, 1699-1721, 1727-32, and 1736-51 cm-1 differentiating the two cell types (Figure
4.12). The squamous cells showed increased peak intensities assigned to cholesterol /
lipids / methionine (409-695cm-1), protein / proline / hydroxyproline / saccharides /
glycogen (853-57, 896-970 cm-1), saccharides / lipids / proteins (1106-1125 cm-1), lipids
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/ proteins / nucleic acids (1296-1333 cm-1), amide I (1656 cm-1), and lipids (1699-1751
cm-1), relative to the bronchial cells. In comparison to the bronchial cells the squamous
cells displayed decreased peak intensities assigned to the pyrimidine ring breathing mode
at 766 cm-1, phenylalanine (1006 cm-1), tyrosine / nucleic acids (1159-91 cm-1), amide III
/ nucleic acids (1217-1268 cm-1), the protein / lipid / saccharide peaks at 1356-1415 cm1

, the lipid / protein peak at 1445 cm-1, disaccharides / amide II / nucleic acids / COO-

(1460-1595 cm-1), and amide I of disordered structure / β sheets (1674-1690 cm-1).

Figure 4.12. The difference spectrum between the mean Raman spectrum from the
cytoplasm of squamous cells from negative cases and the mean Raman spectrum from
the cytoplasm of bronchial cells from negative cases is depicted in blue. Shading indicates
regions of the spectrum that were significantly different (P < 0.01).

4.3.6 Mean cytoplasm spectral analysis of cells from negative cases, SCC cases,
and AC cases
4.3.6.1 Bronchial cell analysis

The mean Raman spectra taken from the cytoplasm of bronchial cells from negative, SCC,
and AC cases are shown in Figure 4.13. Spectral differences between the spectra from the
cytoplasm of bronchial cells from negative cases and spectra from the cytoplasm of
bronchial cells from AC and SCC cases corresponded to peaks relative to lipids (433,
576-633, 1285-1289, ~1425, ~1445, 1465-1468 cm-1) proteins (658-65, 918-40, 1003-
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1005, 1159-1163, 1223, 1249-65, 1285-89, 1330-54, 1360, 1402-1412, 1423-27, 144552, 1465-68, 1492-95, 1567-75, 1590-1666 cm-1), methionine (638-43, 696-731cm-1)
carbohydrates (453-67, 488-529, ~568, ~846 cm-1), and nucleic acids (~672, 676-90, 79499, 1238-43 cm-1), as shown in Figure 4.14.
The difference spectra of the bronchial cells from AC and SCC cases had similar profiles,
with peaks at 509, 599-626, 788, 848, 922, 988, 1230, 1240-1248, 1288-1297, 1429,
1470, 1597-1661 cm-1 differentiating them from the bronchial cells of negative cases.
The bronchial cells from AC and SCC patients had decreased peak intensities at ~440,
462-65, 488, ~492, 576-611, 658-65, 1106-1142 cm-1, and 1621-1661 cm-1, and increased
peak intensities at 846-867, 929-932, ~1005, 1048, 1228-30, 1238-43, 1250-54, 1259-62,
1285-89 cm-1, relative to the bronchial cells from negatives cases. This corresponds to a
lower level of proteins, cholesterol, saccharides, phosphatidylinositol, and amide I, and
an increase in collagen related peaks, glycogen, glucose, proline, tyrosine, valine,
phenylalanine, nucleic acids, and amide III in the bronchial cells of NSCLC patients.
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Figure 4.13. Mean Raman spectra of cytoplasm from negative bronchial cells (n= 33),
bronchial cells (n=68) from SCC cases, and bronchial cells (n=46) from AC cases.
Shading denotes the standard deviation.

Figure 4.14. Difference spectrum between the mean Raman spectrum of negative
bronchial epithelial cell cytoplasm (n=33) and (a) and the mean Raman spectrum of SCC
bronchial epithelial cell cytoplasm (blue, n=68), (b) the mean Raman spectrum of AC
bronchial epithelial cell cytoplasm (red, n=46). Difference spectrum between the mean
Raman spectrum of bronchial cell cytoplasm taken from SCC cases and the mean Raman
spectrum of bronchial cell cytoplasm taken from AC cases (green). Shading indicates
regions of the spectrum that were significantly different (P < 0.01).

4.3.6.2 Squamous cell analysis

The mean Raman spectra taken from the cytoplasm of squamous cells from negative,
SCC, and AC cases are shown in Figure 4.15. As shown in Figure 4.16, the differences
between the spectra taken from the cytoplasm of squamous cells from negative cases and
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the spectra taken from the cytoplasm of squamous cells from AC and SCC cases
corresponded to peaks relative to proteins, carbohydrates, nucleic acids (403 - 1005 cm1

), amide I, II, III, and lipids (1162-1171, 1181-1192, 1214-1292, 1337, 1344-1414, 1466-

1491, 1595-1665, 1674-1688, 1757-1771 cm-1). The difference spectra of the squamous
cells taken from AC and SCC cases display significant peaks at 418, 424-432, 451-502,
508-527, 568-726, 737-744, 748-751, 935, 950-954, 995, 1004, 1165-1171, 1181-1192,
1214-1292, 1336, 1344-1377, 1472-1489, 1594-1657, 1674-1688, 1770 cm-1
differentiating them from the squamous cells of negative cases. Both AC and SCC cases
showed decreased peak intensities at ~418, 424-432, 451-502, 508-527, 568-726, 737744, 748-751, 935, 950-54, 1594-1657, 1750 cm-1, and increased peak intensities at 995,
1004, 1165-1171, 1181-1192, 1214-1292, 1336-1337, 1472-1489, 1674-1688 cm-1,
relative to the negative cases (Figure 4.16).
This corresponds to a lower level of cholesterol (418, 424-432, 608, 614, 702 cm-1),
saccharides (451-502 cm-1), phosphatidylinositol / proteins (508-527 cm-1), proteins /
nucleic acids / carbohydrates / lipids (568-726 cm-1), saccharides / proline / valine(935,
~950 cm-1), amide I (1594-1657 cm-1), and lipid (~1750 cm-1), and an increase in collagen
related protein peaks (1169, 1223, 1240-47, 1265-69, 1278, 1280, 1283, 1336, 1344, 1488
cm-1), phenylalanine (995-1004 cm-1), glycogen (1048 cm-1), tyrosine (1165-1171 cm-1),
amide III / lipids (1219-92, ~1337 cm-1), amide II (1472-89 cm-1), and amide I of
disordered structure / β sheets (1674-1688 cm-1) in the cytoplasm of squamous cells from
AC and SCC cases relative to the negative cases. The squamous cells from SCC cases
also have reduced peak intensities associated with DNA at (772-791cm-1), protein (799860 cm-1), tryptophan (~880 cm-1), and carbohydrates/proteins (896-975 cm-1) compared
to the squamous cells of negative cases.
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In comparison to the cytoplasm of squamous cells from AC cases, squamous cells from
SCC cases are associated with higher peak intensities at 628, 650, 1410, 1445, 1558,
1590, 1611, and 1622 cm-1, and lower peaks at 834, 860, 910, 942, 964, and 1660 cm-1.
This corresponds to higher peaks intensities assigned to tyrosine / methionine (628, 650
cm-1), lipids / proteins (1410, 1445 cm-1), amide II (1558 cm-1), COO- (1590 cm-1), and
the tryptophan / cytosine / amide I peaks at 1611 and 1622 cm-1 associated with the SCC
cases, and higher peak intensities assigned to saccharides (834, 860, 910 cm-1), proline /
valine / saccharides (942 cm-1), protein (964 cm-1), and amide I (1660 cm-1) associated
with the AC cases.

Figure 4.15. Mean Raman spectra of cytoplasm from negative squamous cells (n= 98),
squamous cells (n=91) from SCC cases, and squamous cells (n=43) from AC cases.
Shading denotes the standard deviation.
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Figure 4.16. Difference spectrum between the mean Raman spectrum of negative
squamous cell cytoplasm (n=98) and (a) and the mean Raman spectrum of SCC squamous
cell cytoplasm (blue, n=91), (b) the mean Raman spectrum of AC squamous cell
cytoplasm (red, n=43). Difference spectrum between the mean Raman spectrum of
squamous cell cytoplasm taken from SCC cases and the mean Raman spectrum of
squamous cell cytoplasm taken from AC cases (green). Shading indicates regions of the
spectrum that were significantly different (P < 0.01).

103

4.3.7 Principal component analysis
PCA was then applied to the dataset to investigate if the different data sets could be
discriminated in an unsupervised approach. Figures 4.17-29 demonstrate the PCA scatter
plots developed using the spectral data. The PCs which showed the best discriminatory
performance were used in the scatter plots. If PCA did not effectively discriminate the
negative, SCC and AC subtypes, the first two PCs were depicted in a scatter plot to show
the overlapping clusters. Figure 4.17 depicts a PCA scatter plot of bronchial, squamous
and lymphocyte nuclei from negative cases. The spectra from bronchial and squamous
nuclei form two distinct clusters which are separated along the first principal component.
The lymphocyte spectra are dispersed evenly along PC1 and PC2 and cannot be
discriminated from the bronchial or squamous cells. The loadings of PC1 show peaks
assigned to glycogen / cholesterol / protein / phospholipids (420-690 cm-1), nucleic acids
(762-788 cm-1), glycogen / cholesterol / saccharides / protein / nucleic acids (805-1011
cm-1), peaks related to collagen (1024-32 cm-1), amide III / nucleic acid (1245-60 cm-1),
lipids / protein / amide I (1436-45, 1620-60 cm-1) associated with the squamous cells, and
peaks assigned to lipid / protein / nucleic acids / phosphates (1129-1200, 1351 cm-1), lipid
/ protein / COO- / nucleic acids / cytosine (1450-1546, 1564-82, 1611 cm-1), and amide I
disordered structure/β sheets/lipids (1680-1719 cm-1) associated with the bronchial cells.
The loadings of PC1 are in accordance with the significant peaks identified in the
difference spectrum between the mean bronchial nuclei from negative cases and the mean
squamous nuclei from negative cases. Although it is not shown, PCA was applied to the
bronchial and lymphocyte data but the cell types were not successfully discriminated.
Similarly, PCA of the data from squamous cells and lymphocytes showed no
discriminatory effect.
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Figure 4.17. A PCA scatter plot of bronchial, squamous and lymphocyte nuclei from
negative cases shows that the bronchial and squamous spectra form two distinct clusters
along the first principal component. The lymphocyte spectra are dispersed evenly along
PC1 and PC2 and cannot be discriminated from the bronchial or squamous cells. B The
loadings of PC1 show peaks assigned to glycogen / cholesterol / protein / phospholipids
(420-690 cm-1), nucleic acids (762-788 cm-1), glycogen / cholesterol / saccharides /
protein / nucleic acids (805-1011 cm-1), glycogen / peaks related to collagen (1024-32
cm-1), amide III / nucleic acid (1245-60 cm-1), lipids / protein / amide I (1436-45, 162060 cm-1) on the positive side, and peaks assigned to lipid / protein / nucleic acids /
phosphates (1129-1200, 1351 cm-1), lipid / protein / COO- / nucleic acids / cytosine (14501546, 1564-82, 1611 cm-1), and amide I disordered structure / β sheets / lipids (1680-1719
cm-1) on the negative side.
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Figure 4.18 shows the scatter plot of the PC scores along the first three principal
components, demonstrating overlapping of the spectra taken from the bronchial nuclei of
negative, SCC and AC cases. Although it is not shown, separate PCA of negative cases
versus AC cases, and negative cases versus SCC cases, yielded no discriminatory effect.

Figure 4.18. Three-dimensional scatter plot of the first three principal components
showing no discrimination of spectra taken from the bronchial nuclei of negative, SCC
and AC cases.

In Figure 4.19, a scatter plot shows the distribution of AC and SCC spectra after PCA.
Although the AC and SCC spectra form overlapping clusters, the AC spectra form a tight
cluster in the positive side of PC4, whereas the SCC spectra are widely distributed along
PC4. The loadings of PC4 indicate variation in methionine (715 cm-1), nucleic acids (779
cm-1), saccharides (840, 860 cm-1), phenylalanine (1004 cm-1), amide III / nucleic acids
(1220 cm-1), and amide I (1660 cm-1) associated with the positive side, and peaks assigned
to protein (1100 cm-1), glycogen (1145 cm-1), nucleic acids / protein (1340 cm-1), lipid
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(1379 cm-1), aspartic / glutamic acid (1400 cm-1), protein / collagen (~930, 1445 cm-1),
and COO- (1585 cm-1) associated with the negative side. This indicates a greater variation
in glycogen (1145 cm-1), nucleic acids / protein (1340 cm-1), lipid (1379 cm-1), aspartic /
glutamic acid (1400 cm-1), protein / collagen (~930, 1445 cm-1), and COO- (1585 cm-1)
content in the bronchial cell nuclei of SCC cases in comparison to the bronchial cell nuclei
of AC cases.

Figure 4.19. A Scatter plot showing spectra taken from the bronchial nuclei of SCC and
AC cases. The AC spectra form a tight cluster in the positive side of PC4, whereas the
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SCC spectra are widely distributed along PC4. The loadings of PC4 indicate variation in
methionine (715 cm-1), nucleic acids (779 cm-1), saccharides (840, 860 cm-1),
phenylalanine (1004 cm-1), amide III/nucleic acids (1220 cm-1), and amide I (1660 cm-1)
associated with the positive side, and peaks assigned to protein (1100 cm-1), glycogen
(1145 cm-1), nucleic acids / protein (1340 cm-1), lipid (1379 cm-1), aspartic / glutamic acid
(1400 cm-1), protein / collagen (~930, 1445 cm-1), and COO- (1585 cm-1) associated with
the negative side.
Figures 4.20 and 4.21 shows the score plots for the analysis of spectra taken from
squamous nuclei. The negative, SCC and AC cases were not distinguishable using the
model depicted in Figure 4.20. Similarly, the AC and SCC spectra overlap in Figure 4.21
and cannot be differentiated. Although it is not shown, separate PCA of negative cases
versus AC cases, and negative cases versus SCC cases, yielded no discriminatory effect.

Figure 4.20. PCA scatter plot of the first two principal components showing no
discrimination of spectra taken from the squamous nuclei of negative, SCC and AC cases.
PCA did not discriminate between the negative, SCC and AC cases using a combination
of PC that explained the first 95% of the variance in the dataset.
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Figure 4.21. PCA scatter plot of the first two principal components showing no
discrimination of spectra taken from the squamous nuclei of SCC and AC cases. PCA did
not discriminate between the negative, SCC and AC cases using a combination of PCs
that explained the first 95% of the variance in the dataset.

In Figure 4.22 the distribution of PC1 and PC2 was plotted to visualize the variances
between the lymphocytes from negative cases, SCC, and AC cases. The scatter plot using
PC1 and PC2 was used to demonstrate that the negative, SCC and AC cases could not be
discriminated. Although it is not shown, separate PCA of negative cases versus AC cases,
and negative cases versus SCC cases, yielded no discriminatory effect.
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Figure 4.22. A Scatter plot showing the distribution of spectra taken from lymphocyte
nuclei of negative cases, SCC, and AC cases, along the first and second PCs. PCA did
not discriminate between the negative, SCC and AC cases using a combination of PCs
that explained the first 95% of the variance in the dataset.

Representative spectra from lymphocyte nuclei, bronchial nuclei, and squamous nuclei
of negative cases were selected at random and combined into one negative group.
Similarly, representative spectra from the nuclei of each cell type from each lung cancer
subtype were selected at random and combined into one malignant group. Figure 4.23
shows that the negative cases could not be discriminated from the malignant cases using
PCA. The first two PCs were used to depict the overlapping distribution of negative and
malignant spectra.
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Figure 4.23. PCA scatter plot showing spectra from the nuclei of lymphocytes, bronchial,
and squamous cells of negative cases, SCC cases and AC cases, grouped according to a
negative or malignant diagnosis. The negative cases (blue circles) cannot be discriminated
from the malignant cases (blue circles) using PCA, which is depicted by the distribution
of spectra along the first and second PCs.

Spectra taken from the nuclei of lymphocytes, bronchial and squamous cells from SCC
cases were combined into one SCC group. Similarly, spectra taken from the nuclei of
lymphocytes, bronchial and squamous cells from AC cases were combined into one AC
group. Figure 4.24 shows the PCA scatter plot of the combined SCC group and the
combined AC group. The SCC and AC cases cannot be discriminated with PCA, which
is depicted with a plot of the first two PCs.
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Figure 4.24. PCA scatter plot showing spectra from the nuclei of lymphocytes,
bronchial and squamous cells of SCC, and AC cases grouped according to the lung
cancer subtype. PCA did not discriminate between the SCC and AC groups using a
combination of PCs that explained the first 95% of the variance in the dataset.

Figure 4.25 demonstrates the performance of PCA in discriminating spectra taken from
the cytoplasm of bronchial and squamous cells of negative cases. The scatter plot shows
that the spectra from bronchial and squamous cells form two distinct clusters that are
separated along the first and second principal components. The loadings of PC1 show
peaks assigned to cholesterol / lipids / methionine (409-695cm-1), protein / proline /
hydroxyproline / saccharides / glycogen (853-57, 896-970 cm-1), saccharides / lipids /
proteins (1106-1125 cm-1), amide I (1656 cm-1), and lipids (1699-1751 cm-1) associated
with the squamous cells, and peaks assigned to phenylalanine (1006 cm-1), tyrosine /
nucleic acids (1159-91 cm-1), amide III / nucleic acids (1217-1268 cm-1), the protein /
lipid / saccharide peaks at 1356-1415 cm-1, the lipid / protein peak at 1445 cm-1,
disaccharides / amide II / nucleic acids / COO- (1460-1595 cm-1), and amide I of
disordered structure / β sheets (1674-1690 cm-1) associated with the bronchial cells. The
112

loadings of PC2 show peaks assigned to proline / valine / saccharides (~930 cm-1) and
amide I (1656 cm-1) associated with the squamous cells.

Figure 4.25. A PCA scatter plot of spectra taken from the cytoplasm of bronchial and
squamous cells of negative cases shows that the bronchial and squamous spectra form
two distinct clusters along the first and second principal components. B The loadings of
PC1 show peaks assigned to cholesterol / lipids / methionine (409-695cm-1), protein /
proline / hydroxyproline / saccharides / glycogen (853-57, 896-970 cm-1), saccharides /
lipids / proteins (1106-1125 cm-1), lipids / proteins / nucleic acids (1296-1333 cm-1),
amide I (1656 cm-1), and lipids (1699-1751 cm-1) on the positive side and the pyrimidine
ring breathing mode at 766 cm-1, phenylalanine (1006 cm-1), tyrosine / nucleic acids
(1159-91 cm-1), amide III / nucleic acids (1217-1268 cm-1), the protein / lipid / saccharide
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peaks at 1356-1415 cm-1, the lipid / protein peak at 1445 cm-1, disaccharides / amide II /
nucleic acids / COO- (1460-1595 cm-1), and amide I of disordered structure / β sheets
(1674-1690 cm-1) on the negative side. The loadings of PC2 show peaks assigned to
proline / valine / saccharides (~930 cm-1) and amide I (1656 cm-1) on the negative side.

Figure 4.26 shows the PCA scatter plot of spectra taken from the bronchial cytoplasm of
negative, SCC and AC cases. The three dimensional scatter plot demonstrates the
discrimination of the three clusters of spectra. The first PC separates the SCC cases from
the AC cases. The loadings of PC1 show positive peaks associated with amide III / nucleic
acids (1250 cm-1), proteins (~1330 cm-1), lipids (1445 cm-1), and amide I (1656 cm-1)
associated with the SCC cases, and negative peaks assigned to COO- / amide II /
tyrptophan / amide I (~1500-1620 cm-1) associated with the AC cases. A combination of
PC2 and PC3 separates the negative cases from the SCC and AC cases. The second PC is
mainly responsible for discriminating negative and AC spectra. The loadings of PC2
show peaks assigned to proteins / carbohydrates / nucleic acids (735-890 cm-1),
phenylalanine (1000 cm-1), amide III / nucleic acids (1200-1280 cm-1), and amide I of
disordered structure / β sheets (1690 cm-1) associated with the AC cases, and peaks
assigned to nucleotides / phosphatidylinositol / glycerol (570-620 cm-1), carbohydrates /
proteins / lipids (1100-1145 cm-1), phopsholipids / protein / DNA (~1330 cm-1), protein /
lipid (~1410 cm-1), and amide I (1650 cm-1) with the negative cases. PC3 discriminates
the negative and SCC clusters and the loadings indicate peaks assigned to with increased
saccharides (850 cm-1), proline / valine (930 cm-1), and protein / lipid (1410 cm-1)
associated with the SCC cases and peaks assigned to phosphatidylinositol (~570-80 cm1

), and amide I (1650 cm-1) associated with the negative cases. The loadings of PC1, PC2

and PC3 are in accordance with the significant peaks identified in the difference spectra
between the cytoplasm of bronchial cells from negative, SCC and AC cases.
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Figure 4.26. A PCA scatter plot of spectra taken from the bronchial cytoplasm of negative,
SCC and AC cases. A three dimensional scatter plot demonstrates the discrimination of
the three clusters of spectra. PC1 differentiates the SCC cases and the AC cases. A
combination of PC2 and PC3 separates the negative cases from the SCC and AC cases.
PC2 is mainly responsible for discriminating negative and AC spectra. PC3 discriminates
the negative and SCC clusters. B The loadings of PC1 show positive peaks associated
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with amide III/nucleic acids (1250 cm-1), proteins (~1330 cm-1), lipids (1445 cm-1), and
negative peaks associated with amide I and II (~1500-1650 cm-1). The loadings of PC2
show peaks assigned to proteins/carbohydrates/nucleic acids (735-890 cm-1),
phenylalanine (1000 cm-1), amide III/nucleic acids (1200-1280 cm-1), and amide I of
disordered structure/β sheets (1690 cm-1) on the positive side and
nucleotides/phosphatidylinositol/glycerol (570-620 cm-1), carbohydrates/proteins/lipids
(1100-1145 cm-1), collagen (~1330 cm-1), protein (~1410 cm-1), and amide I (1650 cm-1)
on the negative side. The loadings of PC3 indicate positive peaks associated with
increased saccharides (850 cm-1), proline/valine (930 cm-1), and protein (1410 cm-1), and
decreased phosphatidylinositol (~570-80 cm-1), and amide I (1650 cm-1).

PCA of spectra from the cytoplasm of squamous cells shows variance between the
negative cluster and the NSCLC clusters along PC1, with some overlap (Figure 4.27).
The majority of spectra from negative cases are distributed in the negative side of PC1,
whereas the majority of spectra SCC and AC cases are distributed along the positive side
of PC1. The SCC and AC spectra were not discriminated using PCA. The loadings of
PC1 show peaks assigned to protein / collagen (1169, 1223, 1240-47, 1265-69, 1278,
1280, 1283, 1336, 1344, 1488 cm-1) phenylalanine (995-1004 cm-1), glycogen (1048 cm1

), tyrosine (1165-1171 cm-1), amide III / lipids (1219-92, ~1337 cm-1), amide II (1472-

89 cm-1), and amide I of disordered structure / β sheets (1674-1688 cm-1) associated with
the SCC and AC cases, and peaks assigned to cholesterol (418, 424-432, 608, 614, 702
cm-1), saccharides (451-502 cm-1), phosphatidylinositol / proteins (508-527 cm-1),
proteins / nucleic acids / carbohydrates / lipids (568-726 cm-1), proline / valine(935, ~950
cm-1), amide I (1594-1657 cm-1), and lipid (~1750 cm-1) associated with the negative
cases. The loadings of PC1 are in accordance with the significant peaks identified in the
difference spectra between the cytoplasm of squamous cells from negative, SCC and AC
cases.
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Figure 4.27. A PCA scatter plot of spectra from the cytoplasm of squamous cells showing
variance between the negative cluster and the SCC and AC clusters along PC1, with some
overlap. The majority of spectra from negative cases are distributed in the negative side
of PC1, whereas the majority of spectra SCC and AC cases are distributed along the
positive side of PC1. The SCC and AC spectra form overlapping clusters and cannot be
discriminated with PCA. B The loadings of PC1 show peaks assigned to protein/collagen
(1169, 1223, 1240-47, 1265-69, 1278, 1280, 1283, 1336, 1344, 1488 cm-1) phenylalanine
(995-1004 cm-1), glycogen (1048 cm-1), tyrosine (1165-1171 cm-1), amide III/ lipids
(1219-92, ~1337 cm-1), amide II (1472-89 cm-1), and amide I of disordered structure/β
sheets (1674-1688 cm-1) on the positive side, and cholesterol (418, 424-432, 608, 614,
702 cm-1), saccharides (451-502 cm-1), phosphatidylinositol/proteins (508-527 cm-1),
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proteins/nucleic acids/carbohydrates/lipids (568-726 cm-1), proline/valine(935, ~950 cm1
), amide I (1594-1657 cm-1), and lipid (~1750 cm-1) on the negative side.

Representative spectra from the cytoplasm of bronchial and squamous cells of negative
cases were selected at random and combined into one negative group. Similarly,
representative spectra from the cytoplasm of bronchial and squamous cells from SCC and
AC cases were selected at random and combined into one malignant group. Figure 4.28
depicts a PCA scatter plot of the grouped negative cases and grouped malignant cases.
The negative and malignant cases cannot be discriminated, however the malignant cases
form a cluster along PC1, whereas the negative cases are evenly distributed along PC1.
The loadings of PC1 reveal a greater variation in phosphatidylinositol (575 cm-1), glucose
(908 cm-1), proline / valine / saccharides (~935 cm-1), saccharide (1110 cm-1) and amide
I (1650cm-1) in the cytoplasm of cells from negative cases. The loadings of PC1 are
similar to the loadings discriminating spectra from the cytoplasm of bronchial and
squamous cells from negative cases, indicating that the variation explained by PC1 is
likely differences between the bronchial and squamous cells.
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Figure 4.28. A PCA scatter plot showing spectra from the cytoplasm of bronchial and
squamous cells of negative cases, SCC cases and AC cases, grouped according to a
negative or malignant diagnosis. The negative and malignant cases cannot be
discriminated. The malignant cases (red circles) form a cluster along PC1, whereas the
negative cases (blue circles) are evenly distributed along PC1. B The loadings of PC1
revealed a greater variation in phosphatidylinositol (575 cm-1), glucose (908 cm-1),
proline/valine/saccharides (~935 cm-1), saccharide (1110 cm-1) and amide I (1650cm-1) in
the negative cases. The loadings of PC1 are similar to the loadings discriminating spectra
from the cytoplasm of bronchial and squamous cells from negative cases, indicating that
the variation explained by PC1 is likely the difference between the bronchial and
squamous cells.

Spectra taken from the cytoplasm of bronchial and squamous cells from SCC cases were
combined into one SCC group. Similarly, spectra taken from the cytoplasm of bronchial
119

and squamous cells from AC cases were combined into one AC group. Figure 4.29 depicts
the PCA scatter plot of the combined SCC group and the combined AC group. The SCC
and AC cases cannot be discriminated with PCA, which is depicted with a plot of the first
two PCs. The AC cases (red circles) form a two distinct clusters along PC1. The loadings
of PC1 are similar to the loadings discriminating spectra from the cytoplasm of bronchial
and squamous cells from negative cases, indicating that the two distinct clusters are likely
a separation of the bronchial and squamous cells from AC cases.
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Figure 4.29. A PCA scatter plot showing spectra from the cytoplasm of bronchial and
squamous cells of SCC, and AC cases grouped according to the lung cancer subtype. The
SCC and AC cases cannot be discriminated with PCA, which is depicted with a plot of
the first two PCs. The AC cases (red circles) form two distinct clusters along PC1. B The
loadings of PC1 are similar to the loadings discriminating spectra from the cytoplasm of
bronchial and squamous cells from negative cases, indicating that the two distinct clusters
are likely a separation of the bronchial and squamous cells from AC cases.

4.3.8 PLSDA classification of NSCLC subtypes
In order to evaluate the efficacy of Raman spectroscopy to accurately classify the NSCLC
subtypes, PLSDA classification models were developed. PLSDA employs the same
fundamental principle of PCA, but the PLS components, or latent variables (LVs), are
rotated to maximise the covariance between spectral variation and class membership. This
obtains separation between classes based on the diagnostically relevant spectral
variations. To produce an unbiased classifier, the number of spectra used for each class
was matched. As the diagnostically significant peaks are identified in the first few LVs,
the required number of latent variables in each model was used to set the cross-validation
classification error average at 5%. Utilising more LVs to develop the models increases
the likelihood that classification is based on noise. As Figure 4.30 illustrates, cell types
can be discriminated with PLSDA. The LV score scatter plot of Raman spectra taken
from the bronchial cell nuclei of negative cases, squamous cell nuclei of negative cases,
and lymphocyte nuclei of negative cases, shows separation of the three cell types using
the first 2 latent variables. The spectra from lymphocyte, bronchial and squamous cell
nuclei form three distinct clusters which are separated with the first two latent variables.
The first LV discriminates the cluster of squamous cell nuclei from the bronchial cell and
lymphocyte clusters. The loadings of LV1 show peaks assigned to glycogen / cholesterol
/ protein / phospholipids (421-690 cm-1), glycogen / cholesterol / saccharides / protein /
nucleic acids (762-1011 cm-1), glycogen / peaks related to collagen (1024-32 cm-1), amide
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III / nucleic acid (1221-40, 1245-60 cm-1), lipids / protein / amide I (1436-44, 1620-60
cm-1) associated with the squamous cells, and peaks assigned to lipid / protein / nucleic
acids / phosphates (1129-1200, 1315-20, 1351 cm-1), and lipid / protein / COO- / nucleic
acids / cytosine (1450-1546, 1564-82, 1611 cm-1), and amide I disordered structure / β
sheets / lipids (1680-1719 cm-1) associated with the bronchial and lymphocyte nuclei. The
lymphocyte nuclei from negative cases are differentiated from the bronchial cell nuclei
of negative cases along the second LV. The loadings of LV2 show peaks assigned to
proteins and lipids (421-683), amide II / protein / lipid (1450-1562 cm-1), COO- (1581-97
cm-1), amide I (1607-57 cm-1) and amide I disordered structure / β sheets / lipids (16801719 cm-1) associated with the lymphocyte nuclei from negative cases, and peaks
assigned to glycogen / protein / lipids / saccharides (1022-1099 cm-1), nucleic acids /
amide III / proteins (1146-1325 cm-1), lipid / protein (1433-47 cm-1), nucleic acids (1576
cm-1), and the amide I peak from 1662-70 cm-1 associated with the bronchial cell nuclei
from negative cases. The loadings of LV1 and LV2 are in accordance with the significant
peaks identified in the difference spectra between the lymphocytes, bronchial and
squamous cells from negative cases.
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Figure 4.30. LV score scatter plot of Raman spectra from bronchial cell nuclei of negative
cases (blue circles), squamous cell nuclei of negative cases (green squares), and
lymphocyte nuclei of negative cases (solid red circles). The three-way classification
model used the first 3 latent variables and yielded sensitivities and specificities of 6994% for discrimination based on cell type. B and C Latent variables loadings of the
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developed PLS-DA model for the dataset obtained from the bronchial, squamous, and
lymphocyte nuclei of negative cases.

Cell type can therefore inaccurately influence the performance of a classifiction model
used to classify the NSCLC subtypes. To ensure classification was based on cancer
subtype and not discrepancies in cell type, spectra taken from bronchial cells were
analysed together, spectra from squamous cells were analysed together, and spectra from
lymphocytes were analsyed together.
Table 4.2 shows the results of three separate PLSDA models in discriminating spectra
from bronchial cell nuclei of negative cases from the bronchial cell nuclei of SCC or AC
cases, and the bronchial nuclei of SCC cases from the bronchial nuclei of AC cases. The
performance of each two-way classification is shown using the sensitivity and specificity
of each model. The first 3 latent variables were used in each case to develop the PLSDA
classifier. PLSDA classification of bronchial cells from negative cases vs. bronchial cells
from SCC or AC cases yielded sensitivities of ≥91%, and specificities of ≥89%. The
bronchial cells from SCC cases were discriminated from the bronchial cells of AC cases
with a sensitivity and specificity of 90% and 86% respectively.
Table 4.3 shows the results of the two-way PLSDA classification models used for the
discrimination of spectra from the squamous cell nuclei of negative cases from the
squamous cell nuclei of SCC or AC cases, and spectra from the squamous cell nuclei of
SCC cases from the squamous cell nuclei of AC cases. Each model was developed using
4 latent variables. Each two-way classification model yielded a sensitivity above 73% and
a specificity above 78%.
Table 4.4 shows the results for the PLSDA classification of spectra taken from the
lymphocyte nuclei of negative cases versus spectra taken from the lymphocyte nuclei of
SCC or AC cases, and spectra taken from the lymphocyte nuclei of SCC cases from the
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lymphocyte nuclei of AC cases. Each classification is the result of separate two-way
models using 3 latent variables each. The models yielded sensitivities above of 82% and
specificities above 82% for the discrimination of the SCC and AC subtypes.
Table 4.5 demonstrates the performance of a three-way classification model in
discriminating the bronchial cell nuclei of negative cases, the bronchial cell nuclei of
SCC, and the bronchial cell nuclei of AC cases. The model yielded diagnostic sensitivities
from 81-90% and specificities from 79-91% using the first 5 latent variables. Figure 4.31
is a LV score scatter plot of Raman spectra from bronchial cell nuclei of negative cases,
SCC cases, and AC cases, showing separation of the negative cases and NSCLC subtypes.
The negative cases are separated from the SCC and AC subtypes along LV1. The loadings
of LV1 show peaks assigned to nucleic acids (788 cm-1), proteins / saccharides (848 cm1

) amide III / nucleic acids (1223-1297 cm-1), proteins / lipids / nucleic acids (1350 cm-1)

and amide I of disordered structure / β sheets (1686cm-1) associated with the SCC and
AC cases, and peaks assigned to protein (509 cm-1), cholesterol / lipid / methionine (599626 cm-1), lipids / amide II (1470 cm-1), and amide I (1597-1661 cm-1) associated with
the negative cases. The AC and SCC subtypes form two distinct clusters and can be
discriminated along the second latent variable. The loadings of LV2 indicate variation in
methionine (~700 cm-1), tryptophan / nucleic acids / phosphatidylinositol (760-776 cm1

), saccharides (~840, 860 cm-1), saccharides / proline / valine (930 cm-1), phenylalanine

(1006 cm-1), lipids / saccharides / proteins / nucleic acids (1130-1206 cm-1) amide III /
nucleic acids (1215, 1280 cm-1), protein / lipid (1445 cm-1), amide II (1555 cm-1), and the
amide I peaks at 1611-1628 cm-1 associated with the AC cases, and peaks assigned to
protein (509 cm-1), nucleic acids (788 cm-1), the protein peak at 1100 cm-1, nucleic acids
/ protein (1340 cm-1), lipid (1379 cm-1), amide II / nucleic acids (1480 cm-1), and COO(1585 cm-1) associated with the SCC cases.
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Figure 4.31. A Scatter plot of the latent variables (LVs) obtained from the Raman spectral
dataset of bronchial cell nuclei from negative cases (blue circles), SCC cases (green
squares), and AC cases (solid red circles). B and C Latent variables loadings of the
developed PLS-DA model for the dataset obtained from bronchial nuclei.
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Table 4.6 summarises the results for the three-way classification of the negative, SCC and
AC subtypes, using spectra taken from squamous cell nuclei. The first 6 latent variables
were used to develop the three-way PLSDA model. Squamous cells from negative cases
were discriminated from the squamous cells of SCC and AC cases with a sensitivity and
specificity above 91%. Squamous cells from AC cases were identified with a sensitivity
and specificity of 63 and 79% respectively. The SCC subtype was classified with a
sensitivity of 60%, and a specificity of 78%. Figure 4.32 depicts the scatter plots of the
spectra taken from the squamous cell nuclei of negative cases and spectra from the
squamous cell nuclei of each NSCLC subtype, along the first three latent variables. The
negative spectra can be discriminated from the SCC and AC spectra using a combination
of the first two latent variables. The loadings of the LV1 (figure 4.33) and indicate peaks
assigned to phenylalanine (1006 cm-1), nucleic acids / proteins (1318-1323, 1346-58 cm1

), protein / lipid (1456-1462 cm-1), and amide I (1660 cm-1) associated with the negative

cases, and peaks assigned to nucleic acids (780, 1513-1516 cm-1), amide II (1526 cm-1)
and tryptophan / nucleic acids (1534-38, 1567-72 cm-1) associated with the SCC and AC
cases. The second LV responsible for discriminating the negative cases is LV2 (Figure
4.33). The loadings of LV2 show peaks assigned to polysaccharides (495 cm-1), protein
(504, 597-608), , and amide I (1656 cm-1) associated with the negative cases, and peaks
assigned to amide III / nucleic acids (1200-1206, 1219-1229) and amide I of disordered
structure / β sheets 1686 (cm-1) associated with the SCC and AC cases. LV3 is responsible
for discriminating the SCC and AC clusters. The loadings of LV3 show peaks assigned
to DNA (779 cm-1), amide III / nucleic acids (1230 cm-1), and amide II / COO- / amide I
(1480-1656 cm-1) associated with the AC cases, and peaks assigned to protein /
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carbohydrates (~930 cm-1), proteins / lipids / saccharides / nucleic acids (1370, 1387-1485
cm-1) associated with the SCC cases (figure 4.33).

Figure 4.32. A Scatter plot of the first two LVs obtained from the Raman spectral dataset
of squamous cell nuclei from negative cases (blue circles), SCC cases (green squares),
and AC cases (solid red circles). B Scatter plot of the first and third LVs obtained from
the Raman spectral dataset of squamous nuclei from negative cases (blue circles), SCC
cases (green squares), and AC cases (solid red circles).
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Figure 4.33. Latent variables from PLSDA of Raman spectra from squamous cell nuclei
of negative cases, SCC cases, and AC cases. ). A-C The Latent variables loadings of the
developed PLS-DA model for the dataset obtained from squamous cell nuclei. A depicts
LV1, B shows the loadings of LV2, and C illustrates the loadings of LV3.

Table 4.7 shows the performance of a three-way PLSDA model for the classification of
negative, SCC, and AC using spectra from lymphocyte nuclei. Using 5 latent variables,
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spectra in the negative group were differentiated from the SCC and AC subtypes with a
sensitivity and specificity above 78%. The classification model identified the spectra from
the SCC subtype with a sensitivity and specificity of 80% and 78% respectively, and
spectra from the AC subtype were detected with a sensitivity of 81% and specificity of
88%. Figure 4.34 is a LV score scatter plot of Raman spectra from lymphocyte nuclei of
negative cases, SCC cases, and AC cases. The SCC spectra and the AC spectra form two
separate clusters along the first latent variable, which can be discriminated from the
negative cases along LV2, with some overlap. The loadings of LV1 indicate variation in
thiocyante (735 cm-1), nucleotide conformation (794 cm-1), protein (1106 cm-1), protein /
nucleic acids (1341 cm-1), lipid / amide II (1465-1493 cm-1), COO- (1585 cm-1), and lipid
/ aspartic / glutamic acid (1702 cm-1) associated with the AC cases, and peaks assigned
to phenylalanine (1006 cm-1), cytosine / tyrosine (1161-1174 cm-1), amide III / nucleic
acids (1280 cm-1), lipid / protein / aspartic / glutamic acid (1400-1445 cm-1), amide II
(1560 cm-1), amide I (1606-67 cm-1), and amide I disordered structure / β sheets (1690
cm-1) associated with the SCC cases. The loadings of LV1 are in accordance with the
significant peaks identified in the difference spectrum between the lymphocytes of SCC
cases and the lymphocyte nuclei of AC cases. The loadings of LV2 show peaks assigned
to amide III / nucleic acids (~1240 cm-1), proteins and lipids (1387-1453 cm-1) associated
with the SCC and AC cases, and a peak associated with amide I (1650 cm-1) associated
with the negative cases. The loadings of LV2 are a combination of the two difference
spectra between the lymphocyte nuclei of negative cases and the lymphocyte nuclei of
SCC and AC cases.

130

Figure 4.34. A Scatter plot of the LVs obtained from the Raman spectral dataset of
lymphocyte nuclei from negative cases (blue circles), SCC cases (green squares), and AC
cases (solid red circles). B and C Latent variables loadings of the developed PLS-DA
model for the dataset obtained from lymphocyte nuclei.
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Table 4.8 shows the results of a PLSDA model in discriminating spectra taken from
bronchial cell nuclei of negative cases from the spectra taken from bronchial cell nuclei
of SCC and AC cases combined into one malignant group. In order to produce an unbiased
classifier, the total number of spectra from malignant cases used to develop the classifier
was identical to the number of spectra from negative cases being used. The first 3 latent
variables were used to develop the PLSDA classifier. PLSDA classification of bronchial
cells from negative cases vs. bronchial cells from malignant cases yielded a sensitivity of
82%, and a specificity of ≥88%. Table 4.8 also shows the results of the PLSDA model
used to differentiate between spectra taken from the squamous cell nuclei of negative
cases, and the squamous cell nuclei of AC and SCC cases combined into one malignant
group. The total number of spectra from malignant cases used to develop the classifier
was identical to the number of spectra from negative cases being used. Using 3 LVs the
two-way classifier yielded a sensitivity of 88% and a specificity of 84% for the
classification of squamous cell nuclei from negative and malignant cases. Table 4.8 also
shows the results of a PLSDA model in discriminating spectra taken from the lymphocyte
nuclei of negative cases, and spectra taken from the lymphocyte nuclei of SCC and AC
cases combined into one malignant group. The total number of spectra from malignant
cases used to develop the classifier was identical to the number of spectra from negative
cases being used. The negative and malignant lymphocyte nuclei were classified with a
sensitivity of 81%, and a specificity of 77% using 3 LVs.
Then the ability of PLSDA to correctly classify the NSCLC subtypes using a dataset of
combined cell types was evaluated. Representative spectra from lymphocyte nuclei,
bronchial cell nuclei, and squamous cell nuclei of negative cases were selected at random
and combined into one negative group. Similarly, representative spectra from the nuclei
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of each cell type from each lung cancer subtype were selected at random and combined
into one malignant group. In order to produce an unbiased classifier, the total number of
spectra from malignant cases used to develop the classifier was identical to the number
of spectra from negative cases being used. In addition, the number of spectra used from
each cell type was also matched in the negative and malignant groups. That is, the number
of bronchial spectra used to develop the negative group matched the number of bronchial
spectra used to develop the malignant group, and so on. Table 4.9 shows results achieved
for discriminating spectra from the negative and malignant groups. The two-way
classifier yielded a sensitivity of 89% and a specificity of 79% using 3 LVs. Figure 4.35
shows the discriminatory performance of PLSDA in differentiating the grouped negative
and grouped malignant spectra. The negative cases were discriminated from the
malignant cases with some overlap using the first and third LVs. The spectra from
negative cases are predominantly distributed in the positive side of LV1, whereas spectra
from the malignant cases are predominantly distributed in the negative side of LV1. The
loadings of LV1 show peaks assigned to tyrosine / methionine (628, 658 cm-1),
phenylalanine (1006 cm-1), lipid (~1128 cm-1), the lipid and protein peak at 1445 cm-1,
and amide I (1650 cm-1) associated with the negative group, and peaks assigned to DNA
(780 cm-1), the saccharide / protein / lipid / nucleic acids peaks at 1020-1105 cm-1, lipid
(1379 cm-1), amide II (1489 cm-1), and COO- 1575 associated with the malignant group.
The spectra from negative cases are predominantly distributed in the negative side of
LV3, whereas spectra from the malignant cases are predominantly distributed in the
positive side of LV3. The loadings of LV3 show peaks assigned to proteins (~509 cm-1),
nucleic acids / saccharides / protein / lipids (729-1013 cm-1), protein / lipids (1430 cm-1),
and amide I (~1650 cm-1) associated with the negative group, and peaks assigned to
carbohydrates / proteins / lipids / nucleic acids (1110-1198 cm-1), nucleic acids / protein
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(~1340 cm-1), lipid (1379 cm-1), COO- / amide II / tyrptophan / amide I (~1475-1610 cm1

), amide I of disordered structure / β sheets (1690 cm-1) associated with the malignant

group.

Figure 4.35. A Scatter plot of the first and third LVs obtained from the Raman spectral
dataset of combined bronchial, squamous, and lymphocyte nuclei. Representative spectra
from each cell type from the negative, SCC, and AC cases were grouped according to a
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negative or malignant diagnosis. The negative cases (red circles) are discriminated from
the malignant cases (blue circles) along the first and third LVs. B and C Latent variables
loadings of the developed PLS-DA model for the dataset obtained from bronchial,
squamous, and lymphocyte nuclei.

Spectra taken from the nuclei of lymphocytes, bronchial and squamous cells from SCC
cases were combined into one SCC group. Similarly, spectra taken from the nuclei of
lymphocytes, bronchial and squamous cells from AC cases were combined into one AC
group. In order to produce an unbiased classifier, the total number of spectra from SCC
cases used to develop the classifier was identical to the number of spectra from AC cases
being used. As before, the number of spectra used from each cell type was also matched
in the SCC and AC groups. Table 4.9 shows results achieved for discriminating spectra
from the SCC and AC groups. The two-way classifier yielded a sensitivity of 84% and a
specificity of 69% using 3 LVs. Figure 4.36 shows the PLSDA scatter plot of the
combined SCC group and the combined AC group. The SCC cases were discriminated
from the AC cases with some overlap using the first and second LVs. The spectra from
SCC cases are predominantly distributed in the positive side of LV1, whereas spectra
from the AC cases are predominantly distributed in the negative side of LV1. The
loadings of LV1 indicate variation in protein (509 cm-1), thiocyanate (735 cm-1), nucleic
acids (790 cm-1), protein (1106 cm-1), lipid (1380 cm-1), amide II (1493 cm-1), and COO(1585 cm-1) associated with the AC cases, and peaks assigned to saccharides (840 cm-1),
proline / valine / saccharides (930 cm-1), phenylalanine (1006 cm-1), cytosine / tyrosine
(1161-1174 cm-1), amide III / nucleic acids (1224 cm-1), lipid / protein / aspartic /
glutamic acid (1400-1445 cm-1), and amide I (1666 cm-1) associated with the SCC cases.
The spectra from SCC cases are predominantly distributed in the negative side of LV2,
whereas spectra from the AC cases are predominantly distributed in the positive side of
LV1. The loadings of LV2 indicate variation in protein (509 cm-1), tyrosine / methionine
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(631, 646 cm-1), nucleic acids (790 cm-1), protein (1106 cm-1), lipid (1380 cm-1), amide II
(1493 cm-1), and COO- (1585 cm-1) associated with the SCC cases, and peaks assigned to
saccharides (840, 860 cm-1), proline / valine / saccharides (930 cm-1), phenylalanine (1006
cm-1), cytosine / tyrosine (1161-1174 cm-1), lipid / protein (1445 cm-1), and amide I
(>1600 cm-1) associated with the AC cases.
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Figure 4.36. A Scatter plot showing spectra from the bronchial, squamous, and
lymphocyte nuclei of SCC and AC cases grouped according to the lung cancer subtype.
The AC cases (red circles) are discriminated from the SCC cases (blue circles) along the
first and second LVs. B and C Latent variables loadings of the developed PLS-DA model
for the dataset obtained from bronchial, squamous, and lymphocyte nuclei.
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To evaluate the ability of PLSDA to discriminate negative cases from NSCLC subtypes
using spectra taken from the cytoplasm of cells, spectra taken from the cytoplasm of
bronchial cells were used to develop a supervised classifier. Another classifer was
developed with spectra taken from the cytoplasm of squamous cells. As spectra from the
cytoplasm of bronchial and squamous cells of negative cases were effectively
discriminated using PCA, the two cell types were not comparatively analysed using
PLSDA. Table 4.10 shows that the 3 way classification model discriminated the bronchial
cytoplasmic spectra from negative cases, SCC cases, and AC cases, with sensitivites of
68-97% , and specificities of 85-95% using the first 4 latent variables. Figure 4.37 depicts
the discriminatory performance of the PLSDA model developed using spectra taken from
the cytoplasm of bronchial cells from negative, SCC and AC cases. The first LV separates
the SCC cases from the AC cases. The loadings of LV1 show negative peaks assigned to
proteins (~1330 cm-1), saccharides / proteins (~930 cm-1), lipids (1445 cm-1), and amide
I (1656 cm-1) associated with the SCC cases, and positive peaks assigned to cholesterol /
lipids / nucleic acids (705-820 cm-1), COO- / amide II / tyrptophan / amide I (~1500-1620
cm-1) and the nucleic acids and phosphates peak at 1200 cm-1 associated with the AC
cases. LV2 separates the negative cases from the SCC and AC cases. The loadings of
LV2 show peaks assigned to proteins/carbohydrates/nucleic acids (735-890 cm-1),
phenylalanine (1000 cm-1), amide III / nucleic acids (1200-1280 cm-1), saccharides /
proline / valine (930 cm-1), and protein (1410 cm-1) associated with the SCC and AC
cases, and peaks assigned to nucleotides / phosphatidylinositol / glycerol (570-620 cm-1),
carbohydrates / proteins / lipids (1100-1145 cm-1), phopsholipids / protein/DNA (~1330
cm-1), and amide I (1650 cm-1) associated with the negative cases.
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Figure 4.37. A Scatter plot of the LVs obtained from the Raman spectra taken from the
cytoplasm of bronchial cells from negative cases (blue circles), SCC cases (green
squares), and AC cases (solid red circles). B and C Latent variables loadings of the
developed PLS-DA model for the dataset obtained from the cytoplasm of bronchial cells.
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Table 4.11 shows the results for the discriminant analysis of spectra taken from the
cytoplasm of squamous cells. The three-way PLSDA classification model, which was
developed using the first 4 latent variables, differentiated spectra from the negative cases
from the NSCLC cases with a sensitivity of 88% and a specificity of 94%. Spectra taken
from the cytoplasm of squamous cells from SCC cases were classified with a sensitivity
and specificity above 76%, and the spectra from AC cases were identified by the model
with a sensitivity and specificity of over 78%. Figure 4.38 shows the scatter plot of the
latent variable scores of the spectra taken from the cytoplasm of squamous cells from
negative cases, SCC cases, and AC cases. The spectra from SCC and AC cases are
discriminated from the spectra of negative cases using the first latent variable. The
loadings of LV1 show peaks assigned to cholesterol (418, 424-432, 608, 614, 702 cm-1),
saccharides (451-502 cm-1), phosphatidylinositol / proteins (508-527 cm-1), proteins /
nucleic acids / carbohydrates / lipids (568-726 cm-1), saccharides / proline / valine(935,
~950 cm-1), amide I (1594-1657 cm-1), and lipid (~1750 cm-1) associated with the negative
cases, and peaks assigned to phenylalanine (995-1004 cm-1), glycogen (1048 cm-1),
tyrosine (1165-1171 cm-1), amide III / lipids (1219-92, ~1337 cm-1), amide II (1472-89
cm-1), and amide I of disordered structure / β sheets (1674-1688 cm-1) associated with the
cytoplasm of squamous cells from AC and SCC cases. The second latent variable
differentiates the SCC and AC clusters. The loadings of LV2 show peaks assigned to
tyrosine / methionine (628, 650 cm-1), nucleic acids / lipids / proteins (1371-1446 cm-1),
amide II (1558 cm-1), COO- (1590 cm-1), and the tryptophan / cytosine / amide I peaks at
1611 and 1622 cm-1 associated with the SCC cases, and peaks assigned to saccharides
(834, 860, 910 cm-1), proline / valine / saccharides (942 cm-1), protein (964 cm-1), and
amide I (1660 cm-1) associated with the AC cases.
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Figure 4.38. A Scatter plot of the LVs obtained from the Raman spectra taken from the
cytoplasm of squamous cells from negative cases (blue circles), SCC cases (green
squares), and AC cases (solid red circles). B and C Latent variables loadings of the
developed PLS-DA model for the dataset obtained from the cytoplasm of squamous cells.
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Table 4.12 shows the results of a PLSDA model in discriminating spectra taken from the
cytoplasm of bronchial cells from negative cases, and spectra taken from the cytoplasm
of bronchial cells from SCC and AC cases combined into one malignant group. In order
to produce an unbiased classifier, the total number of spectra in the combined malignant
group was identical to the number of spectra from negative cases being used. The first 2
latent variables were used to develop the PLSDA classifier. PLSDA classification of
bronchial cells from negative cases vs. bronchial cells from malignant cases yielded a
sensitivity of 94%, and a specificity of 94%. Table 4.12 also shows the results of the
PLSDA model used to differentiate between spectra taken from the cytoplasm of
squamous cells from negative cases, and spectra taken from the cytoplasm of squamous
cells of AC and SCC cases combined into one malignant group. The total number of
spectra in the malignant group matched the number of spectra in the negative group.
Using 3 LVs the two-way classifier yielded a sensitivity of 96% and a specificity of 98%
for the classification of squamous nuclei from negative and malignant cases. In a twoway classifier using 4 LVs, spectra from the cytoplasm of bronchial cells from SCC cases
were discriminated from spectra from the cytoplasm of bronchial cells from AC cases
with a sensitivity and specificity of 89% and 90% respectively (Table 4.12). In addition,
Table 4.12 shows the results for the discriminant analysis of spectra from the cytoplasm
of squamous cells from SCC cases and spectra from the cytoplasm of squamous cells
from AC cases. The SCC and AC cases were distinguished with a sensitivity of 81% and
a specificity of 74%.
Representative spectra from the cytoplasm of bronchial and squamous cells of negative
cases were selected at random and combined into one negative group. Similarly,
representative spectra from the cytoplasm of bronchial and squamous cells from SCC and
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AC cases were selected at random and combined into one malignant group. In order to
produce an unbiased classifier, the total number of spectra from malignant cases used to
develop the classifier was identical to the number of spectra from negative cases being
used. As before, the number of spectra used from each cell type was also matched in the
negative and malignant groups. Table 4.13 shows results achieved for discriminating
spectra from the negative and malignant groups. The two-way classifier yielded a
sensitivity of 87% and a specificity of 90% using 4 LVs. Figure 4.39 depicts a PLSDA
scatter plot of the grouped negative cases and grouped malignant cases. The negative and
malignant groups are discriminated by the first two LVs. The spectra from negative cases
are predominantly distributed in the positive side of LV1, whereas spectra from the
malignant cases are predominantly distributed in the negative side of LV1. The loadings
of LV1 reveal peaks assigned to phosphatidylinositol (575 cm-1), proline / valine /
saccharides (~935 cm-1), protein / lipid / saccharides (1101-40 cm-1) and amide I (1650
cm-1) associated with the cytoplasm of cells from negative cases, and peaks assigned to
phenylalanine (1006 cm-1), amide III / nucleic acids (1220-1260 cm-1), lipid (1375 cm-1),
amide II (1489 cm-1), amide I of disordered structure / β sheets (1690 cm-1) associated
with the malignant group. The spectra from negative cases are predominantly distributed
in the positive side of LV2, whereas spectra from the malignant cases are predominantly
distributed in the negative side of LV2. The loadings of LV2 show peaks assigned to
phenylalanine (1006 cm-1), lipid (1375 cm-1), protein / aspartic / glutamic acid (1400 cm1

), lipid / protein / nucleic acids (1430 cm-1), amide II (1555 cm-1), amide I / cytosine /

tryptophan (1611-26 cm-1), associated with the negative group, and peaks assigned to
glucose (908 cm-1), proline / valine / saccharides (~935 cm-1), saccharide (1110 cm-1),
1280-1376 cm-1) and amide I (1650 cm-1) associated with the malignant group.
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Figure 4.39. A Scatter plot showing spectra from the cytoplasm of bronchial and
squamous cells of negative cases, SCC cases and AC cases, grouped according to a
negative or malignant diagnosis. The negative cases (green circles) are discriminated
from the malignant cases (blue circles) along the first and second LVs. B and C Latent
variables loadings of the developed PLS-DA model for the dataset obtained from the
cytoplasm of bronchial and squamous cells.
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Spectra taken from the cytoplasm bronchial and squamous cells from SCC cases were
combined into one SCC group. Similarly, spectra taken from the cytoplasm of bronchial
and squamous cells from AC cases were combined into one AC group. In order to produce
an unbiased classifier, the total number of spectra from SCC cases used to develop the
classifier was identical to the number of spectra from AC cases being used. As before,
the number of spectra used from each cell type was also matched in the SCC and AC
groups. Table 4.13 shows results achieved for discriminating spectra from the SCC and
AC groups. The two-way classifier yielded a sensitivity of 85% and a specificity of 71%
using 2 LVs. Figure 4.40 shows the PLSDA scatter plot of the combined SCC group and
the combined AC group along the first two latent variables. The negative and malignant
groups are discriminated by the first two LVs. The spectra from AC cases are
predominantly distributed in the positive side of LV1, whereas spectra from the SCC
cases are predominantly distributed in the negative side of LV1. The loadings of LV1
reveal peaks assigned to protein (508 cm-1) nucleic acids (790 cm-1), phenylalanine (1006
cm-1), amide III / nucleic acids (1201-1245 cm-1), and amide II / COO- / nucleic acids /
amide I (1495-1656 cm-1) associated with the cytoplasm of cells from AC group, and
peaks assigned to saccharides / proline / valine (930 cm-1), lipids (1131 cm-1), nucleic
acids (1320 cm-1), aspartic / glutamic acid (~1405 cm-1) and lipids / proteins (1445 cm-1)
associated with the SCC group.
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Figure 4.40. A Scatter plot showing spectra from the cytoplasm of bronchial and
squamous cells of SCC, and AC cases grouped according to the lung cancer subtype. The
AC cases (red circles) are discriminated from the SCC cases (blue circles) along the first
LV. B The Latent variable loadings of the developed PLS-DA model for the dataset
obtained from the cytoplasm of bronchial and squamous cells.

.
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Table 4.2. Performance of PLSDA in discriminating bronchial cell nuclei of negative
cases, SCC cases, and AC cases, in separate two-way classifications.
Comparison
Sensitivity Specificity
(%)
(%)
Negative v SCC

91

89

Negative v AC

95

90

SCC v AC

90

86

Table 4.3. Performance of PLSDA in discriminating squamous cell nuclei of negative
cases, SCC cases, and AC cases, in separate two-way classifications.
Comparison
Sensitivity Specificity
(%)
(%)
Negative v SCC

86

84

Negative v AC

87

93

SCC v AC

73

78

Table 4.4. Performance of PLSDA in discriminating lymphocyte nuclei of negative
cases, SCC cases, and AC cases, in separate two-way classifications.
Comparison
Sensitivity Specificity
(%)
(%)
Negative v SCC

89

82

Negative v AC

89

97

SCC v AC

82

85

Table 4.5. Performance of PLSDA in discriminating the bronchial cell nuclei of
negative cases, SCC cases and AC cases.
Histological Sensitivity
Specificity
diagnosis
(%)
(%)
Negative

90

91

SCC

82

84

AC

81

79
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Table 4.6. Performance of PLSDA in discriminating the squamous cell nuclei of
negative cases, SCC cases and AC cases.
Histological
diagnosis

Sensitivity (%)

Specificity (%)

Negative

91

91

SCC

60

78

AC

63

79

Table 4.7. Performance of PLSDA in discriminating the lymphocyte nuclei of negative
cases, SCC cases and AC cases.
Histological
Sensitivity
Specificity
diagnosis
(%)
(%)
Negative

78

85

SCC

80

78

AC

81

88

Table 4.8. Performance of PLSDA in discriminating negative cases from malignant
cases, using spectra from the nuclei of bronchial cells, squamous cells, and
lymphocytes.
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Table 4.9. Performance of PLSDA in discriminating negative cases from malignant
cases, and SCC cases from AC cases using combined spectra from the nuclei of
bronchial cells, squamous cells, and lymphocytes.
Comparison
Sensitivity
Specificity
(%)
(%)
Negative vs Malignant

89

79

SCC vs AC

84

69

Table 4.10. Performance of PLSDA in discriminating the cytoplasm of bronchial cells
from negative cases, SCC cases and AC cases.
Histological
Sensitivity
Specificity
diagnosis
(%)
(%)
Negative

97

95

SCC

68

88

AC

80

85

Table 4.11. Performance of PLSDA in discriminating the cytoplasm of squamous cells
from negative cases, SCC cases and AC cases.
Histological
Sensitivity
Specificity
diagnosis
(%)
(%)
Negative

88

94

SCC

76

79

AC

81

78

Table 4.12. Performance of PLSDA in discriminating negative cases from malignant
cases, and SCC from AC cases using spectra from the cytoplasm of bronchial cells and
squamous cells.
Comparison Bronchial
Squamous
classification
classification
Sensitivity
(%)
Negative vs 94
Malignant

Specificity
(%)

Sensitivity
(%)

Specificity
(%)

94

96

98
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SCC vs AC

89

90

81

74

Table 4.13. Performance of PLSDA in discriminating negative cases from malignant
cases, and SCC cases from AC cases using combined spectra from the cytoplasm of
bronchial and squamous cells.
Comparison
Sensitivity
Specificity
(%)
(%)
Negative vs Malignant

87

90

SCC vs AC

85

71

4.4 Discussion
To our knowledge, this is the first study to apply Raman spectroscopy to bronchoscopy
cytology samples to obtain a biomolecular characterisation of NSCLC subtypes and
provide a marker free diagnosis of NSCLC. Bronchoscopic methods for ascertaining
cellular material, such as BAL and BW, collect a mixture of different cell types. In this
study, to eradicate variation based on cell type, spectral data from the distinct cell types
were processed and analysed separately. This enabled the identification of spectral
differences across the negative, SCC and AC cases. In addition, to conduct a
comprehensive analysis of the dataset, spectral data from different cell types were
grouped by a negative or malignant diagnosis, and by SCC or AC subtype. The different
groupings were comparatively analysed to determine the diagnostic efficacy of
combining the Raman data from different cell types.
It was possible to identify bronchial and squamous cells on the unstained slides due to
their unique morphologies. As lymphocytes are more difficult to identify on unstained
slides, the locations of targeted lymphocytes were mapped during Raman spectroscopic
analysis. Through the application of the Papanicolaou stain and analysis of the nuclear
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patterns and cell morphology, the cell lineage was determined to be immune cell, more
specifically a lymphocyte49. The locations of targeted abnormal squamous cells on the
unstained slides were also marked during spectral acquisition. The Pap stain enabled
visualisation of the neoplastic hyperchromatic cells with abundant cytoplasm and
cytoplasmic projections, and the cells were determined as malignant squamous cells.
Further, cytoplasmic spectra could not be acquired from the morphologically malignant
squamous cells due to photodegradation using the 532 nm laser line. Indeed, further
studies may investigate alternative laser lines to lessen irradiation induced damage. In
addition, the characteristically small cytoplasm of lymphocytes, and the laser spot size of
approximately 1 µm, prohibited the inclusion of representative spectra from the
cytoplasm of lymphocytes without spectral contaminations from the nucleus. On AC
cases, morphologically abnormal cells were not targeted as they could not be identified
on the unstained slides.
The primary objective was to comparatively analyse the spectra from negative cases and
NSCLC cases, and evaluate the differences, if any, between them. Spectral differences
were consistently observed between the negative cases and NSCLC cases with the most
common signals occurring at ~430, ~780, 930, 1006, ~1106, 1175-200, ~1220-50, 1340,
1379, ~1450, 1575, ~1660, and 1686 cm-1, representing significant differences in the
molecular composition of cholesterol, nucleic acids, saccharides, lipids, protein structures
and amides, across the negative and NSCLC cases.
The spectral profiles taken from the morphologically normal and abnormal cells of
NSCLC cases are commonly characterised in this study by an increase in collagen related
peaks, glycogen, nucleic acids and amide III, and a decrease in amide I, showing that
Raman spectroscopy can be used to detect malignancy in morphologically normal cells
of SCC and AC cases. The peaks differentiating negative cases and NSCLC cases are in
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accordance with several previous studies investigating lung tissue samples and cell lines
with spectroscopic methods 50–53. It has been previously reported that elevated glycogen
is a feature in lung cancers. A number of studies generated FTIR spectra from lung cancer
cells and tissue and found a characteristic increase in glycogen associated peaks in
comparison to the negative tissue

50–52

. The increased peak intensities at 1022 cm-1 and

1048 cm-1 observed in the spectra taken from the cells of NSCLC cases may indicate that
increased glycogen levels are detectable in Raman spectra, and could potentially be a
diagnostic biomarker for NSCLC. Of particular interest, peaks relating to an elevated
level of collagen were evident in both the nuclei and cytoplasm of the squamous and
bronchial cells. An increase in collagen related peaks in the Raman spectra of lung cancer
tissue was also reported by Kaminaka et al.53 in a study investigating the molecular
differences between normal lung tissue and SCC using a 1064nm laser. Intracellular
collagen is commonly found in collagen producing cells such as mesenchymal cells, yet
it is not a common protein found in epithelial cells. Epithelial mesenchymal transition
(EMT) is a process that results in the downregulation of epithelial genes and
characteristics, and the upregulation of mesenchymal genes and characteristics 54. While
this process is integral in development, pathological reactivation is associated with
fibrosis and cancer progression. The EMT process induces the transition of epithelial cells
to collagen producing cells and promotes cell invasion

54,55

. Studies have indicated that

EMT may be activated in lung cancer, which may explain the collagen related peaks
observed in this study 56,57. Extracellular collagen is routinely observed in lung tissue as
a response to lung damage, and in many lung cancer cases the patients also present with
interstitial lung diseases, where pulmonary fibrosis is a common feature. Therefore, it
needs to be established if utilising collagen peaks as spectral biomarkers for NSCLC
could lead to potential false positive diagnosis in the presence of fibrosis. In addition, as
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the assignments of the main Raman bands in this chapter were based on the biological
peak assignments confirmed by other studies, further research is required to confirm that
the collagen related peaks observed in this study are indeed related to intracellular
collagen. The increased nucleic acid peak intensities in the NSCLC spectra is a feature
reported in previous studies that investigated lung cancer with vibrational spectroscopic
methods50,52. Aneuploid DNA content is a feature in up to 85% of NSCLC tumours, which
could explain the elevated peak intensity observed in malignant cases in this study 58.
The tumour related biochemical changes observed in the morphologically normal
bronchial and squamous cells of NSCLC cases may be explained by the concept of field
cancerization59. First described by Slaughter et al60 in 1953, field cancerization suggests
early genetic events in carcinogenesis may trigger expansion of the pre neoplastic cells in
the tumour area or field. Further aberrations causes some of these cells to transform into
the malignant phenotype, and are detectable with histopathological methods, however the
remaining genetically altered cells are morphologically normal and are not identified 61–
63

. This concept has been described in a variety of cancers including lung64, and could

explain the high rate of recurrence for lung cancer.
Principal component analysis, an unsupervised classification method, was then applied to
reduce the dimensionality of the data and analyse variance within the dataset. Applied to
spectra acquired from nuclei, PCA was found to be an ineffective tool for discriminating
the negative, SCC and AC cases. The PC scores plots indicate poor separation of the
different groupings when analysing data from the distinct cell types separately, and when
analysing combined data from different cell types. Similarly, PCA of the cytoplasmic data
from the bronchial and squamous cells combined yielded a poor discriminatory
performance, as the loadings spectra of the PCs responsible for the variation between the
negative and malignant groups, and the SCC and AC groups, are similar to the PC
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loadings spectrum discriminating the cytoplasm of bronchial cells from negative cases
and the cytoplasm of squamous cells from negative cases. This indicates that the variation
explained by PCA is likely the difference between the bronchial and squamous cells, and
not the difference between different groups. However, applying PCA to the cytoplasmic
data achieved good differentiation of the negative and NSCLC subtypes when analysing
data from the bronchial and squamous cells separately. Consistent with the significant
peaks identified in the difference spectra, both the squamous and bronchial cells from
NSCLC cases were discriminated from their respective cell types from negative cases
based on an increase in collagen, glycogen, phenylalanine, tyrosine, nucleic acids, and
amide III, and a decrease in cholesterol, saccharides, phosphatidylinositol, and amide I.
This suggests that when analysing the cytoplasm of bronchial and squamous cells with
Raman spectroscopy, these may be effective diagnostic biomarkers for the identification
of NSCLC. Further, applying PCA to spectra taken from the cytoplasm of bronchial cells,
the SCC and AC cases were discriminated based on a variation in amide III / nucleic acid
(1250 cm-1), protein (~1330 cm-1), lipid (1445 cm-1), COO- / amide II / tyrptophan / amide
I (~1500-1620 cm-1), and amide I (1656 cm-1) content. These diagnostic peaks are in
accordance with the significant peaks identified in the difference spectrum between the
cytoplasm of bronchial cells from SCC and AC cases, and may be useful diagnostic
markers for the differential diagnosis of SCC and AC. Based on the results of this study,
applying PCA to cytoplasmic spectra is a more effective method for discriminating
negative and NSCLC cases than applying PCA to nuclear spectra. The cytoplasm is a rich
broth of complex biomolecules and most chemical reactions occur within the cell
cytoplasm, this may account for the greater variation observed in the cytoplasm of cells
from NSCLC cases using PCA.
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As the visual differences between the spectra from cytology samples from negative, SCC
and AC cases are discrete, partial least squares discriminant analysis (PLSDA), a
supervised classification technique, was applied to the data to maximise the diagnostically
relevant spectral variations. Analysing the bronchial nuclei, the SCC and AC subtypes
were detected and discriminated with sensitivities >90% and specificities >86%, and
examining the squamous nuclei, the SCC and AC subtypes were detected and
discriminated with sensitivities >73% and specificities >78%. The model used to analyse
the lymphocyte spectra achieved sensitivities and specificities above 82% for the
identification of and discrimination between the SCC and AC subtypes.
PLSDA was then applied to investigate the ability to discriminate the bronchial nuclei
from negative cases and the bronchial nuclei from the SCC and AC subtypes, all within
the same model. The model yielded a sensitivity of 90% and specificity of 91% for
identification of negative cases. The SCC and AC subtypes were classified with
sensitivities of 82 and 81% respectively although multiple SCC and AC spectra were
misclassified. The LVs distinguishing the negative cases from the NSCLC cases, and
discriminating the SCC and AC cases matched the significant peaks identified in the
difference spectra between the bronchial nuclei of negative, SCC, and AC cases. The LVs
revealed diagnostic information about nucleic acids (788, 1223-1297 cm-1), cholesterol /
lipids / methionine (599-626, 700, 1379 cm-1), proteins / saccharides (848 cm-1), amide
III (1223-1297 cm-1), amide II (1470 cm-1), COO- (1585 cm-1) and amide I (1597-1661,
1686 cm-1). A PLSDA model was then developed to discriminate the squamous nuclei
from negative cases and the squamous nuclei from SCC and AC cases, within in the same
classifier. The negative cases were classified with a good diagnostic sensitivity of 91%
and specificity of 91%. The SCC and AC cases were discriminated with sensitivities of
60-63% and specificities of 78-79%, as observed visually in the scatter plots of the first
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three LVs, there was some overlap of the SCC and AC clusters which explains the lower
performance scores of the model. A combination of the diagnostic peaks identified in the
first two LVs match the significant differences revealed in the difference spectra. The
negative cases were again differentiated from the NSCLC cases based on saccharide,
protein, amide III, amide I, nucleic acid, and lipid content, whereas the diagnostically
relevant peaks discriminating the SCC and AC cases were assigned to saccharides,
nucleic acids, amide II, COO-, amide I, and proteins.
The diagnostic relevance of lymphocytes in NSCLC was demonstrated as the
performance of a three-way PLSDA classifier showed sensitivities of 78-81% and
specificities of 78-88% for the classification of negative, SCC and AC cases. The
dissimilarities in the spectral profiles observed in this study between the lymphocyte
nuclei of the two NSCLC subtypes may be explained by differing immune responses to
tumour subtype. As part of the adaptive immune system, both B and T lymphocytes are
involved in the immune anti-cancer response. Although B and T lymphocytes are
morphologically indistinguishable, they have a variety of different functions in the
immune response to cancer. When activated, B cells have the ability to differentiate into
plasma cells and produce highly specific antibodies

65

. Activated T cells comprise of

helper T cells (CD4+), and cytotoxic T cells (CD8+), depending on the presence of a
surface CD4 or CD8 T cell receptor. Helper T cells secrete cytokines which induce an
inflammatory response to attract other immune cells. Cytotoxic T cells infiltrate the
tumour and are capable of killing cancer cells 66. The differences in the spectra taken from
lymphocytes of NSCLC cases and lymphocytes of negative cases may be spectral
signatures for these immune biochemical responses to the presence of tumour. Although
data is limited in this study, with further investigation the characteristic Raman peaks and
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unique spectral profiles of lymphocytes may prove valuable for delineating NSCLC and
elucidating the role of the immune system in lung cancer.
Notably, similar diagnostic information was provided in the LVs discriminating the
lymphocyte nuclei of SCC cases from the lymphocyte nuclei of AC cases, and the
bronchial nuclei of SCC cases from the bronchial nuclei of AC cases. The spectral profile
of the LVs may represent a similar malignancy dependent change in the biochemical
composition of bronchial cells and lymphocytes. However, it is also possible that
abnormal glandular cells were incorrectly classified as lymphocytes upon microscopic
examination of the stained slides. This may explain the overlap in spectral features
between the bronchial nuclei and lymphocyte nuclei observed in this study. To clarify
that the Raman peaks are indicative of changes detected in lymphocytes, future studies
may consider identification of the cell type through immunohistochemical staining.
Analysing the cytoplasmic data with PLSDA revealed the diagnostic value of the cell
cytoplasm for NSCLC. Objective comparative analysis of bronchial cytoplasm spectra
was achieved by the application of a three-way PLSDA algorithm to the data. The model
achieved sensitivities of 68-97% and specificities of 85-95% for the distinction of
negative, SCC and AC subtypes. The LVs revealed diagnostic peaks in accordance with
the PC loadings discriminating the cytoplasm of bronchial cells from negative, SCC and
AC cases. Regardless of the statistical method used to classify the NSCLC subtypes,
diagnostic peaks relating to nucleotides / phosphatidylinositol / glycerol (570-620 cm-1),
amide III / nucleic acids (1200-1280 cm-1), saccharides / proline / valine (930 cm-1),
proteins (~1330 cm-1), saccharides / proteins (~930 cm-1), lipids (1445 cm-1), and amide
I (1656 cm-1) are found to discriminate the cytoplasm of bronchial cells from negative,
SCC and AC cases.
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In addition, a PLSDA model applied to the spectral data acquired from the cytoplasm of
squamous cells exhibited the ability to identify negative cases with a sensitivity and
specificity of 88% and 94% respectively. The SCC and AC subtypes were discriminated
with sensitivities and specificities ranging from 76-81%. In accordance with the PC
loadings and difference spectra between the cytoplasm of squamous cells from negative,
SCC and AC cases, the LVs extracted information about cholesterol, glycogen,
saccharides, phosphatidylinositol, saccharides / proline / valine, phenylalanine, amide III
/ nucleic acids / lipids, amide II and amide I differentiating the negative cases and NSCLC
subtypes.
Combining the datasets from different cell nuclei, the PLSDA algorithm classified the
negative, malignant, SCC and AC groups with sensitivities and specificities of 69-89%.
The LVs discriminating the combined groups retained many peaks found throughout the
difference spectra and PC loadings associated with nucleic acids, proteins, amides, lipids,
and saccharides. Similarly, combining the datasets from the cytoplasm of different cell
types, the PLSDA algorithm classified the negative, malignant, SCC and AC groups with
sensitivities and specificities of 71-90%. Despite the good performance of the model for
differentiating the negative and malignant groups, the information revealed by the LV
indicates that the spectral variations between the cell types are greater than the variations
between negative and malignant spectral signatures. Combining spectra from different
cell types for PLSDA does not affect the accuracy of disease diagnosis, however
analysing the different cell types separately is a better approach to study the specific
spectral alterations associated with each NSCLC subtype. The results achieved using
Raman spectroscopy and PLSDA with venetian blinds cross-validation show that all cell
types and cell components targeted in this study were found to be diagnostically
significant. In addition, the PLSDA performance scores achieved in this study are similar
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to the findings in other studies that explored the use of Raman spectroscopy to identify
lung cancer using cells or tissue specimens40,42–44,67–72.
As previously mentioned, the discrimination of SCC and AC, along with molecular
profiling of the tumour is now imperative to ensure efficacy of treatment. As the current
diagnostic algorithm for lung cancer greatly reduces the amount of sample for molecular
tests, the demand for diagnostic specimen is rising and a new marker free diagnostic
technique would be largely beneficial to the healthcare system. The results of this study
show that Raman spectroscopy may be utilized to improve the diagnostic algorithm of
NSCLC. In our study good sensitivities (60-90%) and specificities (69-90%) were
achieved for the differentiation of NSCLC subtypes using Raman spectroscopy on BAL
and BW specimens prepared as ThinPrep® cytology slides.
Although the results identify promising diagnostic spectral biomarkers for NSCLC, this
study is limited by several factors. The primary limitation of the study is the low number
of patients. Biomarker discovery customarily requires a minimum of 10-100 patient
samples. In addition, to validate the use of a spectral biomarker for NSCLC diagnosis,
the performance characteristics must be well established with the backing of a wealth of
evidence. To evaluate the performance measures of the diagnostic spectral biomarkers for
clinical application, such as the sensitivity, specificity, reproducibility, and diagnostic
accuracy must be determined with a larger cohort of approximately 200-1000 patients73.
Another limitation of the study is the low number of AC cases. In order to develop
unbiased PLSDA classifiers, the number of AC, SCC, and negative cases had to be
matched in each model. As a result, the number of SCC and negative cases were reduced
to 5 when developing a PLSDA model with AC cases. As residual cytology samples were
used for this study, the amount of cellular material left in the sample vials for analysis
meant we were limited to a maximum of 15 spectra per cell type, per sample. For this
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study this was adequate to develop well working PLSDA models as Beleites et al74
illustrate 75-100 spectra per class is required for a good classifier, however while the
minimum required spectra were met for most classifications in this study, more patient
samples are needed to be able to perform leave one patient out cross-validation. Further
studies may also evaluate the use of alternative laser lines to reduce photo damage of
morphologically abnormal squamous cells.
4.4.1 Summary
In summary Raman signals were acquired from 24 BAL and BW samples, representing
7 negative, 12 SCC, and 5 AC cases. High quality Raman spectra were obtained from the
nuclei of bronchial cells, squamous cells, morphologically abnormal squamous cells, and
lymphocytes, and the cytoplasm of bronchial and squamous cells. Mean spectral analysis
revealed distinctive spectral variations in each cell component and each cell type across
the negative and NSCLC cases. The consistent spectral differences between the negative,
SCC and AC cases, associated with collagen, glycogen, and amide I and III, could prove
to be diagnostically significant, providing insight into the carcinogenic process of
NSCLC. These results also indicate that Raman spectroscopy can detect malignant
signatures in morphologically normal cells. Of particular interest, the spectra from
lymphocytes also showed differences in malignant and benign cases. Future studies may
explore the use of Raman spectroscopy to further understand the role and diagnostic
relevance of lymphocytes in NSCLC.
The PLSDA algorithm was successfully applied to the data and yielded diagnostic
sensitivities and specificities of 60-97% for the discrimination of negative, SCC, and AC
cases using the spectra acquired from the nuclei and cytoplasms of morphologically
normal bronchial and squamous cells. This indicates that both cell types and both cell
components are diagnostically significant. Applying PLSDA to spectra acquired from
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lymphocyte nuclei also yielded high performance scores for the differentiation of
negative, SCC and AC cases. The spectral differences influencing the classification may
be related to differences in immune response to SCC and AC.
The combination of Raman spectroscopy and PLSDA was an effective tool for the
classification of NSCLC, using bronchoscopy attained BAL and BW specimens.
Although data is limited, these results demonstrate the ability of Raman spectroscopy to
effectively detect malignancy on ThinPrep® cytology samples. Applying this technique
to cytology samples may present as a minimally invasive method for identifying and
discriminating NSCLC subtypes while retaining the sample for ancillary molecular tests.

In some NSCLC cases, the diagnosis reported on cytology differs from the histological
diagnosis. Therefore, to build on the findings of this chapter, the next chapter will
investigate the accuracy of Raman spectroscopy on cytology in comparison to the known
histological result.
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Chapter 5: Examination of Raman spectra from NSCLC cases
with cytological analyses reported as diagnostic or no malignant
cells seen
5.1 Introduction
Lung cancer diagnostics are predominantly based on cytology or small biopsy specimens.
As morphological analysis remains the primary method for lung cancer diagnosis, the
overlapping cytomorphologic features of lung cancers, low cellularity of diagnostic
specimens, and inter-observer variability are some of the reported limitations for current
cytological analysis1.
To evaluate the diagnostic accuracy of cytological procedures for lung cancer, Sakr et al2
conducted a retrospective chart review of patients that underwent fibreoptic
bronchoscopy for suspicion of lung cancer, and had both cytological and histological
methods performed. The authors examined the diagnostic agreement between cytological
and histological results and found that only 30% of cases classified as non-malignant on
cytology were indeed false negatives. In addition, false positives were confirmed in only
12% of cases. Further, 60% of negative cases on cytology were deemed true negatives,
and 52% of positive cases on cytology were considered true positives.
As a label free vibrational spectroscopic technique with the ability to provide
comprehensive detail about intracellular biochemistry, Raman spectroscopy could
potentially be an alternative or adjunct tool for the objective measurement of cytological
samples. Raman spectroscopy can detect malignancy associated changes in
morphologically normal cells, and has been to shown be a highly sensitive and specific
tool for detecting lung malignancies3–10.
There is a clinical need for a technology that improves the diagnostic accuracy of
cytological analysis for lung cancer. The purpose of this study was to build on the findings
of chapter 4 by investigating the feasibility of utilising Raman spectroscopy to detect
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malignant signatures in cells from NSCLC cases with NMCS on cytology using
bronchoscopy attained cytology samples, and assess the accuracy of Raman spectroscopy
on cytology in comparison to the known histological result.

5.2 Methods
5.2.1 Study subjects and sample collection
As described in chapter 3 section 3.1.
This study utilised BALs and BWs collected from 19 patients (8 females, 11 males). Lung
cancer was confirmed though final clinical diagnosis and final histology was recorded as:
9 squamous cell carcinoma, 4 adenocarcinoma, and 6 negative (no malignancy seen).
The samples were grouped as depicted in Table 5.1. Spectra taken from samples 1-6
represent true negatives, spectra from samples 7-11 represent SCC on cytology and SCC
on histology, samples 12-15 represent NMCS on cytology and SCC on histology, samples
16 and 17 are AC on cytology and AC on histology, and samples 18 and 19 are NMCS
on cytology and AC on histology. For this chapter, where cytology and histology
correlate, these cases are termed true positive (TP-SCC / TP-AC) and true negative (TN)
as appropriate. In cases where cytology was reported as negative and histology was
positive, these are termed false negative (FN-SCC / FN-AC).
Table 5.1. Patient samples with the corresponding cytology and biopsy reports, as
characterised by a pathologist.
Sample
number

Gender

Cytology
report

Biopsy
report

Termed

1

M

NMCS

Negative

TN

2

F

NMCS

Negative

TN

3

M

NMCS

Negative

TN

4

M

NMCS

Negative

TN
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5

M

NMCS

Negative

TN

6

M

NMCS

Negative

TN

7

F

SCC

SCC

TP-SCC

8

F

SCC

SCC

TP-SCC

9

M

SCC

SCC

TP-SCC

10

F

SCC

SCC

TP-SCC

11

M

SCC

SCC

TP-SCC

12

M

NMCS

SCC

FN-SCC

13

F

NMCS

SCC

FN-SCC

14

M

NMCS

SCC

FN-SCC

15

M

NMCS

SCC

FN-SCC

16

F

AC

AC

TP-AC

17

F

AC

AC

TP-AC

18

F

NMCS

AC

FN-AC

19

M

NMCS

AC

FN-AC

M, male; F, female.
5.2.2 Sample processing and slide preparation
As described in chapter 3 section 3.1.1-2.

5.2.3 Raman Measurement
As described in chapter 3 section 3.2.1-2
For this study, spectra were taken from the nuclei of bronchial epithelial cells and
squamous cells.

5.2.4 Data pre-processing and analysis
All spectral data analysis was conducted using MATLAB software. Data were process as
described in chapter 3 section 3.2.3-.7.
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The data was analysed using Principal Component Analysis (PCA), as described in
chapter 3 section 3.2.8. Partial least squares discriminant analysis (PLS-DA) with
venetian blind cross-validation was also employed to the mean centered Raman spectral
data to identify the diagnostically significant variations between the groups, as described
in chapter 3 section 3.2.10-12.
5.2.5 Pap staining
Following Raman spectroscopy, slides were stained using the Papanicolaou staining
method as described in chapter 3 section 3.3. Using the XY co-ordinates recorded as
described in chapter 3 section 3.2.2, the spectra were correlated with their cell type and
categorised into separate databases according to their cell type.

5.3 Results
5.3.1 Comparative spectral analysis
5.3.1.1 Spectral analysis of bronchial and squamous nuclei from SCC cases with SCC on
cytology, and SCC cases with NMCS on cytology

Figures 5.1 and 5.3 depict the mean bronchial and squamous cell spectra from TN cases,
TP-SCC cases, and FN-SCC cases. The standard deviation shows that there was minimal
variation between the spectra from individual cells and this was the case for all targeted
cells. The features in the bronchial and squamous cell spectra from TP-SCC cases and
FN-SCC cases that differ from the cells from TN cases are demonstrated by the difference
spectra in Figures 5.2 and 5.4. The tentative peak assignments for the significant Raman
bands identified by spectral variation analysis in this study are shown in Table 5.2 11,12.
As depicted in Figure 5.2, the bronchial cells from all SCC cases show elevated peak
intensities at ~780, 1300-1310, 1395 and 1421 cm-1, and decreased peak intensities at
440, ~840, 1622 and 1662 cm-1 in comparison to the bronchial cells from TN cases. This
indicates that the bronchial cells from SCC cases had increased nucleic acids, lipids, and
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decreased cholesterol, proteins and polysaccharides in comparison to the bronchial cells
from TN cases.
In comparison to the mean negative bronchial cell spectrum in Figure 5.1, the bronchial
cells from TP-SCC cases have more significant differences than the bronchial cells from
FN-SCC cases. In addition to the aforementioned spectral differences, bronchial cells
from TP-SCC cases have elevated peaks at 820, 924, 935, 1221-1270, 1290, 1329-1351,
and 1674 cm-1, and decreased peak intensities at 470-491, 506-533, 556, 570, 577-636,
652, 690-727, 1501-1575, and 1584-1621 cm-1, in comparison to the bronchial cells from
TN cases.
The difference spectra in Figure 5.4 show that the squamous cells from TP-SCC cases
and FN-SCC cases have a different biochemistry than the squamous cells from TN cases.
The squamous cells from TP-SCC cases and FN-SCC cases show an increase in nucleic
acids (788, 1515, 1575 cm-1), collagen (1203 cm-1), and amide II (1535 cm-1), and a
decrease in cholesterol (433 cm-1), protein / amide I (615-620,

1640 cm-1), and

methionine (~700 cm-1) compared to the squamous cells from TN cases. Squamous cell
nuclei from TP-SCC cases also had an increase in collagen (978 cm-1), phenylalanine
(989-1007 cm-1), and amide III / nucleic acids (1215-1245 cm-1), and a decrease in
cholesterol (408, 420 cm-1), polysaccharides and protein (470, 486-526 cm-1),
phosphatidylinositol (580 cm-1), protein / glycerol (590-640 cm-1), methionine (657 cm1

), protein / nucleic acids (1320 cm-1), and amide I (1621-1701 cm-1), in comparison to

squamous cells from TN cases.
From TP-SCC cases (Figures 5.2 and 5.4), the bronchial and squamous cells showed
consistent peaks at 435, 470, 506-533, 595-621, 627-636, 700, 789, 1221-1245, and 16211662 cm-1 differentiating them from their respective cell types in TN cases.
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On the FN-SCC cases (Figures 5.2 and 5.4), the bronchial and squamous cells had
elevated peaks at 788, 1535, and 1575 cm-1, and lower peak intensities at 433, 837, 975,
and 1640 cm-1, in comparison to their respective cell types in TN cases. Decreased peak
intensities at 435 and ~1640 cm-1, and an increased peak intensity at ~780-789 cm-1 was
consistent among the bronchial and squamous cells from all SCC cases.
Comparative analysis of the bronchial and squamous cells from TP-SCC cases, and FNSCC cases revealed differences in their spectral profiles (Figures 5.2 and 5.4). The
bronchial and squamous cells from TP-SCC cases indicated a higher level of proline /
hydroxproline / glycogen (911-18 cm-1), pheylalanine (~1004 cm-1) and collagen (103040 cm-1) than FN-SCC cases. The TP-SCC cases also exhibited a decrease in tyrosine /
methionine (638-40 cm-1) and amide I (1651-93 cm-1) content when compared to the FNSCC cases.

Table 5.2. Tentative peak assignments for the prominent significant Raman bands
identified by spectral variation analysis 11,12.
Wavenumber (cm-1)

Raman peak assignments

~420/30/40

cholesterol

580

phosphatidylinositol

486-526

Polysaccharides, proteins

590

Protein/glycerol

640

Tyrosine/methionine

657/~700/10

methionine

~780

Nucleic acids

830-920

Polysaccharides/proline/valine/collagen

~930

Proline/valine/saccharides

1175-1200

Nucleic acids/phophates

1210-1280

Amide III/nucleic acids

~1350

Tyrptophan/guanine/saccharides

1420-50

Proteins/lipids
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~1500-1600

Amide II/ COO-/nucleic acids

1600-1660

Amide I

~1680

Cholesterol/amide I Amide I disordered
structure/β sheets/lipids

~1740

lipids

Figure 5.1. The mean Raman spectra (± standard deviation) taken from the nuclei of
bronchial epithelial cells from negative cases (black, n=70), TP-SCC cases (blue, n=93),
and FN-SCC cases (red, n=48).
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Figure 5.2. Difference spectrum between the mean Raman spectrum of bronchial
epithelial cell nuclei taken from negative cases and (a) the mean Raman spectrum of
bronchial epithelial cell nuclei from TP-SCC cases (blue, n=93), (b) the mean Raman
spectrum of bronchial epithelial cell nuclei from FN-SCC cases (red, n=48). (c)
Difference spectrum between the mean Raman spectrum of bronchial epithelial cell
nuclei from TP-SCC cases and the mean Raman spectrum of bronchial epithelial cell
nuclei from FN-SCC cases (green). Shading indicates regions of the spectrum that were
significantly different (P < 0.01)
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Figure 5.3. The mean Raman spectra (± standard deviation) taken from the nuclei of
squamous cells from negative cases (black, n=94), TP-SCC cases (blue, n=137), and
FN-SCC cases (red, n=35).
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Figure 5.4. Difference spectrum between the mean Raman spectrum of squamous cell
nuclei taken from negative cases and (a) the mean Raman spectrum of squamous cell
nuclei from TP-SCC cases (blue, n=137), (b) the mean Raman spectrum of squamous cell
nuclei from FN-SCC cases (red, n=35). (c) Difference spectrum between the mean Raman
spectrum of squamous cell nuclei from TP-SCC cases and the mean Raman spectrum of
squamous cell nuclei from FN-SCC cases (green). Shading indicates regions of the
spectrum that were significantly different (P < 0.01)
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5.3.1.2 Spectral analysis of bronchial and squamous nuclei from AC cases with AC on cytology
and AC cases with NMCS on cytology

Figures 5.5 and 5.7 depict the mean bronchial and squamous cell spectra from TN cases,
TP-AC cases, and FN-AC cases. The standard deviation shows that there was minimal
variation between the spectra from individual cells and this was the case for all targeted
cells. The features in the bronchial and squamous cell spectra from TP-AC cases and FNAC cases that differ from the cells from TN cases are demonstrated by the difference
spectra in Figures 5.6 and 5.8.
As depicted in Figure 5.6, the bronchial cells from the AC cases showed elevated peak
intensities at ~775, 1179-1182, 1188-1202, and 1291-94 cm-1, and decreased peak
intensities at 1652-61, and 1677-83 cm-1 in comparison to the bronchial cells from TN
cases. This indicates that the bronchial cells from AC cases had increased nucleic acids
(775, 1179-82 cm-1), phosphates (1188-202), and cytosine / methylene (1291-94 cm-1)
and decreased amide I (1652-61, 1677-82 cm-1) in comparison to the bronchial cells from
TN cases. In addition to the aforementioned spectral differences evident in the bronchial
cells from AC cases, bronchial cells from TP-AC cases have elevated peaks at 830-921,
936-947, 978-1001, 1012-1054, ~1215, 1220-1268, ~1276, ~1283, and 1684-1696 cm-1,
and decreased peak intensities at 425-432, 503-514, 524-529, 567,628, 701-704, 14021405, 1542-1552, 1558-1576, and 1583-1650 cm-1, in comparison to the bronchial cells
from TN cases. These significant peaks show that in AC cases where malignancy is
evident on cytology, the bronchial cells have a higher level of collagen related peaks (83091, 936-47, 1012-54, 1283 cm-1), glycogen (1012-54 cm-1), pheylalanine (978-1001 cm1

), proline/hydroxyproline / saccharides (830-91 cm-1), amide III / nucleic acids (1215,

1220-68, 1276 cm-1) and non-hydrogen bonded amide I (1684-96 cm-1) than the bonchial
cells of TN cases. The profile of the difference spectrum also indicates a decrease in
cholesterol (425-32, 701-04 cm-1), amide II (1542-52 cm-1), phosphatidylinositol /
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phosphatidylserine / protein (503-29 cm-1), glycerol (630 cm-1), COO- (1558-76 cm-1) and
amino acid (567, 1402-05 cm-1) content in the TP-AC cases.
The bronchial cells from FN-AC cases exhibited an increase in peaks associated with
thiocyanate (446 cm-1), phophatidylserine (~524 cm-1), cholesterol (539-54 cm-1), nucleic
acids (695, 720, 1421-25, 1429-38 cm-1), methinione (708 cm-1), phosphate ions (804-07
cm-1), collagen (817-821 cm-1), triglycerides (1068-71 cm-1), saccharides (1112-1116 cm1

), glycogen / collagen (1151-1167 cm-1), aspartic / glutamic acid (1404-1416 cm-1), lipid

/ protein (1429-1438 cm-1), and amide II 1516-49 cm-1 in comparison to the bronchial
cells from TN cases. Bronchial cells from FN-AC cases also showed decreased peak
intensities at 1004, 1220-25, 1320-33, and 1466-73 cm-1, in comparison to the bronchial
cells from TN cases, corresponding to a lower level of phenylalanine, guanine, amide III,
amide II, phospolipids, and lipids.
The difference spectra in Figure 5.8 show that the squamous cells from AC cases have an
increase in collagen / nucleic acids (1169-84cm-1) and phosphates (1194-97cm-1), and a
decrease in fatty acids (1130-35 cm-1) compared to the squamous cells from TN cases.
The squamous cells from TP-AC cases also had an increase in nucleic acids (775, 96670, 1217-49 cm-1), hydroxyproline / tryptohpan (878 cm-1), lipid / phosphorylated protein
(966-70 cm-1),

amide III (1217-1249 ,1257-60 cm-1), and lipids (1715-18cm-1) in

comparison to the squamous cells from TN cases. A decrease in phosphatidylinositol /
phosphatidylserine (501-525 cm-1), phenylalanine (621 cm-1), lipids (1438-51 cm-1),
lipids / disaccharides (1459-62 cm-1), and protein (1603-1642 cm-1) was also evident in
the squamous cells from TP-AC cases in comparison to the squamous cells from TN
cases. The squamous cells from FN-AC cases exhibited increased peak intensities at 42528, 439-44, 474-77, 551-54, 710-715, 1104-08, 1118-1120, 1139-1164, 1424-29, 149095, 1501-1623, and 1738-49 cm-1, and decreased peak intensities at 494-98, 648, 835-53,
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859-71, 902, 952, 970, 1004, 1211-17, 1233-36, 1249-60, 1320, and 1651-1702 cm-1, in
comparison to the squamous cells from TN cases. This corresponds to a higher level of
cholesterol and thiocyanate (425-44 cm-1), polysaccharides (474-77 cm-1), glycogen (55154, 1139-64 cm-1), methioine (710-15 cm-1), carotene (1139-64 cm-1), amide II / nucleic
acids (1490-95, ~1501-1600 cm-1) and lipids (1738-49 cm-1) and a lower level of tyrosine
(646, 859-71 cm-1), saccharides (835-53, 902 cm-1), phenylalanine (1004 cm-1), amide III
/ nucleic acids (1211-1260 cm-1), guanuine (1320 cm-1) and amide I (1651-1702 cm-1) in
the FN-AC cases.
From cases where AC was evident on cytology (Figures 5.6 and 5.8), the bronchial and
squamous cells showed consistent peaks at 504, 513, 525, 597-604, 624-26, 770-76, 878,
1016, 1179-82, 1194-98, 1220-49, 1257-60, and 1603-42 cm-1 differentiating them from
their respective cell types in TN cases. This indicated a decrease in the level of
phosphatidylinositol, phosphatidylserine, carbohydrates (1016 cm-1), and amide I, and an
increase in nucleic acids, collagen, phosphates, and amide III in the bronchial and
squamous cells of TP-AC cases.
The bronchial and squamous cells from FN-AC cases (Figures 5.6 and 5.8), had increased
thiocyanate, methionine, glycogen, collagen, phospholipids, deoxyribose, and amide II,
and a decreased pheylalanine, amide III (β sheet structure), guanine, and amide I in
comparison to their respective cell types in TN cases, exhibited by the elevated peaks at
446, 710, 1151-1164, 1175-97, ~1425, and 1516-1549 cm-1, and lower peak intensities at
1004, 1224, 1319- 1333, and 1651-83 cm-1.
The variations in spectral profiles of bronchial and squamous cells from TP-AC cases and
FN-AC cases indicate different biochemical profiles of cells from AC cases with different
cytology reports (Figures 5.6 and 5.8). Cells from the TP-AC cases have an increase in
proline/hydroxyproline / glycogen / collagen (829-73, 877-79, 882-86 cm-1),
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phenylalanine (~1004 cm-1), amide III / nucleic acids / phospholipids (1216-62, 1268-72
cm-1) and a region of the amide I peak (1662-1696 cm-1) in comparison to the cells in FNAC cases. The bronchial and squamous cells from TP-AC cases also show a decrease in
Raman peaks associated with phosphatidylinositol (514-17 cm-1), phosphatidylserine
(524-30 cm-1), cholesterol (609-23 cm-1), lipids (1393-98 cm-1), proteins / lipids (143438 cm-1), and proteins / amide I / II / nucleic acids (1500-1642 cm-1), in comparison to
the FN-AC cases.

Figure 5.5. The mean Raman spectra (± standard deviation) taken from the nuclei of
bronchial epithelial cells from negative cases (black, n=70), TP-AC cases (blue, n=25),
and FN-AC cases (red, n=21).
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Figure 5.6. Difference spectrum between the mean Raman spectrum of bronchial
epithelial cell nuclei taken from negative cases and (a) the mean Raman spectrum of
bronchial epithelial cell nuclei from TP-AC cases (blue, n=25), (b) the mean Raman
spectrum of bronchial epithelial cell nuclei from FN-AC cases (red, n=21). (c) Difference
spectrum between the mean Raman spectrum of bronchial epithelial cell nuclei from TPAC cases and the mean Raman spectrum of bronchial epithelial cell nuclei from FN-AC
cases (green). Shading indicates regions of the spectrum that were significantly different
(P < 0.01)
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Figure 5.7. The mean Raman spectra (± standard deviation) taken from the nuclei of
squamous cells from negative cases (black, n=94), TP-AC cases (blue, n=25), and FNAC cases (red, n=20).
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Figure 5.8. Difference spectrum between the mean Raman spectrum of squamous cell
nuclei taken from negative cases and (a) the mean Raman spectrum of squamous cell
nuclei from TP-AC cases (blue, n=25), (b) the mean Raman spectrum of squamous cell
nuclei from FN-AC cases (red, n=20). (c) Difference spectrum between the mean Raman
spectrum of squamous cell nuclei from TP-AC cases and the mean Raman spectrum of
squamous cell nuclei from FN-AC cases (green). Shading indicates regions of the
spectrum that were significantly different (P < 0.01)
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5.3.2 Principal component analysis
5.3.2.1 PCA of bronchial and squamous nuclei from negative cases, NSCLC cases with
diagnostic cytology and NSCLC cases with NMCS on cytology

Principal component analysis was then applied to reduce the data and extract diagnostic
information. Figure 5.9 shows the scatter plot of the PC scores along the first two principal
components, demonstrating separation of the Raman spectra from bronchial cells from
TN cases and bronchial cells from TP-SCC cases, with some overlap. The spectra from
TN cases and TP-SCC cases form two adjacent, overlapping clusters along the first PC.
The loadings of PC1 indicate variation in tyrosine (650 cm-1), polysaccharides / proline /
valine (850 cm-1), saccharides / praline / valine (925 cm-1), phenylalanine (1004 cm-1),
amide III / nucleic acids (1210-1280 cm-1), tryptophan / guanine / cytosine (~1350 cm1

), nucleic acids / protein / lipids (1450 cm-1), and cholesterol / amide I (β sheet non-

hydrogen bonded) (1680 cm-1) on the positive side, and DNA (780 cm-1) and amide II / I
/ tryptophan / tyrosine (1500-1645 cm-1) on the negative side. Spectra taken from
bronchial cells of FN-SCC cases were distributed evenly along PC1 and PC2 and were
not discriminated using PCA.
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Figure 5.9. A PCA scatter plot of bronchial cells from from negative cases, TP-SCC cases,
and FN-SCC cases. The spectra from TN cases and TP-SCC cases form two adjacent,
overlapping clusters along the first PC. The spectra taken from bronchial cells of FN-SCC
cases were distributed evenly along PC1 and PC2 and could not be discriminated using
PCA. B On the positive side of the first principal component peaks at 650, 850, 925, 1004,
1210-1280 cm-1, ~1350, 1450, and 1680 cm-1 can be distinguished, while peaks at and
780 cm-1 and 1500-1645 cm-1 can be distinguished on the negative side.

Figure 5.10 shows the scatter plot along the first two PCs of spectra taken from squamous
cells of TN cases, squamous cells of TP-SCC cases, and FN-SCC cases. The spectra were
not distinguishable using a combination of the first five PCs, which explained 95% of the
variance in the dataset.
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Figure 5.10. PCA scatter plot of spectra taken from squamous cells from TN cases, TPSCC cases, and FN-SCC cases shows no separation with even distribution along the first
two principal components.
In Figure 5.11 the distribution of PC1 and PC2 was plotted to visualise the variances
between spectra taken from bronchial cells of TN cases, TP-AC cases, and FN-AC cases.
The TP-AC and FN-AC spectra are separated along PC1. Due to the even distribution of
the spectra taken from TN cases along PC1 and PC2, neither the TP-AC nor the FN-AC
clusters can be distinguished from TN cases. On the positive side of the first principal
component, which is responsible for discriminating the TP-AC and FN-AC clusters,
peaks at 650, 850, 1210-1280, 1350, 1420-50, 1680 cm-1 can be distinguished. While
peaks at 780, saccharides (1105cm-1), and 1500-1650 cm-1 can be distinguished on the
negative side.
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Figure 5.11. A PCA scatter plot of bronchial cells from TN cases, TP-AC cases, and FNAC cases. The spectra from TP-AC cases and FN-AC cases form two distinct clusters
along the first principal component. The spectra from negative cases are dispersed along
the first two PCs and cannot be discriminated. B. On the positive side of the first principal
component, peaks at 650, 850, 1210-1280, 1350, 1420-50, 1680 cm-1 can be
distinguished, while peaks at 780, 1105, 1500-1650 cm-1 can be distinguished on the
negative side.

Figure 5.12 demonstrates the PCA scatter plot of spectra taken from the squamous cells
of TN cases, TP-AC cases, and FN-AC cases. The spectra from TP-AC cases and FN-AC
cases form two distinct clusters along PC1. Due to the even distribution of the spectra
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taken from TN cases along PC1 and PC2, the negative cases cannot be discriminated. The
loadings of PC1 indicate variation in 650 cm-1, 850, phenylalanine 1004 cm-1, 1210-1270
cm-1, ~1360, 1420-50, and ~1680 cm-1 on the positive side, and 780 cm-1 and 1480-1655
cm-1 on the negative side.

Figure 5.12. A PCA scatter plot of squamous cells from TN cases, TP-AC cases, and FNAC cases. The spectra from TP-AC cases and FN-AC cases form two distinct clusters
along the first principal component. The spectra from TN cases are dispersed along the
first two PCs and cannot be discriminated. B. On the positive side of the first principal
component, peaks at 650, 850, 1004 cm-1, 1210-1270, ~1360, 1420-50, and ~1680 cm-1
can be distinguished, while peaks at 780 cm-1 and 1480-1655 cm-1 can be distinguished
on the negative side.
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5.3.3 PLSDA classification
The PLSDA classification model was applied to the data to examine whether Raman
spectroscopy could detect malignancy in the NSCLC cases with NMCS on cytology, and
cases where cancer was evident by cytological analysis. The number of spectra in each
class was matched. The required number of latent variables in each model was used to set
the cross validation classification error average at 5%. To ensure discrimination was
based on the detection of malignant signatures in the spectra and not differences in cell
type, the bronchial and squamous cell data were analysed separately.
Table 5.3 shows the results of two separate PLSDA models in differentiating spectra
taken from the bronchial nuclei of TN cases, and the bronchial nuclei of TP-SCC cases
or FN-SCC cases. The first 3 latent variables were used to develop each model. The
spectra taken from bronchial nuclei of TP-SCC cases were discriminated from the
bronchial nuclei of TN cases with a sensitivity and specificity above 91%. The spectra
taken from bronchial nuclei of FN-SCC cases were discriminated from the bronchial
nuclei of TN cases with a sensitivity of 73% and a specificity of 86%.
Table 5.4 shows the performance scores of two PLSDA classifiers in discriminating
spectra taken from the squamous nuclei of TN cases, and spectra taken from the squamous
nuclei of TP-SCC cases or FN-SCC cases. Each two-way model used two latent variables
each. The squamous nuclei of TP-SCC cases were distinguished from the squamous
nuclei of TN cases with a sensitivity and specificity of 87% and 78% respectively. The
squamous nuclei of FN-SCC cases were identified with a sensitivity of 84% and a
specificity of 95%.
Table 5.5 shows the results of the two-way PLSDA classification models used for the
discrimination of spectra taken from the bronchial nuclei of TN cases, and the bronchial
nuclei of TP-AC, or FN-AC cases. Each model was developed using four latent variables.
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Each two-way classification model yielded sensitivities above 86% and specificities
above 81%.
Table 5.6 shows the results of two separate PLSDA models, each using the first 2 latent
variables, in differentiating spectra taken from the squamous nuclei of TN cases, and the
squamous nuclei of TP-AC cases or FN-AC cases. The spectra taken from squamous
nuclei of TP-AC cases were discriminated from the squamous nuclei of TN cases with a
sensitivity and specificity of 73% and 92% respectively. The spectra taken from
squamous nuclei of FN-AC cases were discriminated from the squamous nuclei of TN
cases with a sensitivity and specificity above 91%.
Based on a compilation of the sensitivity ranges achieved in Tables 5.3-5.6, Table 5.7
shows the accuracy of Raman spectroscopy on cytology in comparison to the known
histological result

Table 5.3. Performance of PLSDA in discriminating bronchial nuclei of TN cases from
bronchial nuclei of TP-SCC cases and FN-SCC cases. The first 3 LVs were used in each
case.
SCC cases distinguished from
TN cases

Sensitivity

Specificity

TP-SCC cases

91

92

FN-SCC cases

73

86

Table 5.4. Performance of PLSDA in discriminating squamous nuclei of TN cases from
squamous nuclei of TP-SCC cases and FN-SCC cases. The first 2 LVs were used in
each case.
SCC cases distinguished from
TN cases

Sensitivity

Specificity

TP-SCC cases

87

78
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FN-SCC cases

84

95

Table 5.5. Performance of PLSDA in discriminating bronchial nuclei of TN cases from
bronchial nuclei of TP-AC cases and FN-AC cases. The first 4 LVs were used in each
case.
AC cases distinguished from
TN cases

Sensitivity

Specificity

TP-AC cases

86

92

FN-AC cases

91

81

Table 5.6. Performance of PLSDA in discriminating squamous nuclei of TN cases from
squamous nuclei of TP-AC cases and FN-AC cases. The first 2 LVs were used in each
case.
AC cases distinguished from
TN cases

Sensitivity

Specificity

TP-AC cases

73

92

FN-AC cases

91

100

Table 5.7. Cytology reports with their corresponding biopsy reports and ranges of
sensitivity for malignancy using Raman spectroscopy.
Cytology
report

Biopsy
report

Sensitivity
for
malignancy

SCC

SCC

87-91%

NMCS

SCC

73-84%

AC

AC

73-86%

NMCS

AC

91%
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5.4 Discussion
Though limited material on cytology samples and morphological challenges add to the
difficulty of diagnostic cytology, it is still one of the first line diagnostic specimen types
due to being less invasive and having fewer risks than histology sampling. Objective
technology such as Raman spectroscopy may identify underlying disease in cytology
samples and improve diagnostic accuracy on cytology.
The companion histological reports allowed us to group the cytology spectra according
to their final diagnosis and determine the ability of Raman spectroscopy to accurately
identify underlying malignancy. The results showed that using PLSDA, the Raman
spectra of bronchial and squamous cells could be used to effectively discriminate between
TN and NSCLC histology confirmed cases with negative cytology with sensitivities from
73-91%, and specificities of 81-100%. Comparable performance scores were achieved
for discriminating the TN cases from the NSCLC histology confirmed cases with TP
cytology. These findings show that both the squamous and bronchial cell types are
diagnostically significant in the SCC and AC subtypes, and that the algorithm can classify
spectral changes in the cells from malignant cases with FN cytology. Field cancerization
is a concept which may explain the good discrimination of spectra from TN cases and
NSCLC cases with FN cytology. Field cancerization is when the genetically altered cells
in a tumour area or field remain morphologically normal and are not identified13–17.
However, these malignant associated changes may be detectable in the Raman spectra.
The performance of PLSDA in classifying the NSCLC cases with FN cytology is in
accordance with the sensitivities and specificities achieved for discriminating the NSCLC
subtypes in chapter 4. This suggests that phenotypic features of malignancy are not
required to identify NSCLC with high diagnostic accuracy using Raman spectroscopy on
bronchoscopy cytology samples. The ability of biospectroscopy to detect underlying
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malignancy was also demonstrated in a study by Gajjar et al18. Infrared (IR) spectroscopy
was used to determine the effectiveness of cytological methods in identifying cervical
malignancies using the companion histology results as gold standard for comparison.
Analysis of the spectra revealed underlying pre-invasive cervical disease in cases with
negative cytology. Our study as well as the study by Gajjar et al18 show that objective
spectroscopic techniques have the ability to improve the diagnostic efficiency of
cytological methods and may overcome the current limitations of using cytological
analysis for lung cancer diagnosis.
Comprehensive analysis of the spectra shows that malignant signatures can be detected
in morphologically normal cells in NSCLC cases. Further, there is a difference in the
biochemical composition of cells from NSCLC cases with different cytological reports.
The prominent differences, identified using mean spectral analysis and PCA, between the
TN cases and NSCLC cases are evident in spectral regions associated with saccharides,
lipids, collagen, nucleic acids, amide I / III, glycogen, protein and thiocyanate. After
examination of the spectral data, a reduced phenylalanine peak at 1004 cm-1, and
decreased amide I content is a recurring feature in NSCLC cases with FN cytology. These
characteristic peaks could prove to be effective for detecting NSCLC in cases limited by
the current diagnostic algorithm. With SCC and AC cases, PCA and direct comparison of
the spectra taken from cases with TP cytology and FN cytology indicated that cases with
malignancy evident on cytology were associated with an increase in phenylalanine,
collagen, and glycogen, and a decrease in amide I, in comparison to the cases with FN
cytology. The spectra indicate that as cytomorphology progresses to the malignant
phenotype, the glycogen and collagen content in the cells is elevated, and amide I is
reduced, suggesting that alterations either in the quantity or content of these biomolecules
is a feature of NSCLC in bronchoscopy cytology samples. The significant peaks
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identified in this chapter are similar to the diagnostic peaks discriminating the negative,
SCC and AC cases in chapter 4. This suggests that the differentiation of the negative cases
and NSCLC subtypes in chapter 4 was based on a combination of peaks from cases with
diagnostic cytology and cases with FN cytology.
Importantly, although significant diagnostic Raman peaks were identified in NSCLC
cases with FN cytology, the biological assignments of the main Raman bands were based
on the findings of other studies11,12 and were not experimentally confirmed in this study.
Presently, the cytomorphologic diagnosis of lung cancer leads to highly varied results. In
particular, the identification and subtyping of NSCLC through cytological analysis
generally yields poor accuracy1,2,19. The reporting of false positives and false negatives
based on morphology can have devastating effects on patients and can result in delayed
treatment. This study demonstrates that Raman spectroscopy may be an effective tool for
detecting lung cancer on morphologically normal cytology samples, as detailed analysis
of the Raman spectra revealed malignant signatures in the cases with FN cytology.
Adjunct application of this technique may reduce the rate of false negative diagnoses and
improve the accuracy of cytology reports, minimising the need for invasive biopsy
procedures. Future studies could also evaluate the ability to detect false positives with
Raman spectroscopy on cytology, as false positives can lead to psychological stress for
patients.
This study has some limitations, similar to chapter 4. The main limitations of the study
are the low number of patients and the low amount of cellular material left in the sample
vials for analysis. As a result, the size of the spectral dataset is small. As the dataset is
limited in this study, venetian-blinds cross validation was used to validate PLSDA. Thus,
the performance characteristics of the PLSDA classifier must be determined with a larger
cohort of patients using leave one patient out cross validation. In addition, an inherent
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problem when determining the accuracy of a new diagnostic technique is the limitations
of the current gold standard, to which the new method is being compared. In this study,
the classifications are based on histological reports, which are subject to inter-observer
variability.
Despite the limitation of data size in this study, recurrent patterns were revealed in Raman
spectra of cells from NSCLC cases with differing cytology reports, indicating consistency
in the spectral data. With further investigation, the diagnostic peaks identified could prove
to be useful spectral markers for the detection of NSCLC subtypes. In addition, Raman
spectroscopy used with PLSDA classification distinguished between the TN cases and
NSCLC cases with high sensitivities and specificities. This illustrates the potential of
Raman spectroscopy to improve the diagnostic accuracy of cytological analysis for lung
cancer, unimpeded by the limitations of current cytopathological methods.

As the suitability of using Raman spectroscopy on cytology for NSCLC diagnosis has
been demonstrated, the next chapter aims to compare the diagnostic effectiveness of using
Raman spectroscopy on bronchoscopy attained cytological and tissue samples.
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Chapter 6: Comparison of the diagnostic effectiveness of applying
Raman spectroscopy to cytological specimens and tissue sections
for NSCLC diagnosis
6.1 Introduction
Histological analysis of tissue specimens is the current gold standard diagnostic method
for lung cancer. Histopathology involves the microscopic analysis of cellular patterns and
tissue architecture to make an accurate diagnosis, through the application of
histochemical stains and immunohistochemical markers. For the classification of cancer
type, histopathologists look for specific characteristic features to classify into a diagnosis,
such as the size and shape of cells, size and shape of nuclei, the morphology and
distribution of cells within in the tissue. The tissue architecture is preserved for
histological evaluation, making it advantageous over cytopathology in the current context
of lung cancer diagnosis.
Studies exploring the use of Raman spectroscopy for lung cancer diagnosis on
histological sections have shown the ability of this technique to delineate between normal
and malignant lung tissue with high diagnostic sensitivities and specificities1–9. With
conventional Raman spectroscopy, the 785 nm and 1064 nm laser lines have been used
to reveal distinctive malignant features in the Raman spectra3,10. These studies exhibit the
potential of using Raman spectroscopy for the optical diagnosis of lung cancer, yet the
ability to translate these methods to a clinical setting is a limiting factor.
The primary aim of this chapter was to characterize the Raman spectra taken from
bronchial tissues and compare the diagnostic effectiveness of using Raman spectroscopy
on bronchoscopy attained cytological and tissue samples. The diagnostically relevant
information differentiating the tissue spectra was compared to the diagnostic peaks
identified in chapter 4. To our knowledge, no studies have compared the biochemical
information extracted from the spectra taken from these different diagnostic sample types.
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6.2 Methods
6.2.1 Study subjects and sample preparation
As described in chapter 3 section 3.1.
This study utilised residual tissue blocks from 11 patients who had undergone biopsy
during bronchoscopy for suspected lung cancer. The final histopathological diagnoses,
characterised by a pathologist using gold standard diagnostic methods, was recorded as:
6 squamous cell carcinoma, 3 adenocarcinoma, 1 NSCLC-not otherwise specified
(NSCLC NOS), and 1 atypical carcinoid.
6.2.2 Sample processing and slide preparation
10 µm parallel sections were cut from the FFPP tissue blocks and mounted on glass slides
for Raman spectroscopy. The tissue sections were chemically dewaxed by sequential
immersion of the sections in two xylene baths, and two IMS baths (100%), for 10 minutes
in each bath. Parallel tissue sections were cut at 5 µm and stained with Haematoxylin and
Eosin to allow differentiation between different tissue structures.
6.2.3 Raman Measurement
Raman spectra were acquired using a HORIBA Jobin Yvon Labram HR800 UV system,
which consists of a 50 mW diode laser with 532 nm wavelength. The laser was delivered
to the sample through a x100 objective (NA = 0.9) and the confocal hole was set at 100
µm. The system was calibrated to the 520 cm-1 spectral line of silicon and the spectral
resolution was defined by the grating which was ruled with 600 lines per mm grating.
Backscattered light was detected using an air-cooled CCD detector. Regions of the section
with morphological changes associated with disease (Figures 6.1, 6.2, 6.4 and 6.5), and
regions associated with normal morphology (Figure 6.3) were targeted with the laser.
These regions were identified and marked using parallel H & E stained sections shown in
Figures 6.1-5. Spectra were also recorded from 300 vacant locations on a glass slide, and
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25 locations on wax regions with no underlying tissue. A thirty second integration time
averaged over two accumulations was used in order to obtain representative background
glass and wax spectra.
6.2.4 Data pre-processing and analysis
All spectral data analysis was conducted using MATLAB software. Data were process as
described in chapter 3 section 3.2.3-.7.
The data was analysed using Principal Component Analysis (PCA), as described in
chapter 3 section 3.2.8. Partial least squares discriminant analysis (PLS-DA) with
venetian blind cross-validation was also employed to the mean centered Raman spectral
data to identify the diagnostically significant variations between the groups, as described
in chapter 3 section 3.2.10-12. As described in chapter 3 section 3.2.6

11

, spectra from

cellular components, such as nucleic acids, proteins, lipids etc, and the independently
recorded wax spectra were used to fit the sample spectra and remove the wax contribution.
6.2.5 Haematoxylin and Eosin
Sections were dewaxed and rehydrated to water then stained with Harris’s Haematoxylin
for 5 minutes. After washing in water, the Haematoxylin was then differentiated with acid
alcohol for 2 seconds and checked. Complete removal of the haematoxylin from the cell
cytoplasm was checked promptly with a light microscope, ensuring the slides do not dry.
The slides were then submerged in water to blue the bound stain. Eosin was then added
to the slides for 3 minutes before removing the excess stain with water. After washing
rapidly in 95% IMS, the slides were transferred through absolute alcohols to histoclear
before coverslipping.

6.3 Results
Figures 6.1 to 6.5 show H&E stained tissue sections from each malignant type analysed.
Nuclei are stained dark blue purple, and Eosin has stained cytoplasm and connective
201

tissue pink. SCC lesions with islands of large eosinophilic cells with intercellular bridges
are depicted in Figure 6.1, while Figure 6.2 depicts adenocarcinomas showing acinar
formation, mucinous vacuoles and signet ring cells. Normal bronchial epithelium with
mucinous glands is shown in Figure 6.3 and NSCLC-NOS tissue is depicted in Figure 6.4
which shows abnormal cell and nuclear morphology. Atypical carcinoid tissue is shown
in Figure 6.5 with sheets of tumour cells that have uniform round nuclei. The tumour cells
form nests which are sharply distinct from the stroma12,13.
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Figure 6.1. Cases of SCC stained with Haematoxylin and Eosin. A-F show nests of
malignant squamous epithelial cells with large eosinophilic cytoplasm and intercellular
bridges. A-D are at x200 magnification, E and F are at x400 magnification.
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Figure 6.2. Cases of AC stained with Haematoxylin and Eosin. A-F show
adenocarcinomas with acinar formation, mucinous vacuoles and signet ring cells. A-D
are at x200 magnification, E and F are at x400 magnification.
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Figure 6.3. Normal tissue stained with Haematoxylin and Eosin. A shows normal
bronchial epithelium with mucinous glands at x200 magnification. B shows normal
mucinous glands at x400 magnification. C shows normal bronchial epithelium at x400
magnification. D shows normal bronchial epithelium at x200 magnification. E and F
show normal bronchial epithelium at x400 magnification.
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Figure 6.4. Case of NSCLC-NOS stained with Haematoxylin and Eosin. A and B show
abnormal cellular and nuclear morphology however there are no defining characteristics
for AC or SCC. A is at x200 magnification, B is at x400 magnification.

Figure 6.5. Case of Atypical carcinoid stained with Haematoxylin and Eosin. A and B
Sheets of tumour cells that have uniform round nuclei. The tumour cells form nests which
are sharply distinct from the stroma. A is at x200 magnification, B is at x400
magnification.
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6.3.1 Wax contamination after digital wax removal
As wax contributions in the spectra can cause innaccurate results, the effectiveness of
digital wax removal across the entire dataset was evaluated. To obtain a representation of
wax peaks remaining in all tissue spectra, the Raman spectra from mophologically normal
regions of tissue were combined into a “Negative” group, and spectra taken from
morphologically abnormal regions of tissue were combined into a “Malignant” group for
comparative analysis. The mean Raman spectra of grouped negative tissues and grouped
malignant tissues after chemical and digital dewaxing are depicted in Figure 6.6. The
standard deviation is denoted by shading. Principal component analysis was implemented
on the negative and malignant spectra to determine the discriminatory performance of
PCA and the peak assignments responsible for discrimination. Figure 6.7A shows the
scatter plot of the PC scores along the first and fifth principal components, demonstrating
separation of the Raman spectra along PC5. In Figure 6.7B the loadings of PC5 indicate
that wax peaks, denoted by grey shading, are influencing the separation of negative and
malignant spectra. Retaining variables affected by Raman peaks of wax may innacurately
influence analysis. To ensure reliability of results, the Raman peaks of wax in the spectral
regions of 877 to 895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and 1400 to 1500 cm-1
were removed from the dataset for all further analysis.
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Figure 6.6. Mean Raman spectrum of the grouped negative tissue (black, n= 112). Mean
Raman spectrum of the grouped malignant tissue (red, n=119). Shading denotes the
standard deviation. The spectral data has been subject to NNLS for removal of wax peaks,
however strong wax peaks remain in the spectra at 1060 and 1294 cm-1.
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Figure 6.7. A PCA scatter plot of processed negative and malignant tissue shows a
separation on the fifth principal component with even distribution along the first principal
component. B Wax spectral peaks influence the fifth principal component, along which
the spectra from negative and malignant tissue are separated. Shading denotes the wax
related peaks influencing the fifth principal component.
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6.3.2 Comparison of the mean Raman spectra from bronchial tissues
Good quality Raman spectra were obtained from the chemically and digitally dewaxed
lung tissue sections. There was no intereference of fluorescence from the tissue, and the
Raman signals from the substrate did not appear in the processed spectra. The Raman
peaks of wax in the spectral regions of 877 to 895, 1050 to 1072, 1115 to 1183, 1280 to
1311, and 1400 to 1500 cm-1, appeared in the processed spectra (Figures 6.6 and 6.7).
Accordingly, the corresponding variables were removed from the dataset for comparative
analysis of the mean spectra. Figure 6.8 shows the mean spectrum taken from regions
associated with normal morphology. Shading in Figure 6.8 denotes the standard
deviation. The features in the spectra taken from regions with morphological changes
associated with disease that differ from the morphologically normal tissue are
demonstrated by the following difference spectra in Figure 6.9. The biological
components for the significant Raman peaks were tentatively assigned according to the
studies by Movasaghi et al14, and Naumann et al15.
Spectral differences between the negative tissue and grouped spectra from malignant
tissue corresponded to peaks relative to cholesterol (436-39 cm−1), DNA / glycogen (480
cm−1), glucose / saccharides / phosphatidylinositol / cholesterol (560 cm−1), phospholipids
/ methionine (715 cm−1), saccharides (860 cm−1), proline / valine (930 cm−1), nucleic acids
(1185-1200 cm−1), amide III / nucleic acids (1230 cm−1), lipids / CH rocking / C=O
symmetric stretch (1394-99 cm−1), amide II (1545-61 cm−1), COO- / DNA / cytosine /
tyrosine / amide I (1575-1625 cm−1), and amide I (1637 cm−1). The difference spectra of
the SCC and AC tissues had similar profiles, with significant peaks assigned to at glucose
/ saccharide / phosphatidylinositol / cholesterol (560 cm−1), phospholipids / methionine
(715 cm−1), saccharides (~860 cm−1), proline / valine (925 cm−1), collagen (~1030),
glycogen / collagen (1045-50 cm−1), saccharides / lipids / collagen (1075-1114 cm−1),
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nucleic acids (1185-1201 cm−1), amide III / nucleic acids (1214-35 cm−1), adenine (1510
cm−1), tyrosine / tryptophan(1616 cm−1), and amide I (1657-77 cm−1) differentiating them
from the negative tissue (Figure 6.9). In comparison to AC tissue, SCC tissue had elevated
levels of proteins (623-25cm-1), phospholipids (~720 cm-1), nucleic acids (771-804cm-1),
amide III / nucleic acids (1209-15, 1317-23 cm-1), and aspartic / glutamic acid (16931709 cm-1), and lower levels of cholesterol / thiocyanate (438-44 cm-1), protein /
saccharides / phosphates (843-51, 872-76 cm-1)

proline / glycogen (~918 cm-1),

collagen (1028-29 cm-1), amide III / collagen (1272-79 cm-1), lipids / CH rocking / C=O
symmetric stretch (1384-99 cm-1), amide II / tryptophan / tyrosine (1536-56 cm-1), and
amide I / tryptophan / tyrosine (1596-1651 cm-1) (Figure 6.10).
For the NSCLC-NOS tissue, spectral differences were observed at 780 cm−1, 860 cm−1,
1019-32 cm−1, 1040-50 cm−1, 1075-1114 cm−1, 1185-1200 cm−1, 1270 cm−1, 1342-50
cm−1, and 1650 cm−1. This corresponds to a variation in DNA, protein / phosphate,
saccharides, glycogen, collagen, amide III / nucleic acids, and amide I in the NSCLCNOS tissue in comparison to the negative tissue (Figure 6.9).
Compared to the negative tissue, the atypical carcinoid tissue showed spectral differences
associated with glycogen (480 cm−1), glucose / saccharides / phosphatidylinositol /
cholesterol (560 cm−1), tyrosine (640 cm−1), cytosine (661 cm−1), phospholipids /
methionine (715 cm−1), saccharides (860 cm−1), proline / valine (~930 cm−1), nucleic
acids / amide III (1185-1296 cm−1), collagen (1335 cm−1), saccharides (~1370 cm−1),
COO- (1585 cm−1), and amide I (>1600 cm−1) (Figure 6.9).
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Figure 6.8. Mean spectrum taken from negative tissue (n= 112 spectra). Wax related
peaks in the ranges of 877 to 895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and 1400
to 1500 cm-1 were removed for analysis. Shading denotes the standard deviation.
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Figure 6.9. Difference spectrum between the mean Raman spectrum of negative tissue
and the mean Raman spectrum taken from SCC tissue (blue, n=141), AC tissue (red,
n=70), NSCLC-NOS (green, n=25), atypical carcinoid (magenta, n=25), and grouped
spectra from malignant tissue (light blue, n=119). Shading indicates regions of the
spectrum that were significantly different (P < 0.01). Variables were excluded from
spectral analysis in the ranges of 877 to 895, 1050 to 1072, 1115 to 1183, 1280 to 1311,
and 1400 to 1500 cm-1, as the spectra indicated wax contamination.
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Figure 6.10. Difference spectrum between the mean Raman spectrum of SCC tissue
(n=141) and the mean Raman spectrum taken from AC tissue (n=70). Variables were
excluded from spectral analysis in the ranges of 877 to 895, 1050 to 1072, 1115 to 1183,
1280 to 1311, and 1400 to 1500 cm-1, as the spectra indicated wax contamination.

6.3.3 Principal component analysis
Principal component analysis of the data was conducted on the processed spectra to
extract diagnostic information from the spectra. The five spectral regions from 877 to
895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and 1400 to 1500 cm-1 were affected by
the Raman peaks of wax, therefore the corresponding variables were removed from the
dataset for principal component analysis. To evaluate the ability of PCA to discriminate
between the negative tissue, malignant tissue, and LC subtypes, spectra were grouped for
analysis. Representative spectra from each patient were selected at random and combined
by their subtype and the number of spectra were matched in each group. Figure 6.11
shows the scatter plot of the PC scores along the first and fourth principal components,
demonstrating distinctive clustering of the Raman spectra from malignant and negative
tissue. The malignant and negative spectra form two adjacent, overlapping clusters along
the fourth PC. The loadings of PC4 indicate variation in phosphatidylinositol (570 cm-1),
phenylalanine (1004 cm-1), protein (1106 cm-1), and COO- (1585 cm-1) associated with

214

the malignant tissue, and peaks assigned to phospholipids / methionine (715 cm-1),
saccharides (850 cm-1), proline / valine / saccharides (925 cm-1), amide III / nucleic acids
(1233 cm-1), and amide I (1645 cm-1) associated with the negative tissue.

Figure 6.11. A PCA scatter plot of processed negative and malignant tissue shows a
separation on the fourth principal component with comparable distribution along the first
principal component. B Fourth PC after wax contribution was removed. On the positive
side of the fourth principal component, phenylalanine related peak 570 cm-1, 1004 cm-1
and 1585 cm-1 can be distinguished. While peaks at 715, 850, 925, 1233, and 1645 cm-1
can be distinguished on the negative side. Variables were excluded from PCA analysis in
the ranges of 877 to 895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and 1400 to 1500
cm-1, as the spectra indicated wax contamination.
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Figure 6.12 shows the score plot of the first two PCs developed for the analysis of grouped
SCC spectra versus grouped AC spectra. The SCC and AC spectra were not
distinguishable using a combination of the first five PCs, which explained 95% of the
variance in the dataset.

Figure 6.12. PCA scatter plot of SCC and AC tissue shows no separation with even
distribution along the first two principal components. Variables were excluded from PCA
analysis in the ranges of 877 to 895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and 1400
to 1500 cm-1, as the spectra indicated wax contamination.

In Figure 6.13 the distribution of PC2 and PC3 was plotted to visualize the variances
between SCC, AC, and NSCLC-NOS spectra. The scatter plot using PC2 and PC3 gave
the best discrimination performance, although the clusters overlap. The SCC and
NSCLC-NOS spectra are separated along PC2, yet neither the SCC nor NSCLC-NOS
clusters can be distinguished from AC due to the even distribution of AC spectra along
PC2 and PC3. The loadings of PC2, which is responsible for discriminating SCC and
NSCLC-NOS, indicate peaks assigned to phospholipids/methionine (715 cm-1), nucleic
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acids (780 cm-1), lipid (~1380 cm-1), and COO- / amide II / tyrptophan / amide I (15011600 cm-1) associated with the NSCLC-NOS tissue, and peaks assigned to
phosphatidylinositol / cholesterol (560 cm-1), saccharides (850 cm-1), saccharides / proline
/ valine (945 cm-1), phenylalanine (1004 cm-1), amide III / nucleic acids (1240 cm-1), and
amide I (1650 cm-1) associated with SCC tissue.

Figure 6.13. A. PCA scatter plot of processed SCC, AC and NSCLC-NOS tissue shows
that the SCC and NSCLC-NOS spectra form two distinct clusters along the second
principal component. The AC spectra are dispersed along the second PC and cannot be
discriminated from SCC or NSCLC. B. On the positive side of the second principal
component, peaks at 715, 780, 1185, 1200, ~1360, and ~1575 cm-1 can be distinguished.
While some peaks at 560, 1004, 860, 930, 1030, 1075-1114, 1230, and 1650 cm-1 can be
distinguished on the negative side. Variables were excluded from PCA analysis in the
217

ranges of 877 to 895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and 1400 to 1500 cm-1,
as the spectra indicated wax contamination.

Figure 6.14 visually demonstrates the discriminatory performance of PCA using
representative spectra from negative tissue and each lung malignancy. Representative
spectra from each subtype were selected at random and combined into groups as
previously described. The SCC spectra and the AC spectra form two close clusters using
PC1 and PC3. With a combination of PC1 and PC3, the SCC and AC clusters can be
discriminated from the negative, NSCLC-NOS, and atypical carcinoid spectra, with some
overlap. The loadings from PC1 indicate peaks assigned to proteins / saccharides (660,
845, 860 cm-1) and DNA (780 cm-1) associated with the negative and NSCLC-NOS
tissues. The loadings spectrum of PC3 indicates peaks assigned to nucleic acids /
glycogen / saccharides / phosphatidylinositol / cholesterol (480, 560 cm-1), amide II /
COO- (1580 cm-1), and amide I (>1600 cm-1) associated with the SCC and AC tissue, and
peaks assigned to phospholipids / methionine (715 cm-1), nucleic acids (780 cm-1), amide
III / nucleic acids (1185-1280 cm-1), and saccharides (1370 cm-1) associated with the
negative and NSCLC-NOS tissue. The negative, NSCLC-NOS, and atypical carcinoid
spectra are similarly distributed along both PC1 and PC3, and so can not be distinguished.
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Figure 6.14. A Scatter plot of the principal component scores of representative spectra
from negative, SCC, AC, NSCLC-NOS, and atypical carcinoid tissue. A combination of
PC1 and PC3 separates the SCC and AC clusters from the negative, NSCLC-NOS and
atypical carcinoid spectra, with some overlap. The negative, NSCLC-NOS, and atypical
carcinoid tissue shows similar distribution along the first and third principal components.
B Loadings from PC1 and PC3. Variables were excluded from PCA analysis in the ranges
of 877 to 895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and 1400 to 1500 cm-1, as the
spectra indicated wax contamination.
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6.3.4 PLSDA classification of lung cancer subtypes
PLSDA was used for discriminant analysis and cross-validation. To construct each model
the required number of latent variables were used to set the cross validation classification
error average at 5% and the number of spectra used for each class was matched to prevent
a biased classifier. The performance of each classification is shown using the sensitivity
and specificity of each model.
The five spectral regions from 877 to 895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and
1400 to 1500 cm-1 were affected by the Raman peaks of wax (Figures 6.6 and 6.7), thus
the corresponding variables were removed from the dataset for partial least squares
discriminant analysis.
Table 6.1 shows the performance of the PLSDA model in discriminating the grouped
spectra from morphologically normal tissue and representative spectra from each lung
cancer subtype combined into one malignant group. The first four latent variables were
used to develop the two‐way PLSDA model, which produced a sensitivity of 84% and a
specificity of 89% for detecting malignancy. Figure 6.15 is a LV score scatter plot
depicting Raman spectra from morphologically normal tissue, and morphologically
malignant tissue, showing separation of the two groups. The negative spectra are
separated from the malignant spectra along LV with some overlap.
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Figure 6.15. LV score scatter plot of Raman spectra from negative tissue (blue circles),
and grouped spectra from malignant tissue (red circles). Variables were excluded from
PCA analysis in the ranges of 877 to 895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and
1400 to 1500 cm-1, as the spectra indicated wax contamination.

Table 6.2 summarises the results for the three-way classification of spectra from negative,
SCC and AC tissue. The first 5 latent variables were used to develop the PLSDA model.
Negative tissue was discriminated from SCC and AC tissue with a sensitivity and
specificity above 83%. Spectra from SCC tissue were identified with a sensitivity and
specificity of 76% and 79% respectively, and the AC subtype was classified with a
sensitivity of 90%, and a specificity of 89%. Figure 6.16 depicts the scatter plot of the
latent variable scores of the spectra taken from negative, SCC, and AC tissue. Using the
first two latent variables to plot the scatter plot, the negative, SCC, and AC spectra form
three distinct clusters. The negative spectra can be discriminated from the SCC and AC
spectra using a combination of the first 2 latent variables, and the SCC and AC clusters
are separated along the second LV.
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Table 6.3 shows the results of 2 separate PLSDA models in discriminating spectra from
negative tissue from the spectra taken from tissue classified as NSCLC-NOS or atypical
carcinoid tissue. The first 4 latent variables were used in each case to develop the PLSDA
classifier. PLSDA classification of negative tissue and NSCLC-NOS or atypical carcinoid
yielded sensitivities and specificities over 92%.

Figure 6.16. LV score scatter plot of Raman spectra from negative tissue (blue circles),
SCC tissue (green circles), and AC tissue (red circles). Variables were excluded from
PCA analysis in the ranges of 877 to 895, 1050 to 1072, 1115 to 1183, 1280 to 1311, and
1400 to 1500 cm-1, as the spectra indicated wax contamination.
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Table 6.1. Performance of PLSDA in discriminating Raman spectra from negative and
malignant tissue.
Histological
diagnosis

Sensitivity
(%)

Specificity (%)

Negative

89

84

Malignant

84

89

Table 6.2. Performance of PLSDA in discriminating the Raman spectra from negative,
SCC, and AC tissue.
Histological
diagnosis

Sensitivity (%)

Specificity (%)

Negative

83

85

SCC

76

79

AC

90

89

Table 6.3. Performance of PLSDA in discriminating Raman spectra taken from negative
tissue, NSCLC tissue, and atypical carcinoid tissue.
Tumour type
distinguished from
negative tissue

Sensitivity (%)

Specificity (%)

NSCLC-NOS

92

96

Atypical carcinoid

100

92

6.4 Discussion
Diagnostic samples such as lung tissue biopsies are commonly preserved in paraffin wax.
Chemical dewaxing is generally sufficient to remove wax from embedded sections and
prepare the tissue for histochemical diagnostic techniques, however due to the sensitivity
of Raman spectroscopy, further digital dewaxing is often required. In this study the nonnegatively constrained least squares method was applied to the data to remove
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contaminating wax peaks, although spectral contaminants were still observed in the data.
This may be caused by the microcrystalline structures within paraffin wax, which are
randomly oriented in relation to the polarizing laser, resulting in an inhomogeneous
response depending on sampling location. A larger matrix of wax spectra, accounting for
more of the inhomogeneity may therefore result in more effective wax removal

11

. To

ensure the results of this study are reliable, the Raman peaks associated with wax
contamination were removed from the data for all further analysis.
The results of this exploratory study demonstrate that there are significant differences in
the Raman peak intensities of negative tissue and lung cancer subtypes. Spectral
differences were consistently observed between the negative and lung cancer subtypes
with the strongest signals occurring at ~560, 715, ~780, ~860, ~925, ~1045, 1075-1114,
1185-1200, ~1230, 1278, ~1395, 1510, 1545, 1575-1700 cm−1, representing significant
differences in the molecular composition of saccharides, phosphatidylinositol, cholesterol
nucleic acids, phospholipids, protein structures and amides, across the negative and lung
cancer tissues. These consistent spectral differences between the negative and malignant
tissues are reflective of the malignancy-associated changes that occur in lung
carcinogenesis and are mainly in accordance with the characteristic lung cancer peaks
identified in previous studies using tissue samples1,16–19. The narrow and broad Raman
peaks differentiating the malignant tissues from the negative tissue represent differences
in the vibrational modes of biomolecules in the malignant cells. As the broad Raman
bands are a result of Raman scatter from overlapping vibrational modes of biomolecules,
mapping these broad bands to a single vibrational mode is not reliable. For this reason,
the full spectral region of broad bands is utilised for the biomolecular correlation of
Raman peaks.
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The difference spectra of SCC, AC, atypical carcinoid and grouped malignant tissue
spectra are characterized by reduced signals for phospholipids/methionine (715 cm-1) and
amino acids/saccharides (860 and 930 cm-1), and elevated broad bands for collagen and
glycogen (~1030, 1045-50 cm−1) saccharides/phosphatidylinositol/cholesterol (560 cm-1)
and amide I (>1600 cm-1), indicating alterations in the content of these biomolecules
relative to the negative tissue. This is a finding also reported by Huang et al3 in a study
comparatively analysing spectra from negative and malignant lung tissue. The Raman
peaks consistent with malignancy in this chapter have previously been reported in other
tissue types including cervix, and skin20,21.
The profile of the difference spectrum between the negative tissue and the NSCLC-NOS
tissue is inconsistent with the other difference spectra. In NSCLC-NOS tissue, the broad
amide I band (>1650 cm-1) was found to decrease relative to the negative tissue. In
addition, the DNA signal at 780 cm-1 was increased in the NSCLC-NOS tissue. The
significant spectral differences between the negative and NSCLC-NOS tissue are
consistent with the significant spectral differences between cells from negative cases and
cells from SCC and AC cases identified in chapter 4. The unique spectral profile observed
for NSCLC-NOS tissue may be a result of the heterogeneity of NSCLC. This is reflected
by the difficulty had by pathologists in classifying the tumour type. The limited spectral
data obtained for NSCLC-NOS in this study is another possible reason for the unique
spectral profile observed.
As the differential diagnosis of SCC and AC is now a part of the diagnostic algorithm of
NSCLC, spectroscopic analysis may be utilised to identify diagnostically significant
Raman peaks that aid discrimination. In this study, the difference spectrum between the
negative tissue and the SCC tissue shows similar prominent peaks to the difference
spectra between the negative tissue and the AC tissue. In comparison to the negative
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tissue, the SCC and AC subtypes showed increased peak intensities at 560, 1075-1114,
1616 and ~1650 cm-1, and decreased peak intensities at 715, 860, ~930, 1214-1230, and
1510 cm−1. This correlates with an increase in the level of lipids, collagen,
tryptophan/tyrosine, cholesterol, phosphatidylinositol and amide I, and a decrease in the
amount of phospholipids, saccharides, methionine, proline and valine, amide III, and
nucleic acids in the SCC and AC tissue. The biochemical profile of these subtypes shows
similarities to the characteristic molecular alterations associated with SCC and AC
identified in a study by Kaznowska et al16 using vibrational spectroscopy on lung tissue.
The spectral profiles of these two lung cancer subtypes reveal a comparable biochemistry.
In chapter 4, the bronchial cells from SCC and AC cases, and the normal and abnormal
squamous cells from SCC and AC cases also displayed elevated peak intensity at ~103050 cm-1. The reduced signals for phospholipids/methionine (715 cm-1) and saccharides
(~930 cm-1) observed in the difference spectra presented in this chapter were also seen in
the cytoplasm of bronchial and squamous cells of SCC and AC cases presented in chapter
4. Significant peaks associated with amide III and I differentiate negative from the SCC
and AC subtypes on both cytology and histology, however the relative peak intensities
are reversed. In the spectra obtained from cytological samples, increased amide
III/nucleic acids and decreased amide I is associated with the NSCLC subtypes, whereas
in the spectra obtained from tissue specimens, decreased amide III/nucleic acids and
increased amide I is associated with the NSCLC subtypes. These results indicate that
regardless of sample type, variations in these specific biomolecules differentiate negative
from the NSCLC subtypes, however the content of these biomolecules can vary
depending on the sampling method. The cells targeted in chapter 4 are from the surface
layer of epithelium, due to the exfoliative and abrasive nature of cytology samples. The
sections of tissue targeted in this chapter represent cells from tumours that have grown
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within the deeper layers of the tissue (as seen in the images), as malignant cells that have
breached the basement membrane into the lamina propria can be sampled with tissue
biopsy. The variation may also be a result of tissue formalin fixation, and processing
through alcohols and xylene, all of which may alter the biochemical composition
In a clinical setting, difficulty differentiating between SCC and AC is common due to
overlapping morphological and molecular features. It is therefore not surprising that they
have similar spectral profiles in this study. Despite their similarities, comparative analysis
of the mean SCC and AC spectra revealed the biomolecular differences between the two
lung cancer subtypes. An elevation in protein, phospholipid, nucleic acid, amide III, and
glutamine content was associated with SCC on tissue sections, whereas AC was
characterised by greater peak intensities associated with carbohydrates, cholesterol /
thiocyanate, proline and valine, glycogen, collagen, amide II, and amide I. AC had an
increased amide I and II in comparison to SCC both in cytological and tissue samples. As
discussed in chapter 4, alterations in glycogen, collagen, and nucleic acid content are
recurring features in lung malignancies. The results of this study is in accordance with
other studies that have demonstrated the ability of Raman spectroscopy to detect
variations in these biomolecules in the spectra of malignant lung tissues 1,17–19,22.
PCA was then conducted to reduce the dimensionality of the data and summarise the
variation between the negative and malignant groups. The fourth PC was the main
contributor to the discrimination of malignant and negative spectra. The loadings plot of
PC4 shares features with the difference spectrum between negative and malignant tissue,
indicating that biochemical alterations in saccharides, phosphatidylinositol, cholesterol,
phospholipids, methionine, proline, valine, phenylalanine, lipid, collagen, nucleic acids,
amide III and amide I in the malignant tissue contribute to the discrimination of malignant
and negative tissue. PCA of the data from SCC and AC tissues could not differentiate

227

between the two NSCLC subtypes. The inability of this unsupervised classification
technique to discriminate between these two lung cancer subtypes shows similarities in
their biochemistry, revealed by comparable spectral profiles. The overlapping spectral
features are depicted visually using a scatter plot of PC1 and PC2.
In the PCA scatter plot of spectra from SCC, AC and NSCLC-NOS tissue, the SCC and
NSCLC-NOS spectra formed two separate clusters along PC2, although the AC spectra
could not be distinguished from SCC or NSCLC-NOS spectra. The peaks influencing
discrimination of the SCC and NSCLC-NOS tissue were tentatively assigned to
saccharides, phosphatidylinositol, cholesterol, phospholipids, methionine, proline, valine,
phenylalanine, collagen, lipids, collagen, nucleic acids, amide III, amide II, COO-, and
amide I. As the spectral data for NSCLC-NOS came from a single case in this study,
interpatient variability is a possible cause of variation between the SCC and NSCLCNOS spectra. However, the pronounced differences between the SCC and NSCLC-NOS
spectra are consistent with the malignant peak assignments observed throughout this
study, which suggests that the variation between the two diagnoses may be a result of
malignant associated alterations. The NSCLC-NOS spectra could not be classified as
either SCC or AC. Increasing the number of patients in the study and thus increasing the
spectral data may help classify future NSCLC-NOS cases.
PCA of Raman spectra taken from negative, SCC, AC, NSCLC-NOS, and atypical
carcinoid tissues showed that the SCC and AC spectra could be discriminated from the
negative spectra based on proteins / saccharides (660, 845, 860, 1004, 1650 cm-1), and
DNA (780 cm-1), nucleic acids / glycogen / saccharides / phosphatidylinositol /
cholesterol (480, 560, 780, 1185-1280, 1370 cm-1), phospholipids / methionine (715 cm1

), amide III (1185-1280 cm-1), amide II / COO- (1580 cm-1), amide I (>1600 cm-1). The

PC loadings spectra display features that are in the difference spectra between the
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negative tissue and the SCC and AC tissue. The recurring differences between the tissues
analysed in this study are evident in spectral regions associated with nucleic acids,
carbohydrates, phospholipids, lipids, amide, and proteins. These biomolecular variations
between malignancy type are consistent with the findings of Kaznowska et al16, which
utilised FTIR spectroscopy in the investigation of lung cancer tissue. With further
research these peaks assignments could prove to be effective for the characterization of
lung cancer tissues.
Partial least squares discrimination analysis, a supervised classification method, was then
applied to the dataset to differentiate between negative and malignant tissue, and lung
cancer subtypes. The results of this study demonstrate that PLSDA on processed Raman
spectra can be used to delineate between negative and malignant tissue, with sensitivity
and specificity over 84%. The diagnostic performance of Raman spectroscopy in this
study is in accordance with other studies that applied Raman spectroscopy to lung tissue
to detect malignancy

2,3,6

. It is plausible that perfect sensitivity and specificity was not

achieved because morphologically normal tissue adjacent to the tumour tissue is exposed
to the same carcinogenic insults as the tumour. These normal cells may have undergone
malignant associated changes which is reflected in the cellular biochemistry and detected
in the Raman spectra23. This may explain the misclassified malignant and negative
spectra. Field cancerization is another plausible reason for the misclassified spectra,
whereby genetically altered cells in the tumour area or field remain morphologically
normal and are not identified 24–28. PLSDA was then applied to discriminate the spectra
taken from negative tissue and the spectra from SCC and AC tissue, all within the same
model. The model yielded a sensitivity of 83% and specificity of 85% for identification
of negative tissue. AC was detected with a sensitivity of 90%, and the SCC subtype was
classified with a sensitivity and specificity of 76 and 79% respectively. The algorithm
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misclassified 13 SCC spectra as AC. The lower discrimination performance for the
classification of SCC using PLSDA on lung tissue spectra is similar to the results yielded
using PLSDA on spectra from cytology samples in chapter 4. The misclassification of
SCC and AC spectra observed in this study complies with the reported difficulty in
differentiating these subtypes in a clinical setting. The heterogeneity of these
malignancies results in overlapping features in the cellular biochemistry, which are
reflected in the spectra

29–31

. The SCC subtype was classified with marginally lower

accuracy than the other subtypes in each of the bronchoscopic diagnostic sample types
analysed with Raman spectroscopy.
Objective comparative analysis of negative, NSCLC-NOS, and atypical carcinoid tissue
spectra was achieved by the application of two-way PLSDA algorithms to the data. The
models achieved sensitivities and specificities over 92% for the detection of NSCLCNOS and atypical carcinoid tissue. Although, as these results are limited by the low
number of patients, classification may be based on interpatient variability. The PLSDA
performance scores achieved for the classification of lung malignancies using tissue
sections in this chapter (sensitivities and specificities of 76-100%) are comparable to the
diagnostic sensitivities and specificities yielded using cytological specimens in chapter 4
(sensitivities and specificities of 60-97%), however cytology samples yielded more varied
results.
The difference spectra in this study show that there are many broad Raman bands
differentiating the negative and malignant tissue types. The broad bands observed in the
difference spectra in this chapter indicate substantial overall variation between the spectra
from different tissue types. Comparatively, the difference spectra between cells from
cytological samples in chapter 4 have more narrow peaks differentiating the lung cancer
subtypes, suggesting less overall variation between the spectra taken from different
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subtypes. This is not surprising as specific cells and components were being targeted and
directly compared on the cytology samples. When applying Raman spectroscopy to tissue
samples the cell types and components are not easily distinguished and therefore cannot
be targeted. Hence, the spectra are influenced by a combination of nuclei and cell
cytoplasm. Greater variation between individual spectra and tissue types is therefore
inevitable and leads to broader bands of significant differences between tissue types. As
narrow Raman peaks are assigned to specific vibrational modes of biomolecules more
easily than broad peaks, using cytology samples for Raman spectroscopic analysis may
be more reliable for identifying diagnostically significant peaks for lung cancer. In
addition, cytology may be more appropriate for analysis of the entire spectrum, as large
spectral ranges were removed from the tissue spectra due to wax interference.
In this study, good sensitivities and specificities were achieved for the identification of
lung cancer using Raman spectroscopy on formalin fixed paraffin embedded tissue
sections. Our findings compare well with those of other studies

2,5,7,32

and suggest that

Raman spectra may potentially be used to effectively identify characteristic biochemical
changes in lung cancer subtypes. Comparing the findings of this chapter and chapter 4,
lung malignancies were detected with comparable sensitivities and specificities using
cytological samples and tissue sections. Using Raman spectroscopy on cytological
samples could be a minimally invasive and effective technique for lung cancer diagnosis,
as cytological sampling methods are less invasive than biopsies for obtaining material to
investigate lung lesions, and are not limited by wax interference. However, the results
show that Raman spectroscopy appears to be diagnostically effective on both tissue and
cytology samples.
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The secondary objective of the PhD is based on investigating the suitability of Raman
spectroscopy for detecting malignant thyroid lesions on FNAC samples. The following
chapters aim to prove this concept, and to identify and address complications arising from
using Raman spectroscopy on clinical FNAC samples. The next chapter is a proof of
concept study demonstrating the ability of Raman spectroscopy to discriminate between
thyroid cancer subtypes using cell line models.
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Abstract
Objective: In 2016 there were an estimated 56,870 new cases of thyroid cancer (TC) in
the United States. Fine needle aspiration cytology (FNAC) is the most safe, accurate and
cost-effective method for the initial investigation of thyroid nodules. FNAC is limited by
the inability to accurately diagnose malignancy in follicular-patterned lesions, and as a
result 20% to 30% of cases under investigation for TC are classified as cytologically
indeterminate, illustrating a problem with current FNAC procedure. Raman spectroscopy
has shown promising results for the detection of many cancers however to date there has
been no report on the performance of Raman spectroscopy on thyroid cytological
samples. The aim of this study was to examine whether Raman spectroscopy could be
used to correctly classify cell lines representing benign thyroid cells and various subtypes
of TC.
Methods: A benign thyroid cell line and seven TC cell lines were prepared as ThinPrep®
cytology slides and analysed with Raman spectroscopy. Principal components analysis
(PCA) and linear discriminant analysis (LDA) were implemented to develop effective
diagnostic algorithms for classification of Raman spectra of different TC subtypes.
Results: The spectral differences separating benign and TC cell lines were assigned to
differences in the composition of nucleic acids, lipids, carbohydrates and protein in the
benign and cancer cells. Good sensitivities (74 - 85%), specificities (65 - 93%) and
diagnostic accuracies (71 – 88%) were achieved for the identification of TC.
Conclusion: These findings suggest that Raman spectroscopy has potential for
preoperative TC diagnosis on FNAC samples.
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7.1 Introduction
In 2016 there were an estimated 56,870 new cases of thyroid cancer (TC) in the United
States 1. Women account for approximately 75% of these cases, exhibiting a substantially
higher rate of incidence of the disease compared to men, but similar mortality. TC
incidence has been steadily increasing in recent decades, as reported in the TC
epidemiology studies

2,3

. Although improved diagnostic methods, notably ultrasound

(US) examination, are the likely reason for the global increase in incidence (especially of
smaller nodules), recent studies show that the incidence of aggressive forms associated
with higher mortality is also increasing 4.
Of the wide array of malignancies that are characterised as TC, papillary thyroid
carcinoma (PTC) is the most common, accounting for approximately 80% of cases. Other
histological types include follicular thyroid carcinoma (FTC), Hürthle cell carcinoma,
poorly

differentiated

carcinoma,

medullary

thyroid

carcinoma

(MTC),

and

undifferentiated or anaplastic carcinoma (UTC or ATC, respectively). PTC and FTC
emanate from thyroid follicular epithelial cells and are commonly referred to as well
differentiated thyroid carcinomas (DTC) 5,6. MTCs are derived from neuroendocrine cells
and represent approximately 5 to 10% of TC 7.
The most common manifestation of TC is as a thyroid nodule. Thyroid nodules are
common in the general population, with a prevalence of 2-7% when detected by palpation
and 50% when searched for using US examination 5,8. Despite thyroid nodules having a
high incidence rate, approximately 60%-80% are classified as benign, with only 3.5% 10% presenting as malignancies. Fine needle aspiration cytology (FNAC) is the most
accurate and cost-effective method for the initial management of thyroid nodules, and its
accuracy is higher when it is conducted under US guidance. FNAC is limited by the
inability to accurately diagnose malignancy in follicular-patterned lesions, and as a result
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more than 20% of cases under investigation for TC are classified as cytologically
“indeterminate”

9–12

. The indeterminate category often requires surgical resection to

definitively exclude malignancy; however, since approximately 70% of these lesions are
finally shown to be benign, surgery is an unnecessary procedure for the vast majority of
cases 13,14.
In an attempt to overcome limitations of cytology in the detection of cancer, optical
spectroscopic techniques have been investigated as adjunct or alternative approaches 15.
Optical spectroscopic methods use the interaction of light with matter to provide a
detailed description of the molecular composition of biological tissue, and so these
techniques can be employed to detect biochemical profiles associated with health or
disease.
Raman spectroscopy is a form of vibrational spectroscopy based on inelastic scattering.
Raman spectra are obtained by irradiating a sample with monochromatic laser light,
which interacts with molecules within the sample and induces molecular vibrations. The
change in energy between the incident and inelastically scattered light is called the Raman
shift. The Raman spectrum is a plot of the intensity of the scattered light versus the change
in energy, given in wavenumbers, cm-1

16–18

. The spectrum produced by the probed

molecular vibrations represents a detailed biochemical fingerprint of the cellular
components.
Raman spectroscopy has shown promising results for the detection of multiple cancers
including cervical, gastrointestinal, breast, brain, and lung cancer

19–22

. The application

of Raman spectroscopy for TC diagnosis has also been investigated in studies utilizing
cell lines 23–25, and tissue sections 26–32. Harris et al.23 applied Raman spectroscopy to two
thyroid cell lines, one cancer cell line (8505C, representing UTC) and one benign cell line
(Nthy-ori 3-1), to analyse the cellular differences between benign and malignant cells.
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Distinct differences in the nucleic acid content of the cancer cells were revealed, and,
using neural network analysis a diagnostic sensitivity of 95% was achieved for
discrimination of the cancer cell line. Building on Harris’ work, Lones et al.24 applied
Raman spectroscopy to analyse one benign thyroid cell line and four TC cell lines
representing PTC, FTC, MTC and UTC. Alterations in either the molecular conformation
or concentration of DNA/RNA, amide I and aromatic amino acids were found to be
indicative of cancer. The authors reported good discrimination of the benign cell line from
MTC and UTC, and a lower discrimination between cell lines with the same cell of origin,
namely benign versus DTC cell lines.
Recent studies have also investigated the feasibility of applying Raman spectroscopy to
thyroid tissue samples to detect cancer. These studies used multivariate statistical analysis
of Raman spectra to achieve high diagnostic sensitivities and specificities for
discrimination between healthy thyroid tissue and TC, and follicular patterned thyroid 27–
30

.

Application of Raman spectroscopy to thyroid FNAC has not yet been reported. As a first
step, the present proof-of-concept study builds on the aforementioned studies by
investigating the application of Raman spectroscopy to a benign thyroid cell line and a
large number of TC cell lines prepared as ThinPrep® cytology slides, representing FNAC
cytological specimens.

7.2 Materials and Methods
7.2.1 Cell cultures
Cell lines used were representative of benign thyroid cells and four subtypes of TC: one
benign follicular epithelial cell line (NThy-ori 3-1), two PTC cell lines (K1 and TPC1),
one FTC cell line (XTC1), two UTC cell lines (8505C and C643) and two MTC lines
(CRL-1803TT and MZCRC1). The Nthy-ori 3-1 cell line [catalog no. 90011609, lot no.
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13B007, passage no. 16 (p16)] was purchased from Sigma and used at p18. The TT cell
line was obtained from the American Type Culture Collection (ATCC CRL1803 TT, lot
no. 58785858, no passage information) and was used at p3. All other cell lines (K1, used
at p9; TPC1, used at p29; XTC1, used at p17; 8505C used at p21; C643, used at p31;
MZCRC1, used at p14 were kindly provided by Prof. Paula Soares (Institute of Molecular
Pathology and Immunology of the University of Porto, Portugal). All cell lines were
maintained in standard culture conditions at 37°C in a humidified incubator under 5%
carbon dioxide. RPMI-1640 with 10% fetal bovine serum (FBS) and 1% Pen-Strep was
the medium for most cell lines, with the following exceptions: K1 cells were cultured in
DMEM/F12 medium supplemented with 10% FBS; CRL1803TT cells were cultured in
F-12K Nutrient Mixture Kaighn's Modification with 10% FBS; MZCRC1 cells were
cultured in DMEM with 15% FBS. All culture media were from Invitrogen. Slides for
Raman analysis were prepared using a ThinPrep® processor and air dried without final
staining.
7.2.2 Raman Measurement
As described in chapter 3 section 3.1.1.
Thirty cells were recorded from each slide. For each cell, a single spectrum was recorded
from the cell nucleus, corresponding to the average of two accumulations of 30 seconds.
Spectra were also recorded from 30 vacant locations on a ThinPrep® glass slide with
identical exposure time in order to obtain representative background glass spectra.
The signal to noise ratio (SNR) was calculated by dividing the difference between the
peak signal at 1665 cm-1 and the baseline intensity (smooth region after 400 cm-1) by the
standard deviation of the peak signal, as described by Desroches et al 33. The mean SNR
of all of the spectra included was 102 dB, which was calculated from a range of 77 - 159
dB.
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7.2.3 Data pre-processing and analysis
All spectral data analysis was conducted using R software. Data were process as described
in chapter 3 section 3.2.3-.7. The data was analysed using Principal Component Analysis
(PCA) and Linear Discriminant Analysis (LDA), as described in chapter 3 section 3.2.8
and section 3.2.9 respectively. The first PCs that explained approximately 95% of the
variance within the data were used in the PC-LDA classification models.

7.3 Results
7.3.1 Mean spectral analysis
Figure 7.1 depicts the mean benign thyrocyte cell line (Nthy-ori3-1) spectrum and the
biological components corresponding to each spectral region. The standard deviation
shows that there was minimal variation between the spectra from individual cells and this
was also the case for all cell lines. The features in the TC cell line spectra that differ from
the benign cell line are demonstrated by the difference spectra in Figures 7.2-4.
The significant Raman peaks and their corresponding biological components are shown
in Table 7.1. Spectral differences between the benign thyroid cell line and the TC cell
lines corresponded to peaks relative to lipids and proteins (524, 820, 1225, 1278, 1310,
1343, 1402, 1435, 1453, 1570, 1661, 1677 cm-1), carbohydrates (477, 941, 1343 cm-1),
phosphates (1190 cm-1) and nucleic acids (780, 1330 cm-1), as shown in Figures 7.2-4.
The difference spectra of the FTC and PTC cell lines had similar profiles, with significant
peaks at 1225, 1435, 1456 and 1690 cm-1 differentiating them from the benign cell line
(Figure 7.2). For the UTC cell lines, consistent spectral differences were observed at 780,
1343, 1190, 1280, 1450 cm-1 (Figure 7.3). Compared to the benign cell line, the MTC cell
lines showed consistent spectral differences at 780, 1450, 1570, 1645, and 1673 cm-1
(Figure 7.4).
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Figure 7.1. Mean Raman spectrum of the benign cell line (NThy-ori 3-1) with the standard
deviation shown as shading, and the different spectral regions with corresponding
biomolecules.
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Figure 7.2. Difference spectrum between (a) Nthy-ori 3-1 (benign) and FTC cell line
XTC1; (b) Nthy-ori 3-1 and PTC cell line K1; (c) Nthy-ori 3-1 and PTC cell line TPC1.
Shading indicates regions of the spectrum that were significantly different (p<0.05).

Figure 7.3. Difference spectrum between (a) Nthy-ori 3-1 (benign) and 8505C (UTC);
and (b) Nthy-ori 3-1 and C643 (UTC). Shading indicates regions of the spectrum that
were significantly different (p<0.05).
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Figure 7.4. Difference spectrum between (a) Nthy-ori 3-1 (benign) and CRL1803TT
(MTC); (b) Nthy-ori 3-1 and MZCRC1 (MTC). Shading indicates regions of the spectrum
that were significantly different (p<0.05).

Table 7.1. Tentative peak assignments for the significant Raman bands identified by
spectral variation analysis 34,35.
Wavenumber Raman peak assignments
-1
(cm )
430

Cholesterol ester

454

Ring torsion of phenyl

477

Polysaccharides

509

S-S disulphide stretching band of collagen

524

S-S disulphide stretching in proteins
Phosphatidylserine

614

Cholesterol ester

645

C-C twisting mode of phenylalanine

700

Amino acid methionine

729

Adenine

780

Uracil based ring breathing mode
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820

Protein band
Structural protein modes of tumours
Collagen I

855

Proline, tyrosine

880

Tryptophan

941

Skeletal modes of polysaccharides

970

Phosphate monoester groups of phosphorylated proteins and
nucleic acids

~1000

Phenylalanine

1100-375

Several bands of moderate intensity belonging to amide III and
other proteins

1310

CH3/CH2 twisting or bending mode of lipid/
collagen

1230

Antisymmetric phosphate stretching vibration

1330

Region associated with DNA & phospholipids
Collagen

1343

CH3,CH2 wagging (collagen assignment)
Glucose
CH residual vibrations

1392

C-N stretching, in quinoid ring-benzoid
ring-quinoid ring

1402

Bending modes of methyl groups
Amino acids aspartic and glutamic acid

1436

CH2 scissoring

1450

C-H deformation bands (CH functional groups in lipids, amino
acids side chains of the proteins and carbohydrates)

1453

Protein bands
Structural protein modes of tumors

1499

C=C stretching in benzenoid ring

1570

COOAspartate and glutamate

1645

Amide I (α helix)

1650

C=C Amide I
Protein amide I absorption

1667

Protein band
Carbonyl stretch C=O

1677

Amide I (proteins)
C=O stretching (lipids)
T, G, C ring breathing modes of DNA/RNA bases
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7.3.2 Linear Discriminant Analysis
In order to evaluate the efficacy of Raman spectroscopy to accurately classify the benign
and TC cell lines, PC-LDA classification models were developed using the principal
components from PCA of the benign thyroid cell line and each of the TC cell lines. Table
7.2 shows the results of seven separate PC-LDA models used to classify the benign
thyroid cells and each of the TC cell lines. The performance of each two way
classification is shown using the sensitivity, specificity and diagnostic accuracy of each
model. Diagnostic accuracy is used to describe the proportion of correctly classified
spectra (true positive + true negative) among all the classified spectra (true positive + true
negative + false positive + false negative) 36. The first 5 PCs in each case were used to
develop the PC-LDA classifiers. PC-LDA classification of Nthy-ori 3-1 (benign) vs. PTC,
FTC and MTC cell lines yielded sensitivities of ≥90%, specificities of ≥80% and
accuracies of ≥89%. Lower performance was observed for the models discriminating the
benign cell line from the UTC cell lines with sensitivity, specificity, and diagnostic
accuracy of 77%, 73% and 75% for 8505C, and 87%, 77%, 82% for C643, respectively.
Table 7.2. Performance of the PC-LDA classification model in discriminating the benign
thyroid follicular cell line Nthy-ori 3-1 from each TC cell line.
TC cell line distinguished
from Nthy-ori 3-1

Subtype of
TC

Sensitivity

Specificity

(%)

(%)

Diagnostic
accuracy (%)

XTC1

FTC

100

80

90

K1

PTC

90

87

89

TPC1

PTC

97

87

92

8505C

UTC

77

73

75

C643

UTC

87

77

82
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MZCRC1

MTC

100

97

99

CRL-1803TT

MTC

100

93

97

To evaluate the ability of PC-LDA to discriminate benign cells from TC subtypes, cell
lines were grouped by their TC subtype. To produce an unbiased classifier, representative
spectra from each cell line were selected at random and combined by TC subtype,
matching the number of spectra used for the benign cell line. As XTC1 was the only cell
line representing FTC, all spectra from this cell line were used, matching the number of
spectra used for the benign cell line. Table 7.3 shows the results achieved for
discriminating the benign cell line from the TC cell lines grouped by subtype. Separate
two-way classification models using 5 PCs each were developed to discriminate the
benign cells from each TC subtype. The MTC and PTC subtypes were discriminated from
the benign cell line with diagnostic accuracies of at least 82%. The UTC subtype was
classified at a lower accuracy of 71%. Due to similarities in their cellular biochemistry
observed in this study, the well differentiated PTC and FTC subtypes were grouped
together for analysis, yielding a diagnostic accuracy of 74%.
Table 7.3. Performance of the PC-LDA classification model in discriminating the benign
thyroid follicular cell line Nthy-ori 3-1 from TC cell lines grouped by TC subtype.
TC subtype distinguished
from Nthy-ori 3-1

Sensitivity
(%)

Specficity
(%)

Diagnostic
accuracy
(%)

PTC†

85

79

82

UTC‡

77

65

71

MTC§

84

93

89

DTC¶

74

74

74

247

†

PTC includes K1 and TPC1. ‡UTC includes 8505C and C643. §MTC includes CRL1803TT and
MZCRC1. ¶DTC includes PTC (K1 and TPC1) and FTC (XTC1).

Table 7.4 shows the results of the two-way PC-LDA classification models used for the
discrimination of the PTC and UTC cell lines, each was developed using 4 PCs. Each
two-way classification model yielded sensitivities, specificities and diagnostic accuracies
above 92% for each cell line classification. Grouped together, the PTC and UTC subtypes
were discriminated with a diagnostic accuracy of 81%.
Table 7.4. Performance of the PC-LDA classification model in discriminating PTC from
UTC cell lines.
Comparison

Sensitivity

Specificity

Diagnostic
accuracy (%)

(%)

(%)

K1 vs. 8505C

93

90

92

K1 vs. C643

93

97

95

TPC1 vs. 8505C

97

93

95

TPC1 vs. C643

93

93

93

PTC† vs. UTC‡

80

82

81

†

PTC includes K1 and TPC1, ‡UTC includes 8505C and C643

Table 7.5 shows the results for the PC-LDA classification of MTC cell lines versus the
PTC cell lines. Each classification is the result of separate two-way models using 4 PCs
each. The models yielded specificities and diagnostic accuracies ≥93% for each cell line
classification, and a diagnostic accuracy of 86% for the two-way discrimination of the
MTC and PTC subtypes.
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Table 7.5. Performance of the PC-LDA classification model in discriminating MTC from
PTC cell lines.
Comparison

Sensitivity

Specificity

(%)

(%)

CRL1803TT vs. K1

100

97

99

MZCRC1 vs. K1

100

93

97

CRL1803TT vs.
TPC1

100

100

100

MZCRC1 vs. TPC1

100

100

100

MTC† vs. PTC‡

90

82

86

†

Diagnostic
accuracy (%)

MTC includes CRL1803TT and MZCRC1. ‡PTC includes K1 and TPC1.

Table 7.6 shows the performance of separate two-way PC-LDA models in discriminating
FTC cell lines from PTC, MTC and UTC cell lines. Discrimination of the follicular XTC1
cell line from the PTC cell lines was achieved using 4 PCs in each PC-LDA model.
Diagnostic accuracies of 87% and 85% were obtained for the K1 and TPC1 cell lines
respectively. The FTC cell line was discriminated from the UTC cell lines with diagnostic
accuracies above 94%, and from the MTC cell lines with 100% accuracy, each model
using 4 PCs. When cell lines were grouped by subtype, FTC was distinguished from MTC
with an accuracy of 99% (using 4 PCs), from UTC with a diagnostic accuracy of 89%
(using 3 PCs), and from PTC with 79% accuracy (using 5 PCs).
Table 7.6. Performance of PC-LDA classification of FTC lines from PTC, MTC and UTC
cell lines.
Comparison

Sensitivity
(%)

Specificity (%)

Diagnostic accuracy
(%)

XTC1 vs. K1

97

77

87
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XTC1 vs. TPC1

89

80

85

XTC1 vs. 8505C

100

87

94

XTC1 vs. C643

97

97

97

XTC1 vs. CRL1803TT 100

100

100

XTC1 vs. MZCRC1

100

100

100

FTC† vs. PTC‡

89

69

79

FTC† vs. MTC§

100

98

99

FTC† vs. UTC¶

97

81

89

†

FTC includes XTC1. ‡PTC includes K1 and TPC1. §MTC includes CRL1803TT and
MZCRC1. ¶UTC includes 8505C and C643.

Table 7.7 summarises the results achieved for separate two-way classifications of the
MTC and UTC cell lines. The MTC cell lines were discriminated from the UTC cell lines
with diagnostic accuracies ≥97% using 3 PCs in each model, and when grouped together,
the MTC cell lines were discriminated from the UTC cell lines with an accuracy of 84%
using 4 PCs.
Table 7.7. Performance of the PC-LDA classification model for discriminating the MTC
from UTC cell lines.
Comparison

Sensitivity Specificity Diagnostic
accuracy (%)
(%)
(%)

CRG1803TT vs.
8505C

100

93

97

MZCRC1 vs. 8505C

100

97

99

97

97

CRG1803TT vs. C643 96
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MZCRC1 vs. C643

100

100

100

MTC† vs. UTC‡

78

90

84

†

MTC includes CRL1803TT and MZCRC1. ‡UTC includes 8505C and C643.

Table 7.8 demonstrates the performance of a five-way classification model developed
using the benign cell spectra and spectra from all the TC subtypes. Representative spectra
from each cell line were selected at random and combined into TC subtypes as previously
described. The model yielded diagnostic sensitivities from 57-100%, specificities ≥91%,
and an overall diagnostic accuracy of 78% using 5 PCs. Figure 7.5 depicts the scatter plot
of the linear discriminant scores of the benign spectra and spectra from each TC subtype.
The FTC spectra and the PTC spectra form two close clusters using the first two
discriminant functions, which can be discriminated from the benign spectra with some
overlap. The MTC spectra form a cluster along the first discriminant function which is
distinct from the benign spectra. The UTC subtype clusters adjacent to the benign spectra
along the first discriminant function, although using only the first two discriminant
functions to plot the scatter plot of the linear discriminant scores, the UTC and benign
spectra overlap.
Table 7.8. Performance of the PC-LDA classification model for discriminating the benign
and TC subtypes.
Comparison

Sensitivity
(%)

Specificity (%)

Benign

57

98

FTC†

94

92

PTC‡

63

91

UTC¶

79

96
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MTC§

100

96

†

FTC includes XTC1. ‡PTC includes K1 and TPC1. ¶UTC includes 8505C and C643.
§
MTC includes CRL1803TT and MZCRC1.

Figure 7.5. Scatter plot of the linear discriminant scores of the benign spectra and
representative spectra from each TC subtype using PC-LDA.

Table 7.9 shows the performance of the PC-LDA model in discriminating the benign cell
line from all of the TC subtypes combined into one group. As before, in order to produce
an unbiased classifier, representative spectra from each TC subtype were selected at
random and combined into one TC group, giving a total number of TC spectra that was
similar to the number of benign spectra. The first 5 PCs were used to develop the twoway PC-LDA model which produced a sensitivity of 74%, specificity of 87%, and overall
accuracy of 81% for discriminating benign spectra from the TC spectra.
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Table 7.9. Performance of the PC-LDA classification model for discriminating the benign
cell line from all TC lines.
Comparison

Sensitivity
(%)

Specificity
(%)

Diagnostic
accuracy (%)

Benign vs TC†

74

87

81

†

TC includes representative spectra from FTC, PTC, UTC, and MTC.

7.4 Discussion
Raman microspectroscopy was performed in this study to obtain a biomolecular
characterisation of eight thyroid cell lines. Spectral differences were consistently
observed between the benign and TC cell lines with the strongest signals occurring at
~470, ~780, 855, 941, ~1230, 1278, 1343, 1402, 1436, 1456, 1571, 1650, 1690 and 1677
cm-1, representing significant differences in the molecular composition of carbohydrates,
nucleic acids, lipids, protein structures and amides, as mapped by Movasaghi et al.

35

,

across the benign and TC cell lines. These peaks differentiating benign thyroid cells and
TC cells are in accordance with several of the characteristic TC peaks identified in
previous studies using tissue samples and cell lines

23,24,31

. The consistent spectral

differences between the benign and TC cell lines observed in our study may be reflective
of the malignant transformation that occurs due to the carcinogenic progression of TC
35,37

. These Raman peaks represent the vibrational modes of biomolecules that are altered

in quantity or conformation in the malignant cells.
The difference spectrum between the benign cell line and the FTC cell line (XTC1),
shows identical strong bands to the difference spectra between the benign cell line and
the PTC cell lines. The similar profiles of the difference spectra reveal a comparable
biochemistry in the FTC and PTC subtypes. In comparison to the benign cell line, the
PTC and FTC cell lines showed an increased peak intensity at 1225 cm-1 and 1435 cm-1,
and a decreased peak intensity at 1456 cm-1 and 1690 cm-1. This indicates an increase in
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the level of amide III, proteins, and nucleic acids, and a decrease in the amount of lipids
and amide I in the cancer cells

35

. The spectral profile of these DTC cell lines show

similarities to the characteristic FTC peaks identified in a study by Teixeira et al. using
thyroid tissue30. As both PTC and FTC emanate from epithelial follicular cells and are
often even analysed as one group in terms of prognosis, it is plausible that the similarities
in their biochemistry observed may be explained by the common origin of PTC and FTC
5,6

.

Regarding the UTC cell lines (8505C and C643), both exhibited elevated nucleic acids
(~1343 cm-1) and polysaccharides (477 cm-1) in comparison to the benign cell line. A
lower peak intensity for amide III was observed for both cell lines in comparison to the
benign cell line, which is evident by the broad band in the difference spectrum between
~1190 cm-1 and 1280 cm-1. The 8505C cell line showed an increased peak intensity at
both 780 cm-1 and 830 cm-1, corresponding to increased nucleic acids, which is consistent
with the findings of Harris et al 23. The 8505C cell line also showed a higher peak intensity
at 1450 cm-1 in comparison to the benign cell line, which suggests an increase in the level
of proteins and lipids in the cancer cells35. UTC is a heterogenous disease at a molecular
level, making it difficult to find commonalities between cases, which may explain the
dissimilarities in the spectral profiles observed in this study between the two UTC cell
lines 38.
The difference spectra of the benign versus the MTC cell lines (MZCRC1 and
CRL1803TT) showed consistent spectral bands at 780, 1450, 1570, 1645, and 1673 cm-1
that differentiate the MTC cell lines from the benign cell line. In comparison to the benign
cell line, the MTC cell lines exhibited a lower peak intensity at 1450 cm-1, indicating
lower levels of lipids, carbohydrates and amino acids in the MTC cells. In comparison to
the benign cell line, both MTC cell lines exhibited greater peak intensities at 780 cm-1,

254

1570 cm-1and 1670 cm-1, indicating an increase in the level of nucleic acids (780 cm-1),
aspartate and glutamate (1570 cm-1), and amide I (1670 cm-1). As MTCs emanate from
the neuroendocrine parafollicular C cells and not from the follicular epithelial cells like
the other cell lines, the distinct overlapping spectral features that differentiate the
MZCRC1 and CRL1803TT cell lines from the benign cell line may be explained by the
distinct origin of MTC 7.
The main focus of this investigation was to evaluate the potential use of Raman
spectroscopy as an enhanced diagnostic technique for TC. Objective comparative analysis
of the spectra was achieved using linear discriminant analysis (LDA) on already PCAtransformed data sets for maximum class separation. Application of the PC-LDA
algorithm to the data achieved diagnostic accuracies up to 99% for the distinction of
benign and TC cell lines. The well differentiated PTC and FTC cell lines were detected
with sensitivities >90% and specificities >80%, although the model yielded lower
performance scores for identifying the UTC cell lines (sensitivities of 77 and 87%,
specificities of 73 and 77%, and diagnostic accuracies of 75 and 82% for the 8505C and
C643 cell lines, respectively). The heterogeneity and wide variability of molecular
profiles of UTCs may explain the poorer performance of the model for discriminating
benign cells from individual UTC cell lines as well as the grouped UTC cell lines
(diagnostic accuracy of 71%).
A PC-LDA model was applied to examine whether Raman spectroscopy could be used
to correctly classify cell lines representing the various subtypes of TC. Diagnostic
accuracies from 92%-97% were achieved for the discrimination of the UTC cell lines
from FTC and PTC cell lines. The MTC cell lines were discriminated from the PTC, FTC
and UTC cell lines with classification model performance scores >93%. The high
accuracy observed for the classification of the MTC cell lines may be due to the different
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origin of MTCs from other TCs, as discussed previously. FTC (XTC1) and PTC (K1) cell
lines were discriminated with an accuracy of 87% and the FTC cell line (XTC1) and PTC
cell line (TPC1) were discriminated with an accuracy of 85%. Cell lines from the same
subtype of TC were then grouped together for analysis. Diagnostic accuracies >81% were
achieved for discriminating UTC from the PTC, FTC and MTC subtypes. The model also
retained a high level of performance for the discrimination of the MTC subtype from PTC
and FTC, with respective diagnostic accuracies of 86 and 99%. The well differentiated
PTC and FTC subtypes were then discriminated with a marginally lower diagnostic
accuracy of 79%, which may be explained by the common origin of PTC and FTC.
PC-LDA was then applied to investigate the ability to discriminate the benign cells and
all the TC subtypes within the same model. The model yielded a poor sensitivity (57%)
for the benign cells as benign spectra were misclassified as PTC. Multiple PTC spectra
were classified as FTC, resulting in a low diagnostic sensitivity of 63% for PTC. The low
discrimination accuracy achieved in this study between cells derived from the same origin
is similar to the findings of Lones et al 24. The MTC and FTC subtypes were discriminated
with sensitivities of 100 and 94% respectively, as observed visually in the scatter plot of
the linear discriminant scores. The model also yielded a sensitivity of 79% for the UTC
subtype. Multiple UTC spectra were misclassified as PTC and benign, as observed in the
overlap of the clusters of these subtypes in the scatter plot of the linear discriminant
scores.
The benign thyroid cell line could be discriminated from all of the TC subtypes combined
into one group with a diagnostic accuracy of 81%. This is slightly higher than the 78.3%
reported by Medeiros Neto et al.
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, which was achieved applying PC-LDA to Raman

spectra obtained from patient thyroid tissue.
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The paramount information required from the thyroid FNAC procedure is the
differentiation between benign and malignant thyroid nodules. FNAC is the current
favoured diagnostic method for the initial investigation of thyroid nodules, with reported
sensitivity and specificity ranges of 65%-98% and 78%-100%, respectively

39–42

. The

results of this study show that Raman spectroscopy may also be utilized to improve the
accuracy of FNAC. In our study, good sensitivities (63%-100%), specificities (65%100%) and diagnostic accuracies (71%-99%) were achieved for the identification of TC
using Raman spectroscopy on TC cell lines prepared as ThinPrep® cytology slides.

7.5 Conclusion
In summary, Raman spectroscopy together with PC-LDA classification models was
applied to identify the molecular differences between a benign thyroid epithelial cell line
and seven TC cell lines. The spectral differences separating benign and TC cell lines were
assigned to differences in the molecular composition of nucleic acids, lipids,
carbohydrates and protein in the benign and cancer cells. PC-LDA classification models
discriminated between the benign and cancer cell lines as well as between the different
TC subtypes with high diagnostic accuracy. This chapter showed good potential of
Raman spectroscopy for TC diagnosis using cell line models prepared as ThinPrep®
cytology slides. The next chapter will aim to investigate clinical thyroid FNAC samples,
but first a methodology needs to be developed for sample preparation, as blood
contamination in FNAC samples interferes with the cellular Raman spectrum.
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Chapter 8: Development of a blood removal protocol suitable for
thyroid FNAC samples
8.1 Introduction
Based on the previous chapter, Raman spectroscopy could be implemented as an adjunct
diagnostic technique to thyroid FNAC samples to improve the limitations of current
methods and provide an objective diagnosis. Applying Raman spectroscopy to biological
specimens ordinarily requires minimal sample pretreatment, however as the thyroid is a
very vascular organ receiving a high blood supply from the superior and inferior thyroid
arteries, thyroid FNAC samples often contain blood 1. Blood in the FNA sample will often
cover and surround the diagnostic cell groups and interfere with microscopic
interpretation. To reduce interference from blood, during the ThinPrep® procedure for
thyroid FNA, the patient cellular material is transferred to CytoLyt, an alcohol based
lysing agent for red blood cells. However, Raman spectroscopy is a highly sensitive
method and can detect trace amounts of blood.
The main limitations with Raman spectroscopy in cellular analysis include the
autofluorescence of biological material creating a background in the spectra, substrate
interference, and residual blood can be a limiting factor in the case of clinical specimens.
The presence of these contaminants reduces the reliability of the information attained
from the biological Raman spectrum and it is therefore paramount to remove any
unwanted spectral signatures prior to analysis. Applying algorithms for baseline
correction and substrate spectrum removal to the data reduces spectral contamination
from autofluorescence and substrates2,3. Blood contamination however must be removed
from the sample by chemical means prior to acquiring Raman spectra. Previous studies
4,5

explored the utilisation of hydrogen peroxide to remove blood contamination from

cytological samples in preparation for Raman spectroscopic analysis. Bonnier et al5
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reported obtaining reproducible Raman spectra with no blood features by applying a
hydrogen peroxide wash step on the prepared ThinPrep® slide during cytological sample
preparation. The authors noted that their blood removal method was applicable to cervical
liquid based cytology samples with low levels of blood contamination. Traynor et al4
improved the protocol and prepared excessively bloody cervical liquid based cytology
samples for Raman spectroscopic analysis. The improved blood removal was achieved
following a hydrogen peroxide treatment in the collection vial, as opposed to on the
prepared ThinPrep® slide. The findings of Traynor et al4 and Bonnier et al5 indicate that
H2O2 may be useful to remove blood from thyroid FNAC samples in preparation for
Raman spectroscopic analysis.
The aim of this study was to develop a blood removal method, suitable for application to
thyroid FNAC specimens, which allows uncontaminated Raman spectra to be obtained
from the cell samples. In section A, a HeLa cell line was contaminated with human blood
to replicate the complications encountered when applying Raman spectroscopy to thyroid
FNAC samples. Different combinations of washes and chemical treatments were applied
to the HeLa cells. The optimum blood removal protocol was investigated by assessing the
presence of blood associated peaks in the cellular Raman spectra. Section B is a
preliminary study investigating the use of Raman spectroscopy for the discrimination
between normal and malignant thyroid FNAC samples. The blood removal method
developed in section A was applied, with minor adjustments, to ‘mock’ thyroid FNAC
samples taken from thyroid biopsies and Raman spectra were acquired and analysed.
Finally, in section C, clinical thyroid FNAC samples were analysed and the method
developed in section A and adjusted in section B was found to be not effective for these
samples and required further optimisation.
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8.2 Section A
8.2.1 Materials and Methods
8.2.1.1 Cell culture

The immortal cervical cancer HeLa cell line was provided by the American Type Culture
Collection (ATCC) and were cultured in Roswell Park Memorial Institute medium (RPMI
1640) supplemented with 10% fetal bovine serum (FBS), and L Glutamine. The culture
was maintained at 37 degrees and 5% carbon dioxide in an air humidified atmosphere. In
order to prevent the cells from being exposed to a deprivation of nutrients, the cells were
split into new T-75 culture flasks once 80 percent confluency was reached.
8.2.1.2 Blood contamination

The experimental component of section A was conducted in conjunction with a final year
student as part of their research project in DIT (TU Dublin). This study utilised human
blood, which was donated by a healthy donor. The TU Dublin School of Biological and
Health Sciences have ethical approval for staff members to donate blood for teaching and
educational purposes.
After culturing, the cells were transferred to falcon tubes and contaminated with human
blood in an effort to resemble the conditions of clinical thyroid FNAC samples. The blood
scale index, which is used in cytology laboratories, in Figure 8.1 was used as a reference
to develop different levels of blood contamination. Group 0, which has no blood, was
used as a negative control. Samples with group 1-3 contamination were utilised to develop
the blood removal protocol. Group 1 represented low level contamination, group 2
represented medium level contamination, and group 3 represented heavy contamination.
A sample with group 2 contamination which did not receive blood removal treatment was
utilised as a positive control.
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Figure 8.1. Blood scale index used to classify patient samples as having no blood
contamination (Group 0), low contamination (Group 1), medium contamination (Group
2), and heavy contamination (Group 3).

8.2.1.3 ThinPrep filter

To evaluate whether gynae or non-gynae filters enhanced blood removal while preparing
slides, two group II samples were treated with an identical blood removal process of 5
Cytolyt washes and 3 minutes exposure to H2O2 on the prepared slide. One slide was
prepared using a gynae ThinPrep® filter, and the other using a non-gynae ThinPrep®
filter.
8.2.1.4 Development of an optimal blood removal process

Three groups representing low (Group 1), medium (Group 2) and heavy (Group 3) blood
contamination were utilised. To analyse whether H2O2 had a greater blood removal effect
when applied at various stages of sample preparation, the experiments shown in Tables
8.1 and 8.2 were designed. Table 8.1 demonstrates the combination of washes and H2O2
treatments which were applied to each sample to remove contaminating blood. After each
wash in CytoLyt, the sample was centrifuged, the CytoLyt was decanted and the cell
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pellet vortexed to mix. After the appropriate number of CytoLyt washes, the cell pellet
was transferred directly into PreservCyt for step 2. H2O2 was applied to the cells in step
3 after they were fixed to the ThinPrep® slide. Sample 10 and 11 represent the negative
and positive controls respectively.
Table 8.1. Stepwise protocol for blood removal with H2O2 treatment on the slide.
Blood
contamination

Step 1: No. of
CytoLyt
washes

Step 2:
ThinPrep
filter

Step 3:
Time treated
with H2O2
(minutes)

(Group 1)
Sample 1

3

Non-gyn

3

Sample 2

3

Non-gyn

5

Sample 3

4

Non-gyn

3

(Group 2)
Sample 4

4

Non-gyn

5

Sample 5

5

Non-gyn

3

Sample 6

5

Non-gyn

5

(Group 3)
Sample 7

5

Non-gyn

5

Sample 8

6

Non-gyn

3

Sample 9

6

Non-gyn

5

(Group 0)
Sample 10

-

Non-gyn

3

(Group 2)
Sample 11

-

Non-gyn

-

Table 8.2 demonstrates the combination of washes and H2O2 treatments that were applied
to each sample to remove contaminating blood. After each wash in CytoLyt, the sample
was centrifuged, the CytoLyt was decanted and the cell pellet vortexed to mix. After the
appropriate number of CytoLyt washes, the CytoLyt was decanted and H2O2 was added
into the tube directly to the cell pellet for the time indicated. The H2O2 was then diluted
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with PreservCyt and the cells were transferred directly to a PreservCyt vial for step 3.
Sample 10 and 11 represent the negative and positive controls respectively.
Table 8.2. Stepwise protocol for blood removal with H2O2 treatment in the tube.
Blood
contamination

Step 1: No. of
CytoLyt
washes

Step 2: Time
treated with
H202

Step 3:
ThinPrep filter

(Group 1)
Sample 1

3

3

Non-gyn

Sample 2

3

5

Non-gyn

Sample 3

4

3

Non-gyn

(Group 2)
Sample 4

4

5

Non-gyn

Sample 5

5

3

Non-gyn

Sample 6

5

5

Non-gyn

(Group 3)
Sample 7

5

5

Non-gyn

Sample 8

6

3

Non-gyn

Sample 9

6

5

Non-gyn

(Group 0)
Sample 10

-

3

Non-gyn

(Group 2)
Sample 11

-

-

Non-gyn

8.2.1.5 Slide preparation of cytological specimens (ThinPrep method)

As described in chapter 3 section 3.1.2.
8.2.1.6 Raman Measurement

As described in chapter 3 section 3.2.1.
For each cell, a single spectrum was recorded from the cell nucleus, corresponding to the
average of 2 accumulations of 30 seconds. A total of 15 spectra were acquired for each
sample. Spectra were also recorded from 30 vacant locations on a ThinPrep® glass slide
with identical exposure time in order to get representative background glass spectra.
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8.2.1.7 Data mining and spectral analysis

Spectral data analysis was conducted using R software. Data were processed as described
in chapter 3 section 3.2.3-.7. The mean spectra of the cells for each treatment were then
comparatively analysed.
8.2.2 Results
8.2.2.1 ThinPrep® filter influence on blood removal

Figure 8.2 (a) and (b) are both treated group 2 which received an identical blood removal
protocol, differing only by the type of ThinPrep® filter (gynae or non-gynae) used to
prepare the slides. The comparable quantities of residual blood observable on the slides
indicate that gynae filters do not provide superior blood removal than non-gynae filters.
For this reason, non-gynae filters were utilised for the remainder of the investigation.

Figure 8.2. Group 2 samples which received 5 cytolyt washes and 3 minutes H2O2 on the
slide. (a) Prepared using a gynae filter for ThinPrep®, and (b) Prepared using a non-gynae
filter. The red arrows highlight areas with an accumulation of blood debris. (a) and (b)
are at x400 magnification.
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8.2.2.2 Slide analysis - H2O2 treatment on slide

Figures 8.3 to 8.5 show the unstained HeLa cells after receiving the assigned blood
removal treatments shown in Table 8.1. Residual blood is highlighted by red arrows to
demonstrate the level of blood on the ThinPrep® slides. Figure 8.3 depicts a comparison
of the negative control (sample 10) and the group 1 cells corresponding to sample 2. The
comparable presentation of the 2 slides indicates that microscopic traces of blood have
been successfully eliminated from sample 2. The combination of 3 CytoLyt washes and
5 minutes hydrogen peroxide in sample 2 was effective, producing a similar ThinPrep®
to the negative control.

Figure 8.3. (a) Group 0 cells representing a negative control for the presence of blood
(sample 10). (b) Group 1 which received blood removal treatment (sample 2). The
comparable presentation of the slides indicates that microscopic traces of blood have been
successfully removed from sample 2. (a) and (b) are at x200 magnification.

The group 2 and group 3 samples showed similar patterns of blood contamination on the
slides, thus one sample from each group is depicted as a representative for that group.
Accumulations of blood debris are visible on the group 2 and 3 slides, shown in Figures
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8.4 and 8.5 respectively. Although the group 2 and 3 slides received blood removal
treatment according to Table 8.1, they exhibit similarities to the positive control as blood
is still microscopically visible, suggesting that the blood removal processes applied did
not effectively remove the contaminating blood.

Figure 8.4. (a) A positive control for the presence of blood (sample 11). (b) Group 2 which
received blood removal treatment (sample 6). The red arrows highlight areas with an
accumulation of blood debris. (a) and (b) are at x200 magnification
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Figure 8.5. (a) A positive control for the presence of blood (sample 11). (b) Group 3 which
received blood removal treatment (sample 8). The red arrows highlight areas with an
accumulation of blood debris. (a) and (b) are at x200 magnification.

8.2.2.3 Slide analysis – H2O2 treatment in falcon tube

Figures 8.6 to 8.8 show the unstained HeLa cells after receiving the assigned blood
removal treatments shown in Table 8.2. Residual blood is highlighted to demonstrate the
level of blood on the ThinPrep® slides. Figure 8.6 depicts a comparison of the negative
control (sample 10) and the group 1 cells corresponding to sample 3. The comparable
presentation of the 2 slides indicates that microscopic traces of blood have been
successfully eliminated from sample 3. The combination of 4 CytoLyt washes and 3
minutes hydrogen peroxide in sample 3 was sufficient to produce an identical ThinPrep®
to the negative control.
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Figure 8.6. (a) Group 0 cells representing a negative control for the presence of blood
(sample 10). (b) Group 1 which received blood removal treatment (sample 3). The
comparable presentation of the slides indicates that microscopic traces of blood have been
successfully removed from sample 3. (a) and (b) are at x400 magnification.

As most group 2 and group 3 samples showed similar patterns of blood contamination on
the slides, only one sample from each group is depicted. Residual blood can be observed
coating the group 2 and group 3 cells, shown in Figures 8.7 and 8.8 respectively, and
accumulations of blood debris on the slides are visible. Although the group 2 and 3 slides
shown in Figures 8.7 and 8.8 received blood removal treatment, they exhibit similarities
to the positive control as blood is still microscopically visible, suggesting that the blood
removal processes applied were not successful in eradicating the contaminating blood.
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Figure 8.7. (a) A positive control for the presence of blood (sample 11). (b) Group 2 which
received blood removal treatment (sample 5). The red arrows highlight areas with an
accumulation of blood debris. (a) and (b) are at x400 magnification.

Figure 4.8. (a) A positive control for the presence of blood (sample 11). (b) Group 3 which
received blood removal treatment (sample 7). The red arrows highlight areas with an
accumulation of blood debris. (a) and (b) are at x400 magnification.
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8.2.2.4 Mean spectral analysis

Blood was successfully removed from group I samples and remained in the group 2 and
3 samples at a microscopic level. To evaluate whether blood interfered with the cellular
Raman signals of the treated group 1-3 cells, Raman spectroscopic analysis was applied
to the slides. Figure 8.9 depicts the mean HeLa cell spectrum with no blood contamination
(group 0), utilized as a negative control. The positive control, which is a spectrum taken
from blood, is depicted in Figure 8.10.

Figure 8.9. Mean spectrum of a HeLa cell line. The cells were not contaminated with
blood and are used as a reference spectrum or negative control.
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Figure 8.10. Spectrum of blood representing the positive control.

The significant Raman peaks and their corresponding biological components are shown
in Table 8.3, and the peak assignments for the spectrum of blood are shown in Table 8.4.
Table 8.3. Tentative peak assignments for the significant Raman bands identified by
spectral variation analysis 6.
Wavenumber (cm-1) Raman peak assignments
481
524

DNA
S-S disulphide stretching in proteins
Phosphatidylserine

678

Ring breathing modes in the DNA bases

720-780

DNA

1453

Guanine/Adenine
CH deformation (proteins, lipids, carbohydrates, DNA
and RNA)
Ring breathing modes of Guanine/Adenine
Amide I (proteins)

1575
1667
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Table 8.4. Peak assignments for the significant Raman bands of the spectrum of blood 5.
Wavenumber (cm-1)

Blood component

746

Haemoglobin/ hemin/ proto porphyrin

995

Haemoglobin/ hemin

1126

Haemoglobin/ hemin/ proto porphyrin

1171

Haemoglobin/ hemin/ proto porphyrin

1220

Haemoglobin/ hemin/ proto porphyrin

1304

Haemoglobin/ hemin

1338

Haemoglobin/ hemin/ proto porphyrin

1357

Haemoglobin/ hemin/ proto porphyrin

1394

Haemoglobin/ hemin

1430

Haemoglobin/ hemin

1550

Haemoglobin/ hemin/ proto porphyrin

1585

Haemoglobin/ hemin/ proto porphyrin

8.2.2.5 Spectral variation analysis - H2O2 treatment on slide
The Raman spectra obtained from the group 1-3 samples exposed to H2O2 treatment on
the slide (Table 8.1) indicated burning. As there are no distinct biological features in the
spectra from these samples, spectral variation analysis was not conducted. Figure 8.11
depicts the typical spectral profile obtained for the group 1-3 samples exposed to H2O2
treatment on the slide.
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Figure 8.11. Raman spectrum taken from a group 1 sample indicating burning. Cells were
exposed to H2O2 on the ThinPrep slide. There are no distinct biological features in the
spectrum.

8.2.2.6 Spectral variation analysis - H2O2 treatment in falcon tube
Raman spectra could be obtained from the group 1-3 samples exposed to H2O2 treatment
in the tube (Table 8.2). The difference spectra depicted in Figures 8.12-8.14, are the
features in the cell spectra from groups 1-3 which differ from the mean HeLa spectrum.
The difference spectra between the mean HeLa cell spectrum and the group 1 cells in
Figure 8.12 (a) and (b) have similar profiles to the spectrum of blood (Figure 8.10) with
prominent peaks at ~750, ~1220, 1305, 1357, 1430, 1550, and 1585 cm-1, indicating that
the blood removal methods applied to samples 1 and 2 were not effective. Blood is not
responsible for the difference spectra between the mean HeLa cell spectrum and sample
3, shown in Figure 8.12 (c). The blood removal method applied to sample 3 is an effective
protocol to eradicate blood from cell samples with group 1 level contamination. The
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significant spectral differences in Figure 8.12 (c) correspond to nucleic acids (481 and
730 cm-1), and demonstrate that blood is not contaminating the spectrum, as spectral
variations are due to cellular biochemistry. Significant spectral differences between the
mean HeLa cell spectrum and cells from group 2 and 3 were revealed at ~750, ~1220,
1305, 1357, 1430, 1550, 1585 cm-1, as shown in Figures 8.13 and 8.14. These spectral
peaks are identical to the prominent peaks in the positive control spectrum, indicating that
the spectral contaminants convey the presence of blood. The profile of the difference
spectra between the mean HeLa cell spectrum and sample 6 (Figure 8.13(c)) displays
prominent peaks corresponding to cellular components such as nucleic acids (783, 1575,
1453 cm-1) and proteins (1667 cm-1), as well as peaks associated with blood
contamination shown in Figure 8.10, suggesting that although spectral information could
be obtained from the cellular components, blood contamination is still evident in the
spectra. The blood removal processes applied in this study to tubes with group 2 and 3
contamination did not effectively remove blood from the samples.

Figure 8.12. Difference spectra of the HeLa cells in group 1. (a) corresponds to sample 1
in Table 8.2 (b) the difference spectra for sample 2, (c) the difference spectra for sample
3, this sample was subjected to 4 CytoLyt washes and 3 minutes exposure to hydrogen
peroxide.
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Figure 8.13. Difference spectra of the HeLa cells in group 2. (a) corresponds to sample 4
in Table 8.2 (b) the difference spectra for sample 5, (c) the difference spectra for sample
6, this sample was subjected to 5 CytoLyt washes and 5 minutes exposure to hydrogen
peroxide.

Figure 8.14. Difference spectra of the HeLa cells in group 3 (a) corresponds to sample 7
in Table 4.2 (b) the difference spectra for sample 8, (c) the difference spectra for sample
9.

8.2.2.7 Blood removal protocol for group 1 samples

The difference spectra from the mean HeLa cell spectrum and sample 3 (Figure 8.12)
indicates that blood has been successfully removed. The combination of CytoLyt washes
and H2O2 treatment in the falcon tube applied to sample 3 (Table 8.2) effectively removed
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blood from the group 1 sample. The working method applied to sample 3, described in
detail below, may be suitable for preparing group I thyroid FNAC samples for Raman
spectroscopic analysis.
Working method for group 1 samples:
1. Centrifuge sample at 1200 rpm for 5 minutes to pellet the cells.
2. Resuspend pellet in CytoLyt and vortex.
3. Centrifuge at 1200 rpm for 5 minutes.
4. Repeat steps 2 and 3 until blood is no longer visible (or for a total of 4 washes).
5. Remove CytoLyt from the cell pellet, vigorously vortex the pellet and pass through a
pipette to break up clumps of cells.
6. Add 1 mL of hydrogen peroxide (30%) to the pellet. Vortex and allow to stand for 3
minutes, inverting occasionally.
6. Dilute sample with 15 mL of PreservCyt.
7. Centrifuge at 1200 rpm for 5 minutes.
8. Transfer cells to PreservCyt vial for ThinPrep®.

8.2.3 Discussion
Blood contamination interferes with the Raman spectrum and inhibits reliable analysis.
To overcome this problem a blood removal protocol was developed to prepare thyroid
FNAC samples for single cell analysis with Raman spectroscopy. Both gynae and nongynae filters were utilised to investigate their ability to disaggregate and remove blood
from the samples. Inspection of the slides revealed that the type of ThinPrep® filter used
did not impact the amount of blood observed on the prepared slides. Accordingly, the
appropriate non-gynae filters were utilised for the study.
Subsequent to implementing the blood removal treatments, the prepared slides were
inspected microscopically to evaluate the effectiveness of each method at removing
blood. Blood remained microscopically visible on all group 2 and 3 slides, showing
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similarities to the positive control. Subsequent to CytoLyt washing, trace amounts of
blood remained in the cell pellets of the group 2 and 3 samples (samples 4-9). Although
small amounts of blood were visible in the cell pellets, additional CytoLyt washes were
not added in order to keep the working method applicable in a clinical setting. This may
explain the aggregations of blood observed on the prepared slides. The group 1 samples
treated with H2O2 in the tube, and the group 1 samples treated with H2O2 on the slides,
both exhibited similarities to the negative control, indicating the complete removal of
blood at a microscopic level. No blood was visible in the cell pellets of the group 1
samples during processing.
Good quality spectra could not be obtained from any of the samples which were exposed
to H2O2 on the slide. Despite the microscopic removal of blood from the group 1 samples,
the Raman spectra indicated burning. It is plausible that the H2O2 could not act upon all
of the remaining blood coating the cells as fixing the cells prior to the application of H2O2
may conceal portions of the cell membranes. Uncontaminated Raman spectra could not
be obtained from cells which were exposed to H2O2 after preparation of the ThinPrep®
slide. This process was therefore not suitable for preparing thyroid FNAC samples for
Raman spectroscopic in this study.
Applying the H2O2 to the cell pellet after the CytoLyt washes while they were still in the
tube allowed the chemical to act on a greater surface area of the cells, increasing the
probability of removing blood and enabling Raman spectra to be obtained. In the case of
the group 1 samples which were treated with H2O2 in the tube, the difference spectra
between the mean HeLa cell spectrum and samples 1 and 2 show significant peaks at
~750, ~1220, 1305, 1357, 1430, 1550, 1585 cm-1, which are consistent with the spectral
profile of blood. This indicates that the methods applied to samples 1 and 2 were not
effective for removing blood from samples with low level contamination. However, the
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difference spectrum between the mean HeLa cell spectrum and sample 3 demonstrates
the complete removal of blood from the sample. The significant spectral differences
between the mean HeLa cell spectrum and sample 3 observed at 481 and 730 cm -1
correlates to nucleic acids and may be explained by variations in the cell cycle, as
although many carcinogenic processes dysregulate cell cycle inhibition, the lack of
available nutrients may impact the rate of proliferation, and therefore a cancer cell line
grown in coincident cultures may have different proportions of proliferating cells with
differing protein and DNA content 7,8. The difference in proliferating status of cell lines
is observable in the Raman spectrum, therefore the variance observed between the mean
HeLa cell spectrum and the mean sample 3 spectrum may be attributed to variations in
cell cycle progress 9, explaining the significant spectral differences observed at 481 and
730 cm-1. This suggests that the combination of CytoLyt washes and H2O2 treatment in
the tube which was applied to sample 3 may be utilised as a new working method to
prepare group 1 thyroid FNAC samples for Raman spectroscopy. This finding also
indicates that the stage at which H2O2 is applied to the sample during preparation is
crucial, as good quality spectra with no blood features could only be obtained from cells
receiving H2O2 treatment in the tube.
The difference spectra for the group 2 and group 3 samples (samples 4-9) which received
H2O2 treatment in the tube indicate that the methods utilised in this study did not
effectively remove blood contamination. The significant peaks in the difference spectra
at ~750, ~1220, 1305, 1357, 1430, 1550, 1585 cm-1 are identical to the spectral profile of
the positive control, signifying that residual blood is coating the cell membranes and
swamping the cellular signals. The profile of the difference spectra between the mean
HeLa cell spectrum and sample 6 displays prominent peaks corresponding to cellular
components including nucleic acids (783, 1575, 1453 cm-1) and proteins (1667 cm-1), as
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well as peaks associated with blood contamination. The presence of peaks corresponding
to cellular components in the Raman spectra are promising, signifying the partial removal
of contaminating blood, although further analysis of the spectra obtained from sample 6
would be unreliable as blood contamination is still evident in the spectra. Further
investigation could explore implementing additional washes or an increased H2O2
exposure time to effectively eradicate blood from group 2 samples.
Despite implementing an array of washes and chemical treatments, persistent blood
contamination inhibits reliable and reproducible data to be obtained from group 2 and
group 3 samples (samples 4-9). Blood was successfully removed from group I samples
with an optimised protocol of 4 CytoLyt washes and 3 minutes exposure to H2O2 in the
tube. This removes blood from the cell surface and allows spectral information to be
obtained from the intracellular biochemistry. The blood removal protocol developed in
this study is only applicable to group 1 samples and may be suitable for preparing group
1 thyroid FNAC samples for Raman spectroscopic analysis. Further investigation is
needed to develop a method for preparing group 2 and 3 samples for Raman spectroscopy.

8.3 Section B - Use of Raman spectroscopy for the discrimination between
normal and malignant FNAC samples prepared from resected thyroid
specimens
The primary aim of this study was to assess the efficacy of the blood removal method
developed in section A in preparing ‘mock’ thyroid FNAC samples for Raman
spectroscopic analysis. In addition, the study aims to examine the ability of Raman
spectroscopy to discriminate normal and malignant thyroid patient samples.
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8.3.1 Methods
8.3.1.1 Study subjects and sample collection

This study had approval from the research ethics committee at Lausanne University
Hospital, Switzerland. Thyroid resections were collected from patients under
investigation for TC. FNA samples were subsequently prepared from the resected thyroid
specimens. Thyroid cancer was confirmed through final clinical diagnosis and final
histology was recorded. The study included samples from 6 patients with thyroid cancer.
Patients one to six had different histological subtypes of TC, listed consecutively from
patient one to six as follows; follicular adenoma, papillary carcinoma, papillary
carcinoma, medullary carcinoma, follicular adenoma, oncocytic follicular carcinoma.
Cytological specimens of both tumour and benign tissue were obtained from each patient.
To yield sufficient cellular material for Raman spectroscopic analysis, patient samples
were combined as depicted in Figure 8.15. Tumour samples from patients one to four
were combined and the new combined sample is referred to in this study as T1. The
tumour samples from patients five and six were also combined into one new sample
referred to as T2. Similarly, benign samples from patients one to four were combined to
form a new sample referred to in this study as N1, and the benign samples from patients
five and six were combined into one new sample referred to as N2.
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Figure 8.15. Depiction of how the samples were combined to yield sufficient cellular
material for Raman spectroscopic analysis.

8.3.1.2 Blood removal from sample vials

The blood removal protocol developed in section A was applied to the FNA samples with
two minor adjustments, as shown with the adjustments highlighted below. Firstly, to
ensure clumps of cells were dispersed so that H2O2 could act on the entire cell surface,
the samples required vigorous vortexing before exposing the cells to H2O2. Secondly, the
‘mock’ FNAC samples were exposed to H2O2 for 90 seconds to eradicate blood
contamination.
Working method for FNAC samples prepared from resected thyroid sections:
1. Centrifuge sample at 1200 rpm for 5 minutes to pellet the cells.
2. Resuspend pellet in CytoLyt and vortex.
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3. Centrifuge at 1200 rpm for 5 minutes.
4. Repeat steps 2 and 3 until blood is no longer visible (or for a total of 4 washes).
5. Remove CytoLyt from the cell pellet, vigorously vortex the pellet and pass
through a pipette to break up clumps of cells. (First adjustment)
6. Add 1 mL of hydrogen peroxide (30%) to the pellet. Vortex and allow to stand
for 90 seconds, inverting occasionally. (Second adjustment)
6. Dilute sample with 15 mL of PreservCyt.
7. Centrifuge at 1200 rpm for 5 minutes.
8. Transfer cells to PreservCyt vial for ThinPrep®.

8.3.1.3 Data pre-processing and analysis

All spectral data analysis was conducted using R software. Data were process as described
in chapter 3 section 3.2.3-.7. The data was analysed using Principal Component Analysis
(PCA) and Linear Discriminant Analysis (LDA), as described in chapter 3 section 3.2.8
and section 3.2.9 respectively. The first PCs that explained approximately 95% of the
variance within the data were used in the PC-LDA classification models.

8.3.2 Results and discussion
8.3.2.1 Mean spectral analysis

The blood removal method completely eradicated blood contamination. Combining the
sample vials to yield sufficient cellular material eliminated the possibility to classify
individual cases, although classifiers can still be developed to discriminate benign and
cancerous cells. The mean Raman spectra of benign and cancerous cells are displayed in
Figures 8.16 and 8.17 with the difference spectra. Spectral analysis shows clear separation
between the benign and malignant cells. Table 8.5 collates each Raman peak with their
tentative corresponding biological component. The spectral profiles in Figure 8.16
indicate a higher level of lipids (1439 cm-1), proteins/lipids (1445 cm-1), proteins (1664
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cm-1), and increased amino acids aspartic and glutamic acid (1400 cm-1) in the tumour
cells (T1) in comparison to the benign cells (N1). The difference spectrum in Figure 8.16
also demonstrates decreased peak intensities at 524-600, 785, 1484, and 1574 cm-1 in the
cancer cells, which is correlated to lower levels of nucleic acids and proteins.

Figure 8.16. (a) Mean spectra of the benign thyroid cells (N1) and the thyroid cancer cells
(T1), (b) the difference spectrum between benign thyroid cells and thyroid cancer cells
with the statistically significant Raman peaks highlighted in grey. Shading indicates
regions of the spectrum that were significantly different (p<0.05).

The difference spectrum in Figure 8.17 demonstrates decreased peak intensity at 929 and
970 cm-1 in the tumour cells, which is correlated with a lower level of phosphorylated
proteins and nucleic acids. The mean cancer cell spectrum (T2) also indicates an increase
in the level of tryptophan in comparison to the benign cells, evident by the peak at ~1360
cm-1. The amide I band at 1664 cm-1, which corresponds to stretching vibrations in
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proteins, is decreased in the tumour cell spectrum. The decreased protein content evident
in the tumour spectrum is most likely due to pathogenic mechanisms of TC which result
in the downregulation of tumour suppressor proteins 10.

Figure 8.17. (a) Mean spectra of the benign thyroid cells N2 and the thyroid cancer cells
(T2), (b) the difference spectrum between benign thyroid and thyroid cancer. Shading
indicates regions of the spectrum that were significantly different (p<0.05).

The spectral variations between normal and tumour cells may reflect the molecular
alterations occurring due to carcinogenic progression. The increased lipid content in the
tumour cells evident by the peak at 1439 cm-1 may indicate dysregulation of lipid
metabolism, which is a common characteristic in malignancies including anaplastic TC
11,12,13,14

. The reduced nucleic acid content in the tumour cell spectra is evident by the

lower peak intensity at 785 cm-1 in comparison to the benign Raman spectra. Genomic
deletions are a type of genomic instability which are a typical component in cancers, and
have been shown to be a feature in some instances of TC 15,16,17,18. This may explain the
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alteration in nucleic acid content of cancer cells observed in this study. The tumour cells
are characterised by a lower level of nucleic acids and an increase of amino acids (aspartic
and glutamic acid) in comparison to the benign cells. The decreased peak intensities at
929 and 970 cm-1 in the tumour cells indicate a lower level of proline / valine,
phosphorylated proteins, and nucleic acids in the tumour cells. Protein phosphorylation
regulates pathways involved in the cell cycle, the diminished rate of phosphorylated
proteins in the tumour cells may indicate a mechanism for thyroid cancer progression 19.
Table 8.5. Tentative peak assignments for the significant Raman bands identified by
spectral variation analysis 6
Wavenumber
(𝐜𝐦−𝟏 )

Raman peak assignments

490

Glycogen

524-600

Disulphide stretching in proteins
Phosphatidylserine
Phosphatidylinositol
Cholesterol

725

Adenine ring
RNA/DNA

785

DNA

880-920

Tryptophan
Saccharides

929

C-C stretching of amino acids proline &
valine/saccharides

970

Phosphate monoester groups
of
phosphorylated proteins/nucleic acids

1247

Amide III

1335

CH3CH2 wagging, collagen (protein

breathing

mode

of

assignment)
CH3CH2 wagging, nucleic acid
~1360

Tryptophan

~1370

Saccharide band
Ring breathing modes of RNA/DNA
(T,A,G)

1400

NH in-plane deformation
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Amino acids aspartic & glutamic acid
1439

CH2 deformation

1445

Bending modes
phospholipids

1484

Amide II (Coupling of CN stretching &
in-plane bending of the N-H group

1574

COONucleic acids

1600-1670

Amide I band of proteins due to C=O
stretching

of

proteins

and

8.3.1.2 Principal component analysis

The distribution of the PCs was visualised by plotting them in scatter plots representing
the component space. The plots in Figure 8.18 illustrate the discrimination of benign
thyroid cells from thyroid cancer cells. It is evident from the PC scores plot in Figure 8.18
(a) that PC2 is responsible for the discrimination of the benign (N1) and cancer spectra
(T1). The discrimination of the N2 and T2 cells was achieved using PC5, shown in Figure
8.18 (b).
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Figure 8.18. PCA scores plot of benign thyroid cells (orange) and tumour cells (blue)
attained from FNAC samples. (a) Scatter plot of T1 (blue) and N1 (orange) using PC2
and PC3. (b) Scatter plot of T2 (blue) and N2 (orange) using PC2 and PC5.

As PC2 is responsible for the discrimination of the benign and cancer spectra in Figure
8.18 (a), the loading profile was attained and is displayed in Figure 8.19. The loading
profile of PC2 shows that peak intensity is highest at 783, 1335, 1371, 1484, 1571, and
1611 cm-1, indicating that these peaks have the highest weights for the PCA
discrimination of benign and cancerous thyroid cells. These peaks are assigned to nucleic
acids and proteins, shown in Table 8.5 6. The tumour cells have a decreased level of
nucleic acids (783, 1371, 1574 cm-1) and proteins / COO- (1335, 1371, 1484, 1571 cm-1),
and an increase in the level of lipids (1439 cm-1) and amide I (1664 cm-1) proteins/lipids
(1445 cm-1), and amino acids aspartic and glutamic acid (1400 cm-1) in comparison to the
benign cells.

Figure 8.19. Loadings plot of PC2 discriminating the benign and cancer cells in Figure
8.18 (a), Peaks with higher intensity highlight the prominent differences between benign
and cancerous thyroid cells.
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As the benign and thyroid cancer spectra in Figure 8.18 (b) were discriminated by PC5,
the loading profile of the PC is displayed in Figure 8.20. The prominent peaks
discriminating the benign and cancer cells correspond to a decrease in the amino acids
proline / valine (929 cm-1) and amide I (1670 cm-1), and an increase of tryptophan (~1360
cm-1) in the tumour cells in comparison to the benign cells.

Figure 8.20. Loadings plot of PC5 discriminating the benign and cancer cells in Figure
8.18 (b).

8.3.1.3 Linear discriminant analysis classification

Linear discriminant analysis (LDA) was used on the PCs from PCA to develop a
classifier. The first PCs that explained approximately 95% of the variance within the data
were used in the PC-LDA classification model. The benign and cancer groups were
discriminated as shown in Table 8.6. The two-way classification models yielded
sensitivities of 87%, specificities of 87% and 93%, and diagnostic accuracies of 87% and
90% for the detection of malignancy.
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Table 8.6. The sensitivity, specificity and classification accuracy of a PC-LDA model for
discriminating the benign spectra from the thyroid cancer cells.
Benign thyroid vs
Tumour sample

Sensitivity (%)

Specificity (%)

Diagnostic
accuracy
(%)

N1 v T1

87

93

90

N2 v T2

87

87

87

The paramount information required from the thyroid FNAC procedure is the
differentiation between benign and malignant thyroid nodules. It is an easy method to
apply and is presently the favoured diagnostic method for the initial investigation of
thyroid nodules, however sensitivity rates as low as 65% and specificity rates as low as
72% have been reported, representing a limitation with the method

20,21,22

. In our study,

high diagnostic accuracies were achieved (over 87%), as were high sensitivities (over
87%) and specificities (over 93%), using Raman spectroscopy to detect malignancy on
thyroid FNAC samples prepared from resected thyroid specimens (‘mock’ FNAC
samples). Significant spectral differences were observed between the benign and
malignant cells corresponding to differences in the molecular composition of nucleic
acids, proteins and lipids. However, the peaks are not consistent across T1 and T2, as
each sample is comprised of a combination of patient samples with differing diagnoses.
The variation in nucleic acid, protein and lipid content revealed in the malignant thyroid
cells is in accordance with the biomolecules identified using cell lines in chapter 7.
The findings of this study suggests potential for using Raman spectroscopy to improve
the preoperative diagnosis of TC, although the method needs to be applied on clinical
FNA of thyroid to evaluate sensitivity, specificity and accuracy as a diagnostic tool. In
the next section, the efficacy of the blood removal protocol developed in sections A and
B will be evaluated using clinical FNAC samples.
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8.4 Section C – Optimising the blood removal method for thyroid FNAC
samples
To evaluate the clinical suitability of the blood removal method devised in sections A and
B, the protocol was applied to, and further developed, using clinical thyroid FNAC
samples.
8.4.1 Methods
8.4.1.1 Study subjects and sample collection

This section was completed in the Nanomedicine and Molecular Imaging Lab in the ICS
Maugeri hospital in Pavia, Italy. This study had approval from the research ethics
committee at ICS Maugeri, Pavia. Six thyroid FNAC samples taken from five patients.
Four of the samples were taken from TIR3A lesions (low risk intermediate lesions), and
two samples were taken from TIR2 lesions (non-malignant/benign)23.
8.4.1.2 Blood removal

Table 8.7 demonstrates the combination of CytoLyt washes and method of H2O2
treatment that was applied to each sample to remove contaminating blood. After each
wash in CytoLyt, the sample was centrifuged, the CytoLyt was decanted and the cell
pellet vortexed to mix. This was repeated for the indicated number of CytoLyt washes.
H2O2 was then added directly to the cell pellet in samples 1, 2A, 3 and 4, before being
diluted with PreservCyt. H2O2 was added to the samples 2B and 5 after they were fixed
to the slide.
Table 8.7. Overview of the number of washes and method of H2O2 treatment used for
each sample.
Sample
Number

CytoLyt
washes

H202
treatment/Time
(seconds)

Sample 1

1

In vial / 90
seconds
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Sample 2A

2

In vial / 90
seconds

Sample 3

3

In vial / 90
seconds

Sample 4

4

In vial / 90
seconds

Sample 2B

1

On the slide/ 30
seconds

Sample 5

1

On the slide/ 30
seconds

8.4.1.3 Working method for clinical thyroid FNAC samples:

Adjustments were made to the blood removal method. The new adjusted working
method for clinical thyroid FNAC samples, which is described below, was applied to
samples 2B and 5.
1. Vortex sample for few seconds.
2. Split sample in two 15 mL Falcon tubes.
3. Centrifuge at 1000 rpm for 5 minutes to pellet the cells.
4. Decant supernatant and resuspend in 1 mL Cytolyt, combining samples.
5. Vortex the pellet and pipette sample to break up clumps of cells.
6. Centrifuge at 1000 rpm for 5 min.
7. Decant supernatant and resuspend in 1 mL PreservCyt.
8. Vortex the pellet and pass through a pipette to break up clumps of cells.
9. Transfer cells to PreservCyt vial and make slide using ThinPrep® 2000.
10. Treat slides with 35% H2O2 for 30 seconds
11. Wash with 70% ethanol for 2 minutes, followed by 100% ethanol for two minutes.
12. Allow the slide to air dry.
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8.4.1.2 Slide preparation

As described in chapter 3 section 3.1.2.
The sample preparation laboratory in ICS Maugeri utilised mirrored stainless steel slides
instead of ThinPrep® glass slides for Raman spectroscopic analysis. Mirrored stainless
steel slides have a low background signal and increase the cellular Raman signal. This is
attributed to a double-pass of the laser through the sample. Photons from the incident
laser and forward scattered Raman signal are reflected from the mirrored surface and
focused towards the collection optics 24. Stainless steel slides were also used because glass
slides are not suitable to use with a 633 nm laser.
8.4.1.3 Raman measurement

As this section was completed in ICS Maugeri, a different Raman spectroscopic system
was used for analysis. The Laboratory of Nanomedicine in ICS Maugeri is equipped with
a Renishaw inVIA confocal Raman microscope system with a 633 nm laser line. The
laser was delivered to the sample through a x100 objective (NA = 0.9) and the confocal
hole was set at 100 µm. The system was calibrated to the 520 cm-1 spectral line of silicon
and the spectral resolution was defined by the grating which was ruled with 1200 lines
per mm grating.
8.4.1.4 Data pre-processing

All spectral data analysis was conducted using Matlab software. Data were process as
described in chapter 3 section 3.2.3-.7.
8.4.2 Results and discussion
When applied to clinical thyroid FNAC samples, the blood removal protocol developed
in section A and B resulted in no cell pellet. Despite repeated CytoLyt washes, the
addition of H2O2 to the cell pellet sheared the cellular material. Figure 8.21 depicts the
slide prepared from sample 1 after treatment, with no cellular material. Identical results
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were observed for samples 2A, 3 and 4. This indicated that buried red blood cells
remained in the cellular material, and the oxidation of haemoglobin by H2O2 may have
produced oxygen bubbles, which may have disrupted the plasma membranes of the
cellular material. Therefore, Raman spectra could not be acquired from the clinical
thyroid FNAC samples using the method developed in section A and B. The artificial
samples used in section A may not have accurately resembled true thyroid FNAC
samples. As thyroid FNAC samples contain follicular conglomerates and are taken from
a lesion with a direct blood supply, the red blood cells appear to be mixed with the cell
clumps, and are difficult to lyse with haemolytic agents. Conversely, the samples in
section A contained single cells mixed with blood, and so haemolytic agents were
effective with low contamination levels.
The FNAC samples prepared from resected thyroid sections used in section B naturally
contained less blood than the FNAC samples in this section as the excised tissue no longer
had a blood supply. Typically, the mock FNAC samples in section B matched Group 0
level contamination in section A. As the clinical thyroid FNAC samples in section C were
obtained directly from the thyroid of a patient undergoing investigation for TC, these
samples contained blood and matched Group 1 level contamination in section A.
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Figure 8.21. Steel slide ThinPrep® made with sample 1 post treatment. No cellular
material can be seen.

As the blood removal protocol developed in sections A and B was not suitable for
preparing clinical thyroid FNAC samples for Raman spectroscopic analysis, adaptations
were made to the method. The new method for clinical thyroid FNAC samples, applied
to samples 2B and 5 reduces the number of CytoLyt washes to a single wash, as additional
washes had no effect on blood removal. It was noted in section B that pipetting breaks up
the naturally forming cell groups, increasing the haemolytic action of CytoLyt and
producing a distribution of more single cells on the slide to facilitate Raman spectroscopy.
Thus, vortexing and pipetting was carried out during the CytoLyt wash and before
transferring the cells to a PreservCyt vial. In the new method for clinical thyroid FNAC
samples, cells were fixed to the steel slide prior to adding H2O2 to retain enough cellular
material spectroscopic analysis. Alcohol washes were then used to remove the H2O2 and
dehydrate the sample. The addition of H2O2 and alcohol washes are similar to the method
devised by Bonnier et al5, however wash times with H2O2 and alcohols are reduced in this
method.
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Figures 8.22 to 8.26 show that the new method for clinical thyroid FNAC samples retains
cellular material for analysis. The raw spectra shown have not been processed to
maximise the intensity of cellular signals and minimise noise. The high background
observed in the raw spectra can be removed digitally or may naturally decrease using a
532 nm laser.

Figure 8.22. Depiction of cellular material and debris on the steel slide after the sample
received treatment. The cell marked with a red box and shown at a greater magnification
was targeted for spectroscopic analysis. Acquired with the laser power set to 50% the raw
spectra indicate the presence of biological peaks with a high background signal.
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Figure 8.23. Depiction of cellular material and debris on the steel slide after the sample
received treatment. The cell marked with a red box and shown at a greater magnification
was targeted for spectroscopic analysis. Acquired with the laser power set to 50% the raw
spectra indicate the presence of biological peaks with a high background signal.
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Figures 8.24-26 indicate that increasing the laser power to 100% effectively increases the
signal to noise ratio to produce strong biological peaks. Good quality Raman spectra
could thus be acquired from the cells of a clinical thyroid FNAC sample.

Figure 8.24. Depiction of cellular material and debris on the steel slide after the sample
received treatment. The cell marked with a red box and shown at a greater magnification
was targeted for spectroscopic analysis. Acquired with the laser power set to 100% the
raw spectra indicate a strong biological signal with a high background signal.
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Figure 8.25. Depiction of cellular material and debris on the steel slide after the sample
received treatment. The cell marked with a red box and shown at a greater magnification
was targeted for spectroscopic analysis. Acquired with the laser power set to 100% the
raw spectra indicate a strong biological signal with a high background signal. Acquired
with the laser power set to 100% the raw spectra indicate a strong biological signal with
a high background signal.
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Figure 8.26. Depiction of cellular material and debris on the steel slide after the sample
received treatment. The cell marked with a red box and shown at a greater magnification
was targeted for spectroscopic analysis. Acquired with the laser power set to 100% the
raw spectra indicate a strong biological signal with a high background signal. Acquired
with the laser power set to 100% the raw spectra indicate a strong biological signal with
a high background signal.

Figure 8.27 shows mean spectrum taken from the nuclei of cells in sample 5. The
spectrum has been processed to maximise the intensity of cellular signals and minimise
noise. No blood peaks are visible in the processed spectrum.
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Figure 8.27. The mean spectrum taken from the nuclei of cells in sample 5. The spectrum
has been processed with Savitsky-Golay smoothing, rubberband baseline subtraction, and
vector normalisation, to maximise the intensity of cellular signals and minimise noise.
Strong cellular peaks in the processed spectrum are not swamped by blood peaks.

The method optimised in this study effectively prepared clinical thyroid FNAC samples
for Raman spectroscopic analysis. Blood peaks do not swamp the cellular signal, and
clear biological peaks are observed. Therefore, by utilising this method, further
investigations may expand on the results observed in section B in this chapter, and explore
the diagnostic capabilities of Raman spectroscopy for the discrimination of normal and
malignant thyroid FNAC samples. However, the method needs to be evaluated on a larger
sample cohort as low sample numbers limits this study. In addition, a limitation of the
new method for clinical thyroid FNAC samples is that pipetting and vortexing breaks up
the normal presentation the sample. In future studies, this may complicate the
identification of cell types if subsequent morphological assessment of the slide is
required.
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8.5 Summary and Conclusion
When applying Raman spectroscopy to cytological samples, the presence of blood can
swamp cellular Raman signals and inhibit a reliable analysis of spectra. Thyroid FNAC
samples regularly contain blood due to the vascularity of the organ. In this study, HeLa
cells were contaminated with human blood to replicate the complications encountered
when applying Raman spectroscopy to thyroid FNAC samples. Different blood removal
methods were analysed and although they were unsuccessful for moderate to high levels
of blood (group 2 and 3), a successful method was developed for low levels (group 1).
The spectral profile of the group 2 and 3 samples indicated burning as blood was not
effectively removed from the cell surface. Subsequently the blood removal protocol
developed in section A was applied to ‘mock’ FNAC samples prepared from thyroid
biopsies in section B. With an additional vortex step and reduced exposure time to H2O2,
good quality Raman spectra were acquired and significant spectral differences were
identified between the benign and malignant cases. The benign and malignant cases were
discriminated with sensitivities and specificities above 87%, although further
investigation is required as there was insufficient cellular material to analyse each patient
sample individually, this preliminary study indicates that applying Raman spectroscopy
to thyroid FNAC samples is a useful tool for the discrimination of malignant and benign
thyroid cells. Finally, in section C, when applied to clinical thyroid FNAC samples, the
protocol developed in section A and B proved to be ineffective and adding H2O2 to the
cell pellet damaged the cellular material. An alternative method including a single
CytoLyt wash, pipetting and vortexing steps, and H2O2 treatment after cells were fixed to
the slide, retained the cellular material and enabled good quality Raman spectra to be
obtained. Although, the study was limited by low sample numbers and needs to be
evaluated on a larger sample cohort, this method may be applied in the future to thyroid
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FNAC samples with blood contamination in preparation for Raman spectroscopic
analysis.
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Chapter 9: Conclusion
9.1 Summary of thesis components
The concept underpinning the thesis is the use of Raman spectroscopy as a diagnostic tool
for cancer using cytological samples, and so the thesis begins with Chapter 1 describing
cytopathology and the principles of Raman spectroscopy. Chapter 2 provides a full
description of all the methods used throughout the thesis. Translating Raman data to a
diagnosis requires the application of pre-processing and chemometric techniques. The
spectral pre-processing and chemometric techniques used throughout the thesis are also
explained in Chapter 2. The third chapter is a published detailed literature review of the
recent progress made using vibrational spectroscopy for NSCLC diagnosis. The review
identified a variety of vibrational spectroscopic systems, biological sample types, and
data mining methods that have been applied for Raman based NSCLC diagnosis to date.
Based on the findings of previous studies, the potential benefits of applying Raman
spectroscopy to bronchoscopy cytology samples for the future diagnosis of NSCLC are
highlighted.
The work presented in Chapters 4 and 5 provide a body of evidence that demonstrates the
suitability of using Raman spectroscopy on bronchoscopy cytology samples to detect and
differentiate the NSCLC subtypes. In Chapter 4, Raman spectroscopy was applied to
patients BAL and BW samples with the aim to accurately identify malignant cases,
discriminate between the NSCLC subtypes, and establish the molecular differences
influencing the discrimination. The results of this study indeed confirm the ability of
Raman spectroscopy to discriminate normal lung cells from malignant lung cells with
high diagnostic sensitivities, specificities, and accuracies. The Raman spectral profiles of
the cells from negative, SCC and AC cases indicated many biochemical alterations
between the SCC and AC subtypes.
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The aim of Chapter 5 was to assess the potential of Raman spectroscopy to identify
malignant signatures in NSCLC cases with clinical cytological analyses reported as
diagnostic or no malignant cells seen (NMCS), and to evaluate the sensitivity and
specificity of Raman spectroscopy on cytology in comparison to the final histology
report. The recurrent patterns in Raman spectra of cells from NSCLC cases with differing
cytology reports demonstrated that Raman spectroscopy may be an effective tool for
detecting lung cancer on morphologically normal cytology samples, as detailed analysis
of the Raman spectra revealed malignant signatures in the cases with NMCS on cytology.
The evidence provided in Chapters 4 and 5 demonstrate the feasibility of using Raman
spectroscopy for the detection of NSCLC on bronchoscopy cytology samples.
In Chapter 6, the thesis analysed the diagnostic effectiveness of applying Raman
spectroscopy to lung tissue sections for NSCLC diagnosis, and compared the results to
the efficacy achieved using cytology samples. In comparison to the negative tissue,
malignant tissues showed significant variations in biomolecular content similar to those
identified in Chapter 4. The PLSDA algorithm yielded good performance scores for the
discrimination of the SCC and AC subtypes in Chapter 6. As broad spectral regions are
significantly different between the negative and malignant lung tissue, applying Raman
spectroscopy to cytology samples may be more suitable for identifying differences in
individual biomolecules between the negative, SCC and AC subtypes.
The work presented in Chapters 7 and 8 demonstrate the feasibility of using Raman
spectroscopy on FNAC samples to diagnose thyroid cancer. In Chapter 7, Raman
spectroscopy was applied to thyroid cancer cell lines with the aim to accurately
discriminate between the cell lines and establish the molecular differences influencing
the discrimination. The results of this proof of concept study indeed confirm the ability
of Raman spectroscopy to discriminate normal thyroid from thyroid cancer with high
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diagnostic sensitivities, specificities, and accuracies. Analysis of the Raman spectral
profiles of the cell lines also revealed molecular differences between the TC subtypes. As
thyroid FNAC samples inevitably contain blood contamination, and blood interferes with
the spectra, the aim of Chapter 8 was to establish a blood removal method, which is
suitable for use on thyroid FNAC samples to allow Raman spectroscopic analysis. The
initial protocol was developed using cell lines and required minor adjustments when
applied to ‘mock’ thyroid FNAC samples taken from surgically removed specimens.
Blood contamination was successfully removed from the ‘mock’ thyroid FNAC samples
and diagnostic peaks discriminating the negative and malignant cases were identified.
However, subsequent application of the protocol to clinical thyroid FNAC samples was
unsuccessful in removing blood. With further optimisation, blood contamination was
eradicated from the spectra, indicating that the method developed is suitable to prepare
thyroid FNAC samples with low levels of blood for Raman spectroscopic analysis.

9.2 Clinical Relevance
The ability to obtain detailed chemical information label-free makes Raman spectroscopy
an attractive method for clinical diagnostic cytology, although translating Raman
spectroscopy to routine clinical use requires some factors to be addressed. Sample
preparation is a fundamental step for preparing cytology specimens for spectroscopic
analysis. Appropriate standard operating procedures should be designed for each
diagnostic sample type, and implemented internationally. Spectroscopic analysis of ex
vivo diagnostic samples also requires the sample to be fixed to a substrate. Glass is the
most applicable substrate for clinical setting as it is cost effective, is already used in
clinical laboratories, and signals derived from glass can be digitally removed from the
spectrum. Standardised data analysis and interpretation is another factor that needs to be
addressed. Many chemometric methods extract diagnostic data from discrete features and
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so considerable care is needed to define diagnostically relevant features. For this reason,
the method of validation of the classifier is crucial for determining the reliability of the
model. Larger studies with large numbers of patients require cross validation methods
such as leave one-patient-out-cross-validation (LOPOCV), as using leave-one-spectrumout cross-validation LOSOCV on larger datasets can over-train the model. LOPOCV is
therefore better for evaluating the performance characteristics of the classifier. Further,
the classifier must be validated with an independent test set to determine how well it
classifies unseen samples. The Raman instrument should be suitable for a diagnostic lab,
and should therefore be easily calibrated and small enough to fit on a benchtop.
The body of work presented in this thesis shows that Raman spectroscopy can
differentiate NSCLC subtypes using cytology specimens, and can even detect malignant
signatures in cytology samples with NMCS reported on cytology. The findings of this
thesis imply that having Raman spectroscopy as part of the diagnostic algorithm for
NSCLC could provide a label free differential diagnosis and preserve the limited cell
sample for subsequent molecular tests, saving patients an invasive surgical procedure to
obtain more tissue for analysis. Although previous studies have explored the use of
Raman spectroscopy on lung tissue sections and in vivo, this thesis shows that Raman
spectroscopic analysis of cytology specimens is comparably effective for NSCLC
diagnosis. Similarly in the case of TC, Raman spectroscopy has the potential to reduce
the number of invasive biopsy procedures required to confirm malignancy. With adequate
sample preparation, quality Raman spectra can be acquired from thyroid FNAC samples,
and with continued research this technique may show the ability to differentiate malignant
and benign thyroid lesions.
Bronchoscopy cytology samples are routinely utilised for first line diagnostics in cases of
NSCLC. Further, FNAC samples are routinely utilised for first line diagnostics in cases
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of TC, yet to our knowledge there is no research investigating the spectroscopic diagnosis
of NSCLC and TC on these diagnostic sample types. The work presented in this thesis is
unique compared to previous published studies as it examines the application of Raman
spectroscopy for the diagnosis of NSCLC and TC on cytology samples prepared as
ThinPrep®.

9.3 Future Work
There were insufficient patient samples obtained in this project to draw clinical
conclusions about the diagnostic capabilities of Raman based NSCLC and TC diagnosis
using cytology samples. The difficulty in obtaining consented samples from patients
undergoing bronchoscopy for the investigation of lung cancer was a factor that was not
fully anticipated. However, this thesis has demonstrated that diagnostically relevant
Raman peaks can be acquired from cytological specimens, warranting a larger scale
investigation.
The findings of this thesis contribute to the application of Raman spectroscopy as a
diagnostic tool on cytology, and it is hoped that the work presented in this thesis will be
a platform from which further studies can be developed. There are several interesting
directions for future studies to build on the work we have done. To address the low
number of patient samples included in this study, a larger patient cohort could be
developed to increase the size of the Raman spectral datasets. As a result of the low
number of patients samples, the venetian blinds cross validation method was used
throughout this thesis to analyse the limited data, as the datasets were too small for
LOPOCV, and LOSOCV would have over-trained the classifiers. With an increased
patient sample number and larger datasets, a cross validation method suitable for larger
datasets, such as LOPOCV, could be utilised to provide an accurate representation of the
diagnostic efficacy of applying Raman spectroscopy to bronchoscopy cytology samples
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for NSCLC diagnosis. Further, with a larger patient cohort, future studies could build on
the findings explored in this thesis by investigating the ability to correlate tumour
mutation profiles with Raman spectra.
Another interesting direction for further work would be to confirm lymphocyte identity.
The results presented in chapter 4 indicate that the differences in the spectra taken from
lymphocytes of NSCLC cases and lymphocytes of negative cases may be spectral
signatures for the immune biochemical responses to the presence of tumour. However the
data is limited in this study, and further identification of lymphocytes on bronchoscopy
cytology samples is required. Continued research could confirm lymphocyte identity with
immunohistochemistry and explore the use of Raman spectroscopy to further understand
the role and diagnostic relevance of lymphocytes in NSCLC.
Studies building from this work could also explore the significance of the collagen related
peaks observed in the epithelial cells in bronchoscopy cytology samples taken from
NSCLC cases. While collagen is associated with EMT and invasion, further
investigations should establish if this could lead to potential false positive diagnosis in
the presence of fibrosis, for example in non-malignant interstitial lung diseases.
With increased sample number future work could also explore the possibility of using
Raman spectroscopy to detect false positives on cytology, as the work presented in this
thesis shows that malignancy can be detected in false negative bronchoscopy cytology
samples, and reducing the rate of false diagnoses would be of great benefit to both patients
and the healthcare system.
A limitation to take into consideration for future studies is the low amount of cell material
in residual samples. Due to the low number of cells retained in residual sample vials,
obtaining sufficient spectra for reliable statistical analysis is difficult. With the
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appropriate ethical approval, acquiring a second sample for research purposes would
overcome this limitation.
The thyroid FNAC sample preparation method developed in this thesis was demonstrated
to be an effective method for preparing the samples for Raman spectroscopic analysis,
yet it needs to be validated on a larger group of patient samples. With the development of
an effective sample preparation method which allows spectroscopic analysis of thyroid
FNAC samples, future research could conduct a clinical study with thyroid FNAC
samples obtained from patients under investigation for thyroid cancer. Using the blood
removal protocol devised in this thesis, the ability of Raman spectroscopy to differentiate
benign and malignant thyroid lesions could be evaluated. The investigation could include
a component for cellular recognition on thyroid FNAC samples. Similar to the method
utilised in this thesis, slides could be Pap stained subsequent to Raman spectroscopic
analysis to identify the targeted cell types marked with XY coordinates.
In the long term, if large sample studies confirm the sensitivity and specificity of Raman
spectroscopy in the diagnosis of NSCLC and TC, there is potential for the development
of an automated Raman system that could identify cell types and acquire and store
spectral data. This could optimise the current time expensive method included in
identifying target cells, recording spectra, staining, cell identification, and developing
distinct databases. A more advanced fully automated system could even potentially apply
data mining techniques to classify the spectra in real time.
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